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Jason Held, Ph.D., Co-Chair

Altering cellular energy metabolism has been highlighted as one of the emerging hallmarks
of cancer. The reprogramming of bioenergetic pathways towards enhanced glycolysis, rather than
the mitochondrial oxidative phosphorylation indicative of normal cells, results in increased
biomass production and is associated with the activation of various oncogenes. The increased or
decreased expression of key metabolic enzymes has been identified as a potential family of
biomarkers that could serve as the targets for novel metabolic-based therapies in cancer.
The serine, glycine, and one-carbon (SGOC) metabolism pathway consists of a series of
enzymes and metabolites that drive protein and lipid production, enhanced DNA synthesis,
increased methylation capacity, and generate antioxidants that regulate redox homeostasis within
the cell. The pathway includes serine and glycine biosynthesis, the folate cycle, the methionine
cycle, and the trans-sulfuration pathways. The metabolite 3-phosphoglycerate (3PG) is synthesized
from glucose through upper glycolysis and is converted into serine through the de novo serine
biosynthesis pathway. A methyl unit, consisting of “one carbon”, is removed from serine and

xxi

shunted into the folate cycle, allowing the generation and salvage of metabolites that make up the
folate cycle and the methionine cycle, as well as sulfur metabolism. As such, the metabolic
enzymes associated with this pathways, including 3-phosphoglycerate dehydrogenase (PHGDH),
pyruvate

kinase

M2

(PKM2),

serine

hydroxymethyltransferase

2

(SHMT2),

and

methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), have been identified as being
overexpressed in a variety of cancers. In particular, given that the de novo biosynthesis of serine
contributes the critical one-carbon unit to the rest of the network, the rate-limiting enzyme of serine
biosynthesis, PHGDH, has been identified as being overexpressed in a number of cancers,
including breast cancer, melanoma, colorectal cancer, and non-small cell lung cancer.
The first research aim was to identify the role of serine and glycine biology in
osteosarcoma, the most common bone cancer in children and young adults. PHGDH was identified
as being overexpressed in osteosarcoma and correlated with significantly poorer relapse-free
survival and overall survival in osteosarcoma patients. NCT-503 and PKUMDL-WQ-2101, small
molecule inhibitors of PHGDH, were used to interrogate the reliance of osteosarcoma on the
SGOC metabolic network. Inhibition of PHGDH resulted in decreased cellular proliferation, but
did not cause cell death, suggesting that while osteosarcoma cells rely on PHGDH for sustained
cellular growth and proliferation, the survival of the cells was not solely reliant on serine
metabolism. Further analysis of osteosarcoma cells treated with PHGDH inhibitors identified
blocked mitochondrial oxidative phosphorylation, causing full shunting of glucose through
glycolysis and into lactate. Furthermore, an increase in neutral fatty acids was observed, suggesting
an altered capacity for fatty acids as a fuel source. Gene expression analysis with PHGDH
inhibition identified that the subsequent metabolite accumulation resulted in an activation of the

xxii

mTORC1 signaling pathway, likely as a cellular attempt to supplement the nutrients no longer
provided by the SGOC pathways.
The second research aim focused on targeting the metabolic pathways induced by PHGDH
inhibition. Previous studies in cancers with elevated PHGDH have utilized PHGDH inhibitors in
conjunction with removing serine and glycine from the environment to cause cell death.
Osteosarcoma cells, possibly due to the bone microenvironment, do not exhibit a modified
response as a result of serine and glycine deprivation, further demonstrating that they are not solely
reliant on serine and glycine biology for survival. Furthermore, translational metabolic therapies
cannot be single-agent treatments, as cells maintain an efficient and dynamic capacity to rewire
metabolic pathways. Rapamycin-based mTORC1 inhibitors have been used in osteosarcoma with
limited success, and the combination of PHGDH inhibition with rapamycin treatment did not result
in any enhanced cell death. However, perhexiline, a non-rapalog mTORC1 inhibitor, was
synergistic with PHGDH inhibition and able to cause cell death in osteosarcoma cells. Using cell
line-derived xenografts in mice, single the combination of NCT-503 with perhexiline was able to
significantly reduce tumor growth.
The final research aim sought to elucidate the mechanism of activity of non-rapalog mTOR
inhibitors in osteosarcoma. Accumulation of SGOC metabolites including S-adenosylmethionine
(SAM) and branched chain amino acids suggested activation of the nutrient sensing components
of the mTOR signaling pathway, including SAMTOR and GATOR1. Fluorescent lysosome
localization studies suggested that there was elevated GATOR1 localization at the mitochondria
with perhexiline and NCT-503 treatment, resulting in inhibition of mTOR. To further specify the
mechanism of non-rapalog based mTORC1 inhibition, an unbiased multiplex protein assay was
used to identify components of PI3K/mTOR metabolism that were not affected by rapamycin

xxiii

treatment, but were affected by treatment with perhexiline or ALPI3MT55, another non-rapalog
mTORC1 inhibitor. Glycogen synthase kinase 3α (GSK3α) and glycogen synthase kinase 3β
(GSK3β) were found to be activated with perhexiline and ALPI3MT55 treatment, but unaffected
by rapamycin. The two isoforms of GSK3 inhibit glycogen synthase, the enzyme responsible for
generation of glycogen from glucose in the cell. PHGDH inhibition resulted in increased flux of
glucose into glucose-1-phosphate, the precursor to glycogen, suggesting that glycogen synthesis
was a potential cellular survival mechanism in response to PHGDH inhibition. The combination
of PHGDH inhibition by NCT-503 and ALPI3MT55 treatment was synergistic in causing cell
death in vitro and in vivo, suggesting that GSK3α/β may be the avenue by which osteosarcomas
are sensitized to non-rapalog mTORC1 inhibition.
Taken together, these aims gave a robust understanding of osteosarcoma biology and
reliance on the SGOC metabolic network and identified a novel avenue of treatment that would be
applicable in a high-risk subset of osteosarcoma patients. This work gives the preclinical
justification for the combination of PHGDH inhibition and non-rapalog mTORC1 inhibition in
osteosarcoma patients with high tumoral PHGDH expression.
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Chapter 1: Bone Biology and Transformation to
Osteosarcoma

This chapter is being submitted for publication as an invited review article. The citation will
be:
Rathore R, Van Tine, BA. “Pathogenesis of and Current Therapies for Osteosarcoma”. Journal
of Clinical Medicine (2021).

1.1 Introduction
Osteosarcomas are the most common pediatric and adult bone tumor, with more than 1,000
new cases every year in the United States alone. Like all sarcomas, osteosarcomas arise from
mesenchymal cells, and are characterized by areas of abnormal bone growth. The various genetic,
epigenetic, and environmental factors that drive mesenchymal stem cells to differentiate into bone
precursor cells also play a role in the abnormal development of osteosarcoma. These molecular
pathways serve as the foundation for the development of therapies for this tumor. This review
describes the basic biology of bone, and how the systems that drive bone development lead to
osteosarcomagenesis. Furthermore, the cellular pathways that contribute to the pathogenesis of the
tumor are explored, and this information is used to describe the avenues for novel treatment
development for osteosarcoma.
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1.2 Bone Biology
Bone consists of four cell types: osteoblasts, osteoclasts, osteocytes, and bone-lining cells.
The bone microenvironment also includes the cartilage surrounding the bone, which consists of
chondrocytes, the bone stroma, consisting of endothelial cells and fibroblasts, as well as bonemarrow derived hematopoietic stem cells and bone-marrow derived mesenchymal stem cells
(Alfranca et al., 2015; Katagiri and Takahashi, 2002; Lu et al., 2017). Mesenchymal stem cells are
the precursor to osteoblasts and osteocytes, as well as fibroblasts and chondrocytes, and
differentiate in response to the expression and absence of various transcription factors.
To

form

osteoblasts,

mesenchymal

stem

cells

first

differentiate

into

osteochondroprogenitor cells, which control the formation of osteoblasts and bone matrix and
recruit hematopoietic cells to incorporate blood vessels. Transcription factors are critical to the
differentiation process of mesenchymal stem cells to bone. PPARγ expression drives the formation
of adipocytes, diverging mesenchymal stem cells away from bone. Runx2 and SOX9 expression
drive the differentiation of these progenitor cells to osteoblasts or chondrocytes (Figure 1.1) (Tam
et al., 2018). Transforming growth factor-beta (TGFβ) expression can further drive differentiation
into chondrocytes, but also stimulates alkaline phosphatase (ALP) activity and calcium deposition
(Broadhead et al., 2017; Tam et al., 2018).
The expression of osterix (Sp7), which can be activated by Runx2, is required to commit
to osteoblast differentiation (Hu et al., 2018; Kansara and Thomas, 2007). Runx2 also increases
expression of osteocalcin, Type I collagen, and ALP to stimulate osteoblast formation. Bone
morphogenic proteins (BMP) comprise of a family of over 30 different proteins, including TGFβ
family members, that further regulate mesenchymal stem cell differentiation into osteoblasts by
activating and inhibiting several genes that affect the expression of Runx2 and Sp7 (Hu et al.,
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2018). Wingless and int-1 (Wnt) signaling proteins and fibroblast growth factors (FGF) further
contribute to this regulation (Hu et al., 2018; Tam et al., 2018).
Finally, Runx2 induces the expression of the CDK2 inhibitor p27KIP1, which coordinates
cell cycle exit and ensures normal development of bone. Importantly, expression of Runx2 and
ALP decreases as cells differentiate into osteoblasts, and low Runx2 expression is required for
normal osteoblast function (Xu et al., 2015). The presence of osteocalcin and osteopontin then
drive the differentiation of osteoblasts into mature osteocytes (Tang et al., 2008).
Bone biology maintains homeostasis by modeling and remodeling; this process is
controlled by osteoblasts and osteoclasts. During development, the body models bone by removing
bone from some areas and synthesizing bone in others. Once development is completed, this
process is termed remodeling, as the bone maintains its location but is constantly replaced with
new bone. Osteoblasts are bone-forming cells, which create cartilage using calcium which is then
hardened into bone. Osteoclasts, which are derived from hematopoietic stem cells, are the bone
resorbing cells, which break down bone using electrolytes and bone-degrading enzymes. Receptor
activator of nuclear-factor kappa B (RANK) ligand (RANKL) presents on the surfaces of
osteoblasts and stromal cells and binds RANK on the surface of osteoclasts. Through varied
expression of RANKL, osteoblasts can control osteoclast differentiation and bone resorption.
Increased calcium levels can also stimulate osteoclast activity and contribute to bone resorption
(Alfranca et al., 2015). Osteoclasts couple with osteoblasts in a negative feedback loop in order to
regulate bone homeostasis, secreting factors that both inhibit osteoclast activity and provide
substrates for osteoblast activity (Mohamed, 2008).
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Figure 1.1 – Differentiation of Mesenchymal Stem Cell to Osteoblast

Figure 1.1 – Differentiation Schema of Mesenchymal Stem Cell to Osteoblast
Mesenchymal stem cells can differentiate into various cell types based on the expression of
different transcription factors and protein families, highlighted in gray.
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1.3 Bone Transformation to Osteosarcoma
1.3.1 Bone Cancer and Sarcoma
Cancer is defined as a disease of abnormal cells that acquire certain capabilities that drive
unchecked, uncontrolled, and invasive growth and division (Hanahan and Weinberg, 2000, 2011).
Cancers are grouped into six categories: carcinomas, sarcomas, myelomas, leukemias,
lymphomas, and mixed types. Carcinomas, which arise from epithelial cells, comprise
approximately 90 % of human cancers. Sarcomas, which have a mesenchymal cell of origin,
consist of only 1 % of adult cancers. Given that the bone consists of a series of cell types that
originating from hematopoietic and mesenchymal stem cells, the tumors that arise in bone all fall
into the sarcoma category.
There are a series of other bone sarcomas, including Ewing’s sarcoma, chondrosarcoma,
malignant fibrous histiocytoma, fibrosarcoma, hemangiosarcoma, giant cell tumor, and chordoma
(Dorfman and Czerniak, 1995; Klein and Siegal, 2006). There are approximately 3,600 new bone
cancer cases every year (Siegel et al., 2020). Osteosarcomas are the most common bone tumor,
consisting of 40-50 % of bone sarcomas.

1.3.2 Osteosarcoma Cell of Origin
Osteosarcomagenesis was originally classified as occurring only from mesenchymal stem
cells, though recent data suggests that osteosarcomas can form at multiple points in bone
development, from both mesenchymal stem cells and osteoblasts, as well as dysregulated
osteoclasts (Lengner et al., 2006; Martin et al., 2012; Spangler, 2008). Unlike other sarcomas, such
as synovial sarcoma or Ewing’s sarcoma, osteosarcomas are primarily sporadic, meaning that there
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are no specific chromosomal or genetic translocations that drive osteosarcoma development
(Rainusso et al., 2013; Tang et al., 2008). However, it is widely understood that alterations to TP53
and RB1 tumor suppressor genes play a role in the development of several cancers. Osteosarcoma
is no exception to this rule, as alterations to TP53 and RB1 have been identified in a majority of
osteosarcoma, and patients with syndromes that relate to these alterations tend to be predisposed
to developing cancers such as osteosarcoma (Alfranca et al., 2015; Chen et al., 2014). The genetic
paradigm of osteosarcomagenesis therefore consists of genes that are secondary and tertiary
drivers to p53 mutation, as well as genes that are primary and secondary drivers without p53
mutations (Figure 1.2).
Genes that relate to osteoblast development have also been associated with
osteosarcomagenesis (Figure 1.2). Wnt protein family members have been identified as playing a
significant role in the development of osteoblasts from mesenchymal stem cells (Adamopoulos et
al., 2016; Hu et al., 2018). Aberrant activation of Wnt family members can drive the further
progression of osteoblasts into osteosarcoma. In fact, β-catenin, a mediator of Wnt family
signaling, has been demonstrated to be expressed in a large percentage of osteosarcoma tumors
(Haydon et al., 2002).
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Figure 1.2 – Dysregulation of Normal Bone Development Leads to
Osteosarcomagenesis

Figure 1.2 – Dysregulation of Normal Bone Development Leads to Osteosarcomagenesis
The expression of certain transcription factors and oncogenes, as well as the dysregulation of
tumor suppressor genes, can drive osteosarcoma development.
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Similarly, BMP/TGFβ family members that drive osteoblast development can also drive
osteosarcoma development. Interestingly, osteosarcoma tumors tend to express higher amounts of
TGFβ1 and TGFβ3, which have been associated with disease progression (Tang et al., 2008).
TGFβ also activates SMAD proteins, which can inhibit osteoblast differentiation by decreasing
expression of osteocalcin (Alliston et al., 2001; Chen et al., 2012). Smad4 gene mutations have
been identified in several cancers, including pancreatic and ovarian cancer, and SMAD proteins
have also been identified as being dysregulated in osteosarcoma (Lamora et al., 2016).
Specific transcription factors that drive osteoblast formation from mesenchymal stem cells
have also been identified as key factors in osteosarcoma development. Elevated expression of
Runx2, one of the main drivers of osteoblast formation from osteochondroprogenitor cells through
the coordinated activation of osteocalcin, Type I collagen, and ALP, has been shown to drive
osteosarcomagenesis (Kansara and Thomas, 2007; Nathan et al., 2009). Runx2 has been shown to
physically interact with and be regulated by Rb and Myc, further demonstrating the complicated
interactions that drive dysregulation of normal development into osteosarcoma (Kansara and
Thomas, 2007). Importantly, p27KIP1, which drives cell cycle exit and normal bone development
upon Runx2-mediated activation, is also lost in differentiated osteosarcoma (Tang et al., 2008).
ALP, another factor elevated by Runx2, is required for the differentiation of mesenchymal stem
cells to osteoblasts, but decreases as normal differentiation continues (Broadhead et al., 2017).
Enhanced serum ALP levels have been identified in osteosarcoma patients, indicating a role in
osteosarcomagenesis (Ren et al., 2015; Wang et al., 2009).
Gli1, an oncogene that drives the sonic hedgehog (Shh) signaling pathway, has been shown
to enhance osteoblast differentiation from mesenchymal stem cells, and Gli1-expressing
embryonic cells have been identified as precursors to osteoblasts in mice (Shi et al., 2017). Gli1

8

expression has also been shown to drive osteosarcoma development and has been associated with
enhanced tumorigenesis, along with other members of the Shh signaling pathway (Angulo et al.,
2017; Kansara and Thomas, 2007).
Several pathways have also been identified that may contribute to the aggressiveness of
osteosarcoma, including the enhanced capacity for migration and invasion and the common
incidence of pulmonary metastases. The ERK1/2 pathway has been demonstrated to be crucial for
the migration and invasion in osteosaorcoma (Beristain et al., 2012). Matrix metalloproteinases
(MMPs) are a protein family that are required for the degradation of extracellular matrix proteins,
which is a process that is critical for the migration and invasion of cancers (Hempel et al., 2009).
MMP-2 and MMP-9 have been demonstrated to be overexpressed in osteosarcoma and promote
lung metastasis, and regulation of these enzymes is associated with other metabolic pathways that
are overexpressed in osteosarcoma, including de novo serine biosynthesis (Kansara and Thomas,
2007; Song et al., 2018; Tang et al., 2008). Finally, alterations to neurofibromatosis-2 (NF2) have
been correlated with increased incidence of several highly metastatic tumors, including
osteosarcoma (Tang et al., 2008). The protein encoded for by NF2, Merlin, has been demonstrated
to stabilize p53; therefore, in patients with NF2 alterations, p53 is also affected, and can thereby
drive incidence and malignancy of osteosarcoma (Kansara and Thomas, 2007; Tang et al., 2008).
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1.3.3 Bone Microenvironment
The bone microenvironment plays a critical role in the development of osteosarcoma. As
previously noted, osteoclasts are regulated by RANK signaling, which is mediated by RANK
ligand (RANKL). Dysregulation of RANKL expression by osteoblasts and other cells in the bone
microenvironment can limit bone resorption by osteoclasts and allows bone to form unchecked.
Factors released by cancer cells including interleukins (IL) such as IL-6 and IL-11, as well as
TGFβ, can also modulate RANK expression on the osteoclast surface, which can further decrease
bone resorption and contribute to tumor progression (Alfranca et al., 2015).
The signaling components of the bone microenvironment also play a role in osteosarcoma
development. BMP2 and TGFβ circulate throughout the bone microenvironment, contributing to
osteoblast formation but also osteosarcoma differentiation and malignancy (Rubio et al., 2014;
Wang et al., 2013). Growth-related factors can also contribute to sarcomagenesis as these factors
are necessary for osteoblast-driven bone formation (de Azevedo et al., 2020). Chondrocytes secrete
high-mobility group box 1 protein (HMGB1) that stimulates osteoblast proliferation and can also
induce osteosarcoma proliferation (Alfranca et al., 2015; Huang et al., 2012).
Bone cancers are not the only cancers that thrive in the bone microenvironment. Many cancers
metastasize to the bone because of its rich tumor-promoting environment, including breast cancer
(Weilbaecher et al., 2011). Interestingly, though osteosarcoma is a bone-producing tumor, various
bone-metastatic breast cancers have been identified as contributing to osteolysis, or the destruction
of bone tissue (Kozlow and Guise, 2005). Enhanced production of the amino acid serine by breast
cancer has been attributed to osteoclastogenesis and increased osteolysis due to bone metastases
(Pollari et al., 2011).
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1.3.4 Osteosarcoma Predisposition
There are several genetic syndromes that predispose patients to developing osteosarcoma
due to the underlying genetic nature of the cancers (Figure 1.2). Li-Fraumeni syndrome is caused
by mutations to TP53, thus making it a predisposition syndrome to a number of cancers, including
osteosarcoma (Olivier et al., 2010). Similarly, retinoblastoma is characterized by mutations to RB1,
the retinoblastoma tumor suppressor gene, which has been identified as a driver of ostesarcoma
(Iurlaro et al., 2014). In older adults, osteosarcoma is also found in patients with Paget’s disease.
Paget’s Disease, identified by Sir James Paget in 1876, is a disease of abnormal bone recycling
that results in misshapen and tumorous bones (Hansen et al., 2006). Osteosarcoma arising in
Paget’s patients have been found to have higher incidence of p53 mutation, as well as mutations
to other tumor suppressor genes, suggesting that a second “hit” is required for osteosarcomagenesis
in patients with Paget’s disease (Nellissery et al., 1998). Other diseases, including Bloom
syndrome, Werner syndrome, and Rothman-Thompson syndrome, have also been correlated with
increased osteosarcoma incidence (Broadhead et al., 2017; Ricafort and Gorlick, 2010; Tang et al.,
2008).
Various external factors have also been identified as risk factors for osteosarcoma. As early
as two years after radiation therapy, osteosarcomas have been observed at the site of radiation;
some tumors have arisen at radiation sites decades after initial radiation therapy (Rainusso et al.,
2013). SV40 viral DNA has also been identified in as much as 50 % of osteosarcoma tumors;
however, there is no data to verify whether this has any causative role in osteosarcoma
development (Fuchs and Pritchard, 2002; Mendoza et al., 1998; Tang et al., 2008).
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1.4 Osteosarcoma Epidemiology and Diagnosis
Osteosarcoma is the most common primary pediatric and adult bone tumor (Geller and
Gorlick, 2010). Approximately 1,000 new cases arise each year in the United States (Siegel et al.,
2020; Tang et al., 2008). Approximately 80 % of osteosarcomas present with a localized, primary
tumor, with the other 20 % presenting initially with pulmonary metastases (Heare et al., 2009).
For patients with metastatic disease, the overall survival rate is less than 20 %, and survival gets
progressively worse as the presence of lung nodules increases (Heare et al., 2009).
Osteosarcoma occurs primarily at the metaphysis of the bone, in regions of rapid bone
growth. Approximately 80 % of osteosarcomas occur in the extremities, primarily in the proximal
tibia, distal femur, and proximal humerus (Heare et al., 2009; Isakoff et al., 2015). Clinically, most
osteosarcoma patients present with pain, usually with swelling or a palpable mass identified at the
site of the pain (Heare et al., 2009). Histologic diagnosis of osteosarcoma is based on morphology
as identified by radiograph or hematoxylin and eosin staining (Klein and Siegal, 2006; Whelan
and Davis, 2018). There are three general classes of osteosarcoma, including osteoblastic,
chondroblastic, and fibroblastic. Osteoblastic osteosarcoma tend to make up the majority of tumors
(approximately 70 %); however, most osteosarcomas are genetically and morphologically
heterogenous, so tumors can contain any combination of these three classes (Klein and Siegal,
2006; Tang et al., 2008).
After resection and chemotherapy, generally with the standard of care known as MAP
(methotrexate, doxorubicin, and cisplatin), the cure rate of osteosarcoma is approximately 60-70
% (Bielack et al., 2015; Heare et al., 2009; Isakoff et al., 2015). Approximately 30 % of patients
do relapse after surgery and chemotherapy, generally within five years, at which point lung and
bone metastases are the most common sites of recurrence (Heare et al., 2009; Tang et al., 2008).
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1.5 Treatment Strategies and Molecular Targets
1.5.1 Current Standard of Care
Current treatment strategies for osteosarcoma are surgical resection, as well as pre- and
post-surgical chemotherapy (known as neoadjuvant and adjuvant chemotherapy, respectively)
with cisplatin, doxorubicin, ifosfamide, and high-dose methotrexate with leucovorin rescue
(Isakoff et al., 2015; Spangler, 2008).
Cisplatin is an antineoplastic alkylating agent that causes DNA damage. The platinum ion
in cisplatin forms bonds with DNA bases, inhibiting DNA replication and cell division (Dasari and
Bernard Tchounwou, 2014). Cisplatin is known to cause nerve damage, but is widely used in
several cancers, including lung cancer, ovarian cancer, and breast cancer, due to its cytotoxic
effects (Bielack et al., 2015; Dasari and Bernard Tchounwou, 2014).
Doxorubicin is an anthracycline, or a DNA intercalator, which also causes DNA damage
by inhibiting topoisomerase II and affecting DNA replication (Meredith and Dass, 2016).
Doxorubicin also functions as a DNA damage agent, and the doses given to patients is sharply
regulated due to potentials for cardiotoxicity. Dexrazoxane may be given to mitigate the possible
damage (Swain et al., 1997).
Ifosfamide is a nitrogen mustard that functions as an alkylating agent that also damages
DNA, thereby stopping cells from proliferating (Jaffe et al., 2013). Ifosfamide creates irreparable
cross links between DNA strands, which stops DNA from replicating (Dechant et al., 1991). High
doses of ifosfamide are known to damage the lining of the bladder; therefore, it is often given with
etoposide or mesna and has been incorporated into multi-drug chemotherapy regimens with
promising results (Balamuth and Womer, 2010; Dechant et al., 1991). It has been approved for use
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in testicular cancer, osteosarcoma, soft tissue sarcoma, bladder cancer, non-small cell lung cancer,
cervical cancer, and ovarian cancer (Dechant et al., 1991; Liu et al., 2015).
Unlike cisplatin, doxorubicin, and ifosfamide, which all function by damaging DNA and
inhibiting cellular division, methotrexate targets dihydrofolate reductase (DHFR), an enzyme in
the folate cycle. In osteosarcoma, methotrexate is given as high doses, defined as > 1 g/m2
(Holmboe et al., 2011). In order to facilitate relatively safe use of high-dose methotrexate (HDMTX), leucovorin rescue is used to block import of methotrexate into healthy cells. Leucovorin
supplies cells with an additional source of tetrahydrofolate (THF), and can thus counter the activity
of methotrexate (Jaffe and Gorlick, 2008; Shea et al., 2013; Tishler et al., 1988). Cancerous cells
lack the leucovorin transporter, and are thus susceptible to inhibition of the folate cycle by HDMTX (Visentin et al., 2012; Wilmanns et al., 1980). This allows the doses of HD-MTX used in
osteosarcoma patients to reach doses as high as 8-12 g/m2.

1.5.2 Clinical Trials: The Future of Osteosarcoma Treatment
The treatment landscape for osteosarcoma has not evolved since the introduction of highdose methotrexate to the standard cytotoxic chemotherapies. Even so, there are over 500 clinical
trials targeting novel pathways of interest in osteosarcoma. Small-molecule inhibitor-based
clinical trials in osteosarcoma are highlighted in Table 1.1. Interestingly, the majority of the trials
currently active and/or recruiting focus on combination therapies in osteosarcoma, highlighting
the need for treatment strategies that exploit cellular pathways that drive specific prognostic factors
in osteosarcoma, rather than neutral combinations of DNA damage agents that have activity – and
side effects – across a number of cancers.
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Table 1.1 – Osteosarcoma Clinical Trials
Identifier

Study Title

Status

NCT00470223

Combined Chemotherapy With or Without Zoledronic Acid for Patients With
Osteosarcoma
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients
With Metastatic or Recurrent Malignant Solid Tumors
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients
With Non Metastatic Osteosarcoma (ISG/OS-2)
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

Active, not
recruiting
Active, not
recruiting
Active, not
recruiting
Recruiting

Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant
Chemotherapy to Treat Osteosarcoma (Li2CO3)
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in
Osteosarcoma
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma
and Neuroblastoma
Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors

Recruiting

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young
Adults With Neuroblastoma and Osteosarcoma
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or
Ewing Sarcoma
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients
With Metastatic Soft Tissue and Bone Sarcomas
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With
Metastatic Bone Sarcomas
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With
Advanced Sarcomas : Multicentre Phase II Trial
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed
Solid Malignancies and Young Adults With Osteosarcoma
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Recruiting

NCT00788125
NCT01459484
NCT01661400
NCT01669369
NCT01833520
NCT01953900
NCT02013336
NCT02173093
NCT02243605
NCT02357810
NCT02389244
NCT02406781
NCT02432274
NCT02470091
NCT02484443
NCT02502786
NCT02517918
NCT02811523
NCT02867592
NCT02945800
NCT03006848
NCT03063983
NCT03277924
NCT03449108

Dinutuximab in Combination With Sargramostim in Treating Patients With
Recurrent Osteosarcoma
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage
Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent
Osteosarcoma
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone
Metastasis and Advanced Pretreated Osteosarcoma
In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

Active, not
recruiting
Active, not
recruiting
Recruiting

Active, not
recruiting
Active, not
recruiting
Recruiting
Recruiting
Active, not
recruiting
Active, not
recruiting
Active, not
recruiting
Recruiting
Recruiting
Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent,
Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare
Tumors
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not
recruiting

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive
Osteosarcoma
Clinical Trial Evaluating Metronomic Chemotherapy in Patients With
Metastatic Osteosarcoma (GLATO2017)
Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft
Tissue and Bone Sarcomas
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian
Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft
Tissue Sarcomas

Active, not
recruiting
Recruiting
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Recruiting

Recruiting
Recruiting

Table 1.1 – Osteosarcoma Clinical Trials (continued)
Identifier

Study Title

Status

NCT03449901

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment
of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung
Cancer
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed
or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma,
Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With
Recurrent or Refractory Osteosarcoma
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors
in Children and Young Adults
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable
Osteosarcoma
Mifamurtide Combined With Post-operative Chemotherapy for Newly
Diagnosed High Risk Osteosarcoma Patients (SARCOME13)
A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of
High-grade Osteosarcoma
M6620 (VX-970) in Selected Solid Tumors
Pulmonary Resectable Metastases of Osteosarcoma With Apatinib and
Chemotherapy
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and
Other Solid Tumor Cancers
Losartan + Sunitinib in Treatment of Osteosarcoma
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase
(CDK) Pathway Alteration
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line
Treatment in Patients With Bone Sarcomas
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With
or Without Lenvatinib in Children, Adolescents and Young Adults With
Relapsed and Refractory Osteosarcoma
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the
Treatment of Osteosarcoma
Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in
Patients With a Poor Response to Preoperative Chemotherapy for Newly
Diagnosed High-grade Osteosarcoma
ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma
of the Extremities
Combination Immunotherapy Targeting Sarcomas
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in
Children and Young Adults
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and
Osteosarcoma

Recruiting

NCT03478462
NCT03598595
NCT03618381
NCT03628209
NCT03643133
NCT03676985
NCT03718091
NCT03742193
NCT03860207
NCT03900793
NCT03932071
NCT03960177
NCT04040205
NCT04055220
NCT04154189
NCT04183062
NCT04294511
NCT04351308
NCT04383288
NCT04433221
NCT04483778
NCT04595994

Table 1.1 – Osteosarcoma Clinical Trials
Current clinical trials using molecular pathway-targeted therapies in osteosarcoma.
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Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting

1.5.3 Folate cycle inhibitors
In addition to DNA damage agents, methotrexate is the targeted component of the standard
of care for osteosarcoma. A cell cycle arrest agent, methotrexate targets the folate pathway, a key
metabolic component of nucleotide biosynthesis. Its structure is similar to that of dihydrofolate
(DHF), and it functions by competitively inhibiting dihydrofolate reductase (DHFR) (Rajagopalan
et al., 2002; Serra et al., 2004), the enzyme needed to recycle THF from DHF. Among other
purposes, THF is required in the biosynthesis of purines and thymidylate from serine. In order to
mediate the toxicity of methotrexate treatment, leucovorin rescue is given, thus allowing for
somewhat targeted delivery of the chemotherapy to cancer cells. Unfortunately, even with
leucovorin rescue, HD-MTX treatments still exhibit high rates of toxicity, and can lead to renal
and liver failure, particularly in adults, as well as leukoencephalopathy, or damage to the white
matter of the brain (Grem et al., 1988; Jaffe and Gorlick, 2008; Patiño-García et al., 2009). Due to
this extremely narrow therapeutic window, an alternative – or ideally, replacement – therapeutic
for HD-MTX would be beneficial.

1.5.4 Targeting p53 and RB
The next possible treatment development strategy would be to look at the most common
genetic alterations in osteosarcoma, which are alterations to RB and p53 tumor suppressor genes
(Alfranca et al., 2015). Genetic abnormalities to RB1 have been found in up to 70 % of
osteosarcoma tumors, and TP53 mutations have been associated with approximately 90 % of
osteosarcoma tumors (Chen et al., 2014; Tang et al., 2008). P53 is a tumor suppressor that can
regulate metabolic reprogramming by acting as a sequence-specific transcription factor and
altering transcription of various metabolic enzymes (Freed-Pastor and Prives, 2012). Mutations to
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TP53 can cause structural and functional changes to the resultant mutant p53 protein, resulting in
either a tumorigenic gain of function of the mutant protein, or a tumorigenic phenotype due to lack
of a tumor suppressor (Freed-Pastor and Prives, 2012). The wildtype p53 protein has been
identified as a negative regulator of osteoblasts, with p53 mutations or knockouts resulting in an
increase in osteoblast function (Wang et al., 2006). This highlights the mechanism by which
osteosarcomas with mutant p53 are able to form bone.
Furthermore, in tumors that retain wild-type p53 status, gene MDM2 has been found to
inactivate p53 activity (Ladanyi et al., 1993). MDM2 has been shown to be preferentially amplified
in sarcomas, and specifically in osteosarcoma (Lonardo et al., 1997). MDM2 codes for the protein
Mdm2, which is a p53 binding protein that functionally inactivates p53 transcription factor activity
by binding to the N-terminal end of p53 (Ladanyi et al., 1993; Manfredi, 2010; Yoshida et al.,
2012). To disrupt this binding, Nutlin-3a, an Mdm2 antagonist, is utilized to interrupt the binding
of Mdm2 to p53, freeing p53 to localize to the nucleus and carry out its transcriptional function
(Ou et al., 2015).
Importantly, while p53 and RB are the most common alterations in osteosarcoma, these
mutations are not directly targetable in the clinic due to the complex nature of their incorporation
into normal and cancerous cell biology. Mutant p53-reactivating compounds are being explored
as a possible mechanism by which to selectively target mutations to TP53, which is encouraging
for the field (Bykov et al., 2018). However, identifying and targeting the pathways driven by
altered p53 or RB would allow for more directed approaches.
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1.5.5 ABCB1
The p53 protein has a binding site on the promoter of ATP Binding Cassette Subfamily B
Member 1 (ABCB1), a protein in a family of multidrug transporters (Bush and Li, 2002; Zawadzka
et al., 2020). ABCB1 in particular is a drug efflux pump, making it a critical component in multidrug resistance (MDR) (Liu et al., 2016a). Mutations in these transporters have been implicated in
cancer progression and drug response in a variety of cancers, including osteosarcoma and nonsmall cell lung cancer, as certain single nucleotide polymorphisms (SNPs) can alter the function
of the transporter (Xiaohui et al., 2014; Zawadzka et al., 2020). Recent clinical trials have explored
the efficacy of various chemotherapies stratified by ABCB1 expression to characterize the role of
ABCB1 expression in MDR and osteosarcoma patient outcomes (NCT identifier: NCT01459484
and NCT04383288). CRISPR/Cas9 mediated inhibition of ABCB1 may also help to combat MDR
in osteosarcoma (Liu et al., 2016a).

1.5.6 Tyrosine kinase inhibitors
Tyrosine kinases are enzymes such as tyrosine-protein kinase Met (c-Met) and vascular
endothelial growth factor receptor 2 (VEGFR2), that phosphorylate tyrosine residues on proteins
using ATP as a phosphate donor (Paul and Mukhopadhyay, 2004). Tyrosine kinases are activated
by ligand binding and have been implicated in various roles that drive the aggressive growth,
migration, and invasion of osteosarcoma. As such, tyrosine kinase inhibitors have been approved
in several cancers, including renal cell carcinoma and hepatocellular carcinoma Tyrosine kinases
are interesting therapeutic options, as drugs that target this class of enzymes tend to be
promiscuous. One such tyrosine kinase inhibitor, cabozantinib, inhibits c-Met and VEGFR2, in
addition to other tyrosine kinases, and has been explored as a therapeutic option in osteosarcoma
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in multiple trials with positive results (Italiano et al., 2020). Regorafenib targets VEGFR2, plateletderived growth factor receptor (PDGFR)-β, and tunica interna endothelial cell kinase 2 (TIE2),
and has been demonstrated to have less severe side effects than sorafenib (Liu et al., 2019a).
Regorafenib treatment has been demonstrated to have activity in progressive metastatic
osteosarcoma (Davis et al., 2019). Sorafenib, another tyrosine kinase inhibitor, targets extracellular
signal-related kinase (ERK), VEGFR, and PDGFR-α and -β. Use of single-agent sorafenib in
osteosarcoma has demonstrated anti-tumor activity, but osteosarcoma has been shown to progress
through sorafenib treatment for several reasons (Cathomas et al., 2015; Grignani et al., 2015;
Raciborska and Bilska, 2018). Tyrosine kinase inhibitors have therefore been explored in greater
detail in combination with other therapies (Arora and Scholar, 2005).

1.5.7 Gemcitabine and Docetaxel
Combination therapies have been the standard for osteosarcoma since the adoption of the
MAP regimen as standard of care (Bielack et al., 2015). Gemcitabine is a fluorinated version of
the nucleoside deoxycytidine that is taken up by the nuceloside transporter SLC29A1, or human
equilibrative nucleoside transporter 1 (hENT1) (Maki, 2007; Zakeri-Milani et al., 2017).
Gemcitabine incorporates into DNA as a fraudulent base pair, resulting in premature DNA strand
termination (Maki, 2007). Docetaxel is a mitosis inhibitor that functions by stabilizing tubulin
(Maki, 2007). Recent studies have also shown that docetaxel can aid in the transition of stabilized
c-Myc to the nucleus (Prudner et al., 2019). C-Myc increases transcription and translation of
hENT1, thereby increasing cellular capacity for gemcitabine uptake. Gemcitabine and docetaxel
have been combined in multiple cancers, including soft tissue sarcoma, and have demonstrated
synergy (Maki, 2007; Prudner et al., 2019). Some clinical trials have also explored the addition of
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selinexor, a drug that reduces the expression of DNA damage repair proteins, to this regimen, in
order to enhance the DNA damage effects of the combination (Kashyap et al., 2018).

1.5.8 Immune checkpoint inhibitors
Immunotherapies have come to the forefront in recent years as anticancer therapies
(Thanindratarn et al., 2019). Programmed cell death 1 (PD-1) is a cell surface protein that is
expressed on activated immune cells, including CD8+ T lymphocytes, B cells, and natural killer
cells, that can also be expressed in tumor cells (Thanindratarn et al., 2019). The ligand of PD-1,
PD-L1, has also been demonstrated to be overexpressed in cancer cells and associated with poorer
prognosis (Brahmer et al., 2012). Camrelizumab and pembrolizumab are humanized antibodies
against PD-1 and used in several cancers as immunotherapies. In a trial of pembrolizumab in
osteosarcoma patients, one of the 22 patients given pembrolizumab demonstrated an objective
response (NCT identifier: NCT02301039) (Tawbi et al., 2017). A trial of camrelizumab in
combination with apatinib in osteosarcoma also seemed to slightly prolong progression-free
survival, though the response rate to these therapies is as of yet not optimized (Xie et al., 2020).

1.5.9 RANKL
RANK signaling has been demonstrated to be important in osteosarcoma development,
growth, and motility, and overexpression of RANK and RANKL have been correlated with poorer
outcomes (Isakoff et al., 2015). Osteoblast-secreted RANKL has therefore been explored as a
possible target for antibody-based therapies, as inhibiting RANK signaling on osteoclasts could
decrease osteosarcoma cell migration and invasion abilities. Denosumab, an antibody to RANKL,
is an anti-resorptive agent that has been used in patients with osteoporosis, and is being explored
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in patients with refractory or relapsed osteosarcoma (Cathomas et al., 2015; Hu et al., 2018; Isakoff
et al., 2015). In combination with sorafenib, a protein kinase inhibitor, denosumab treatment was
able to cause complete metabolic remission in an osteosarcoma patient case study (Cathomas et
al., 2015).

1.5.10

mTOR inhibitors

There are many alterations in the phosphoinositide 3-kinase (PI3K)/mammalian target of
rapamycin (mTOR) pathway that are present in osteosarcoma, thereby suggesting mTOR as a valid
target for therapy (Perry et al., 2014). The mTORC1 signaling pathways are also activated by
several oncogenes, indicating baseline activation in osteosarcoma (Xie et al., 2016). Rapamycin
binds to FKBP12, a receptor for immunosuppressant molecules that was found to also be a
component of the protein complex that makes up mTOR complex 1 (mTORC1) (Leone et al.,
2006). Rapamycin has been utilized in osteosarcoma, but has only shown cytostatic, rather than
cytotoxic, effects (Xie et al., 2016). This is in part because rapamycin preferentially targets
mTORC1, allowing mTOR complex 2 (mTORC2) to activate protein kinase B (PKB)/AKT
signaling and enhance mTOR activity (Rodrik-Outmezguine et al., 2011). Various analogs of
rapamycin, including everolimus and temsirolimus, have been explored in the clinic with some
anti-tumoral activity (Table 1.1) (Mita and Tolcher, 2007). The feedback mechanisms associated
with the complex biology of mTOR are elaborated on in Chapter 2.4; importantly, the adaptability
of mTOR signaling in the cell allows the cell to counteract and develop resistance to mTOR
inhibitors (Ding et al., 2016).

22

1.6 Concluding Remarks
Though rare, osteosarcomas are the most common primary bone tumor in children and
young adults. The transformation of normal functioning bone cells into osteosarcoma has been
demonstrated to occur at multiple levels in mesenchymal stem cell differentiation, whereby
mesenchymal stem cells can transform directly into osteosarcoma, or can undergo various stages
of differentiation into osteoblasts before becoming tumorigenic. Numerous factors that are
involved in osteoblast differentiation can be overexpressed or dysregulated to drive abnormal bone
production and osteosarcomagenesis.
The current treatment regimen for osteosarcoma involves the use of cisplatin, doxorubicin,
ifosfamide, and high-dose methotrexate. High-dose methotrexate has demonstrated significant
toxicity in the liver, kidney, and brain, and novel therapies that are more specifically targeted to
osteosarcoma are needed. The heterogeneity of osteosarcoma tumors necessitates that there are
other potential biomarkers that could contribute to osteosarcomagenesis and be opportune targets
for the development of novel chemotherapies. A critical component of cancer development, the
metabolism of the tumor, offers a wide variety of upregulated pathways and overexpressed
biomarkers that could encourage the development of a class of novel therapies. Elucidating role of
tumor metabolism in the progression of osteosarcoma is therefore necessary.
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Chapter 2: Cancer Metabolism and Associated
Pathways

2.1 Cancer Metabolism and the Warburg Effect
Cancer metabolism consists of a series of enzymatic pathways that generate the amino
acids, nucleotides, lipids, and cofactors required for cellular growth and proliferation, as well as
pathways that regulate redox homeostasis and bioenergetics (Sotgia et al., 2012). As such,
metabolism is a critical component of cancer initiation, progression, and aggressiveness.
Metabolism can be efficiently rewired in response to energy status, nutrient availability, and ROS
levels, thus providing a dynamic mechanism for tumors to increase fuel demands and promote
aggressiveness. In 1924, Otto Warburg identified a critical metabolic rewiring that occurred in
cancer, whereby cancer cells would increase glucose uptake to utilize glycolysis, or the catabolism
of glucose, and fermentation, or the conversion of glucose to pyruvate and subsequently lactate, to
generate ATP, rather than using mitochondrial oxidative phosphorylation (Warburg, 1956;
Warburg et al., 1924). This form of energy production was originally thought to occur only in
anaerobic conditions, and uniquely identified an aspect of cancer metabolism that would occur
even in the presence of oxygen. This was deemed the Warburg effect, and opened a new avenue
of exploration into metabolism and energy production as uniquely targetable moieties in cancer.
Conversion of glucose to pyruvate is catalyzed by the enzyme pyruvate kinase (PK) (Lunt
et al., 2015). PK has two isoforms: the highly active PKM1, and the less efficient PKM2
(Chiavarina et al., 2011). Lack of active PKM2, as well as normal levels of the non-cancerous
isoform, PKM1, allows for glycolytic intermediates to shuttle back upstream through to the
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pentose phosphate pathway and serine (and subsequent glycine) biosynthesis (Chiavarina et al.,
2011; Christofk et al., 2008). Interestingly, serine acts as an allosteric activator of PKM2
(Chaneton et al., 2012; Ye et al., 2012). Overexpression of PKM2 has been shown to promote
cancer cell growth and survival through induction of the cell cycle regulator CCND1 and inhibition
of the cell cycle regulator CDKN1A (Zheng et al., 2018). PKM2 has also been identified as being
overexpressed and associated with poor prognosis in osteosarcoma (Liu et al., 2016b).
Furthermore, increased PKM2 expression has been associated with induced cisplatin resistance,
highlighting the capacity of cells to modulate metabolic enzymes in response to environmental
stressors (Wang et al., 2017b).
Once glycolytic carbons pass through PKM2 and reach pyruvate, two directions can be
taken. To complete the fermentation process, lactate dehydrogenase (LDH) converts pyruvate to
lactate and regenerates NAD+ (Mohammad et al., 2016). The lactate produced is then either
retained or exported from the cell. Through pyruvate decarboxylation, a series of enzymatic
reactions mediated by the pyruvate dehydrogenase (PDH) complex, pyruvate can also be converted
into acetyl-coA. The complex utilizes thiamine pyrophosphate (TPP) and coenzyme A to
ultimately generate acetyl-coA and NADH, the reduced form of NAD+. The PDH complex is
inhibited by pyruvate dehydrogenase kinase-1 (PDK-1), which is in turn regulated by hypoxiainducible factor 1α (HIF-1α) expression (McFate et al., 2008). Enhanced HIF-1α expression has
been correlated with numerous cancers, and the subsequent inhibition of the PDH complex and
other acyl-coA dehydrogenases thereby drives the Warburg effect in those cancers (Huang et al.,
2014; McFate et al., 2008). Conversely, overexpression of LDH and PKM2 have also been
correlated with poor prognosis in several cancers, including pancreatic cancer (Mohammad et al.,
2016).
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2.2 Serine, Glycine, and One Carbon Metabolism
Serine, glycine, and one carbon (SGOC) metabolism consists of a series of pathways that
are critical to the maintenance of the normal and cancerous cell. SGOC metabolism drives protein,
amino acid, and lipid production, enhanced DNA synthesis, increased methylation capacity and
epigenetic regulation, and generation of antioxidants that regulate redox homeostasis within the
cell. These processes occur within de novo serine and glycine biosynthesis, the folate cycle, the
methionine cycle, and the trans-sulfuration pathways.
The first component of SGOC metabolism is de novo serine biosynthesis, whereby
glycolytic intermediates are shunted into serine by way of 3-phosphogylyerate (3PG). In the ratelimiting step of serine synthesis, 3PG is converted to 3-phosphohydroxypyruvate (3PHP) by the
enzyme 3-phosphoglycerate dehydrogenase (PHGDH). From there, 3PHP is quickly converted to
3-phosphoserine (3PS), which is dephosphorylated to produce serine. Serine can be interconverted
to the amino acid glycine by the enzyme serine hydroxymethyltransferase (SHMT1/2).
As mentioned earlier, several chemotherapies target SGOC metabolism within the cancer
cell. For example, methotrexate, a critical component of osteosarcoma standard of care, targets the
folate cycle. DHFR, the target of HD-MTX, reduces dihydrofolate (DHF) to tetrahydrofolate
(THF) (Serra et al., 2004). Progression through the folate cycle requires THF conversion to 5,10methylenetetrahydrofolate (5,10-meTHF), by the addition of a single carbon unit. When serine is
metabolized to glycine by SHMT1/2, a single carbon unit from the CH2-OH side chain of serine
is donated to THF, causing the conversion from THF to 5,10-meTHF (Figure 2.1) (Locasale,
2013). Accordingly, the conversion between serine and glycine charges the folate cycle, providing
the necessary carbon units for nucleotide biosynthesis.
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The folate cycle continues by converting 5,10-meTHF to 5-methyltetrahydrofolate
(mTHF), which connects the folate cycle to the methionine cycle. This also serves as the precursor
to pyrimidine synthesis, as mTHF is recycled down to DHF, which catalyzes the conversion of
dexoyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), leading to the
thymine and cytosine synthesis. The recycling of mTHF back to THF allows the single carbon unit
to transfer from the folate cycle into the methionine cycle, where homocysteine receives the
methylene unit and is converted into methionine. Methionine transfers the single carbon unit to Sadenosylmethionine (SAM), which can then be recycled to S-adenosylhomocysteine (SAH) by
transferring the carbon unit during the process of methylation. Methylation, along with acetylation
and other forms of histone modification, is the key process by which epigenetic regulation occurs,
thereby linking serine metabolism to the mechanism by which the cell alters its gene expression in
response to the environment (Jaenisch and Bird, 2003).
Furthermore, the amino acids produced through SGOC metabolism – namely, serine,
glycine, cysteine, homocysteine, and methionine – provide the precursors to protein synthesis and
biomass production within the cell.
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Figure 2.1 – One Carbon Tracking Through SGOC Metabolism

Figure 2.1 – One Carbon Tracking Through SGOC Metabolism
Red circle marks methyl unit that is transferred from serine through several pathways into
downstream metabolites, nucleotides, methylation, etc. (THF, tetrahydrofolate; 5,10-meTHF,
5,10-methylenetetrahydrofolate; 5-meTHF, 5-methyltetrahydrfolate; SAM, Sadenosylmethionine; SAH, S-adenosylhomocysteine; DNA, deoxyribonucleic acid).
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2.3 The Fuel Sources of the TCA Cycle
Serine synthesis is a branching pathway off of glycolysis (Ganapathy-Kanniappan and
Geschwind, 2013). Glycolysis results in either fermentation of pyruvate to lactate, or PDHmediated production of acetyl-coA from pyruvate. Acetyl-coA can then enter the mitochondria
for oxidative phosphorylation to occur. Oxidative phosphorylation utilizes oxygen to fuel the TCA
cycle and electron transport chain. In the mitochondria, acetyl-coA is incorporated into the TCA
cycle, which utilizes a series of metabolites to generate the energy precursors needed for the
electron transport chain in the form of NADH and flavin adenine dinucleotide (FADH2). NADH
and FADH2 transfer energy in the form of protons to Complex I and Complex II of the electron
transport chain, respectively, driving a proton gradient through Complex III and Complex IV, and
oxygen consumption leads to the synthesis of ATP by Complex V, known as ATP synthase.
Mitochondria utilize three main fuel sources for oxidative phosphorylation: glucose (in the
form of pyruvate), glutamine, and fatty acids (Tedeschi et al., 2013). Glutamine is primarily used
as a carbon source for the TCA cycle, as it can be interconverted into glutamate, and subsequently
α-ketoglutarate (DeNicola and Cantley, 2015). Fatty acids, conversely, can be oxidized to produce
ATP through beta-oxidation. Fatty acids also serve a critical role in proliferation, as they are
required for the generation of cellular membranes (DeNicola and Cantley, 2015). In cancers where
glycolysis is not dominant, such as prostate cancer, fatty acid oxidation emerges as a more
dominant bioenergetic pathway (Liu, 2006). Use of other fuel sources also allows glucose-derived
metabolites to be used for other forms of biomass production and redox homeostasis, such as the
pentose phosphate pathway and serine biosynthesis, as discussed in chapter 2.1 (Wu et al., 2011).
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2.4 Nutrient Sensing by the mTOR Pathway
2.4.1 The mTOR signaling pathway
The mammalian target of rapamycin (mTOR) signaling pathway plays a key role in cellular
signaling, growth, and regulation, and aberrant activation of mTOR signaling has been noted in
several cancers, including osteosarcoma (Ding et al., 2016). Principally, mTOR signaling controls
mRNA translation through the phosphorylation of various targets. This pathway drives anabolic
cellular processes including protein synthesis (through the phosphorylation of eukaryotic initiation
factor 4E binding protein 1 [4EBP1] and p70 ribosomal S6 kinase [p70S6K]), lipid synthesis
(through phosphorylation of sterol regulatory element binding protein 1 [SREBP1] and PPARγ),
nucleotide synthesis (also through p70S6K), and autophagy (through phosphorylation and
inactivation of unc-51-like kinase 1 [ULK1] and autophagy-related gene 13 [ATG13]) (Laplante
and Sabatini, 2009a). mTOR is regulated by nutrient availability and transcription factor pathways
and exists as two complexes: mTOR complex 1 (mTORC1) and complex 2 (mTORC2) (Xie et al.,
2016). mTORC1 uniquely contains the protein Raptor, which is required for the subcellular
localization of mTORC1 at the lysosome, while mTORC2 specifically complexes with the protein
Rictor (Kim and Guan, 2019; Toschi et al., 2009).
The regulation of mTOR is a complex process that is mediated by a series of pathways.
Tuberous scelrosis complex (TSC) is a key suppressor of mTORC1 activity (Kim and Guan, 2019).
TSC consists of TSC1, TSC2, and TBC1D7. TSC2 in particular is responsible for regulating
mTORC1 activity, as TSC2 is a GTPase-activating protein (GAP) that can inhibit the Rheb
GTPase associated with mTORC1 (Kim and Guan, 2019). PKB/Akt can inhibit TSC2 by
phosphorylating it, thus serving as positive regulators of mTORC1 activity (Huang and Manning,
2009). Conversely, Wnt signaling can also activate mTORC1 through TSC2, as Wnt signaling
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inhibits glycogen synthase kinase 3β (GSK3β). GSK3β can directly phosphorylate TSC2 at a
different site from PKB/Akt, thereby activating TSC2 and inhibiting mTORC1 (Hermida et al.,
2017; Kim and Guan, 2019).
mTOR can also be regulated by metabolic pathways, including serine synthesis and one
carbon metabolism, which drive changes in growth factor signaling, cellular energy levels, oxygen
levels, and amino acids (Zeng et al., 2019).

2.4.2 Amino acid sensing by mTOR
A network of signaling molecules coordinate to signal amino acid and nucleotide levels to
mTOR. Ras-related GTPases (Rag) have been implicated as an amino acid sensing component of
mTOR signaling, whereby amino acids stimulate the localization of mTOR to the lysosome, and
Rheb GTPases activate mTOR in a Rag-dependent manner (Jung et al., 2015; Kim and Guan,
2019). This also requires the presence of the Ragulator protein complex, without which Rag does
not localize to the lysosome, and mTORC1 cannot be recruited in response to amino acid levels
(Jung et al., 2015; Kim and Guan, 2019). Sestrins serve as cytosolic leucine sensors, and can also
inhibit mTORC1 activation through regulation of the GATOR complexes (Parmigiani et al., 2014;
Wolfson et al., 2016). GATOR1 is a protein complex consisting of NPRL2, NPRL3, and DEPDC5
that directly interacts with RagA/B, inhibiting mTORC1 (Kim et al., 2015; Ma et al., 2017).
GATOR2, another protein complex consisting of WDR24, WDR59, MIOS, SEH1L, and SEC13,
inhibits GATOR1 to activate mTORC1 (Cai et al., 2016; Parmigiani et al., 2014). When cells are
starved of leucine, sestrin can bind to and inhibit GATOR2. When leucine is present, it binds to
sestrin instead, allowing GATOR2 to bind to GATOR1 and activate mTORC1 (Kim and Guan,
2019; Parmigiani et al., 2014).
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Methionine levels can also be sensed by mTOR signaling pathway components, albeit not
directly. S-adenosyl methionine (SAM) levels are sensed by SAM sensor upstream of mTORC1
(SAMTOR). SAMTOR interacts with GATOR1, inhibiting mTORC1 (Gu et al., 2017). When
there are sufficient levels of SAM, SAM binds to SAMTOR, disrupting its interaction with
GATOR1, and thereby activating mTORC1 (Gu et al., 2017; Kim and Guan, 2019).
To add to the complexity, some amino acids levels are sensed by amino acid transporters,
that can signal mTOR in a Rag-dependent or Rag-independent manner (Goberdhan et al., 2016).
For example, glutamine can promote mTORC1 localization to the lysosome even in cells with Rag
knocked out (Jewell et al., 2015; Nguyen et al., 2017). Interestingly, glutamine efflux through the
bidirectional amino acid transporter SLC7A5/SLC3A3 results in increased leucine uptake, which
can also regulate mTOR activity through Sestrin2 and GATOR complexes (Jewell et al., 2015;
Wolfson et al., 2016).

2.4.3 Oxidative stress sensing by mTOR
The energy status of the cell is signaled to mTOR through AMP-activated protein kinase
(AMPK), which can activate and phosphorylate TSC2 based on the ratio of ATP to ADP and AMP
in the cell (Laplante and Sabatini, 2009a). In cases of mild hypoxia or low cellular glucose, cellular
ATP levels can be reduced and AMP levels can increase, inducing AMPK activation. AMPK
activity conserves ATP levels in the cell, reducing anabolic pathways and increasing glucose
uptake and ATP synthesis (Tokunaga et al., 2004). Hypoxia can also drive TSC1 and TSC2 by
inducing regulated in development and DNA damage response 1 (REDD1) (Laplante and Sabatini,
2009a). REDD1 decreases mTORC1 activation by disrupting TSC2 binding with regulatory
proteins (Saxton and Sabatini, 2017). When there is greater oxidative stress, mTOR can also
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modulate metabolism by activating HIF-1α, increasing glycolytic flux and decreasing PDH
complex-mediated entry of pyruvate into the mitochondria (McFate et al., 2008; Yeung et al.,
2008).
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Chapter 3: PHGDH as a Mechanism of Resistance in
Metabolically-Driven Cancers

This chapter was adapted from the following published journal article:
Rathore R, Schutt CR, Van Tine BA. “PHGDH as a Mechanism for Resistance in MetabolicallyDriven Cancers”. Cancer Drug Resistance (2020). doi: 10.20517/cdr.2020.46.

3.1 Abstract
At the forefront of cancer research is the rapidly evolving understanding of metabolic
reprogramming within cancer cells. The expeditious adaptation to metabolic inhibition allows cells
to evolve and acquire resistance to targeted treatments, which makes therapeutic exploitation
complex but achievable. 3-phosphoglycerate dehydrogenase (PHGDH) is the rate-limiting enzyme
of de novo serine biosynthesis and is highly expressed in a variety of cancers, including breast
cancer, melanoma, and Ewing’s sarcoma. This review will investigate the role of PHGDH in
normal biological processes, leading to the role of PHGDH in the progression of cancer. With an
understanding of the molecular mechanisms by which PHGDH expression advances cancer
growth, we will highlight the known mechanisms of resistance to cancer therapeutics facilitated
by PHGDH biology and identify avenues for combatting PHGDH-driven resistance with inhibitors
of PHGDH to allow for the development of effective metabolic therapies.
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3.2 Introduction
Recent advances in anti-cancer treatments have been based on the increased identification
of biomarkers that allow for tumour-specific therapy. Biomarker-driven therapies allow for the
differentiation between cancer and host cells, with the potential to decrease the side-effects often
associated with chemotherapy in normal tissue. The hallmarks of cancer, such as rapid growth,
sustained proliferation, and increased invasion and metastasis, can be traced to the activation or
suppression of oncogenes, which can then be used as biomarkers for targeting therapeutics
(Hanahan and Weinberg, 2000).
The progression of cancer is dependent on the cellular metabolism of the tumour (Pavlova
and Thompson, 2016). As such, developing therapeutic methods that target tumour metabolism
has been a growing field. One-carbon metabolism is of importance in cancer metabolism, as this
pathway is necessary for the de novo generation of biomass and other nutrient precursors. Onecarbon metabolism consists of serine biosynthesis, betaine biosynthesis, the folate cycle, and the
methionine cycle. The products of one-carbon metabolism contribute to nucleotide, lipid, and
methylation metabolism, as well as nicotinamide adenine dinucleotide phosphate (NADPH),
reactive oxygen species (ROS), and glutathione synthesis (Corbin and Ruiz-Echevarría, 2016;
Rosenzweig et al., 2018). Of these, the serine biosynthetic pathway is of interest because the rate
limiting enzyme, 3-phosphoglycerate dehydrogenase (PHGDH), is highly expressed in a variety
of cancers and contributes to drug resistance. Both of these facets of PHGDH metabolism are
discussed in detail below.
Importantly, tumor metabolism is highly adaptable, and the metabolic systems of cancer
cells can reprogram in response to nutrient and anabolic precursor availability. As a result, there
is a risk of innate or acquired drug resistance to metabolic inhibitors. In this review, the
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requirement of serine synthesis for cancer metabolism and tumour progression is explored.
Through the biology of PHGDH, mechanisms of resistance to current cancer treatments, as well
as proposed novel treatments, are identified. Understanding the mechanisms of resistance to
metabolic treatments allows for the design of conditionally lethal combination therapies based on
the inherent properties of tumour metabolism that can combat acquired resistance.
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3.3 The Biological Role of PHGDH in Cancer
3.3.1 PHGDH in the untransformed cell
PHGDH is the rate-limiting enzyme of de novo serine biosynthesis. PHGDH catalyses the
conversion

of

the

glycolytic

intermediate

3-phosphoglycerate

(3PG)

to

3-

phosphohydroxypyruvate (3PHP). The PHGDH enzymatic reaction utilizes nicotinamide adenine
dinucleotide (oxidized form, NAD+; reduced form, NADH) as a cofactor, generating NADH as
3PHP is biosynthesized. Phosphoserine aminotransferase (PSAT1) subsequently uses glutamate
to confer a nitrogen unit onto 3PHP, producing alpha-ketoglutarate (αKG) in addition to the serine
precursor, 3-phosphoserine (3PS) (Fan et al., 2015). Finally, phosphoserine phosphatase (PSPH)
converts 3PS to serine (Figure 3.1) (Yang and Vousden, 2016).
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Figure 3.1 – Serine Biology Drives Resistance to Chemotherapies

Figure 3.1 – Serine Biology Drives Resistance to Chemotherapies
PHGDH expression drives resistance to a variety of chemotherapeutics (shown in red) through
modulation of metabolic pathways. (3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP,
phosphoenolpyruvate; PKM2, pyruvate kinase M2; TCA cycle, citric acid cycle; αKG, αketoglutarate; D-2HG, D-2-hydroxyglutarate; PHGDH, 3-phosphoglycerate dehydrogenase; 3PHP, 3-phosphohydroxypyruvate; PSAT, phosphoserine aminotransferase; 3PS, 3-phosphoserine;
PSPH, phosphoserine phosphatase; NAD+, nicotinamide adenine dinucleotide, oxidized; NADH,
nicotinamide
adenine
dinucleotide,
reduced;
Glu,
glutamate;
SHMT,
serine
hydroxymethyltransferase; DHFR, dihydrofolate reductase).
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Serine is required for a variety of biosynthetic and signalling processes (Figure 3.2). Serine
itself can be used for protein and lipid biosynthesis (Gao et al., 2018). The removal of a methylene
unit from serine by serine hydroxymethyltransferase (cytosolic, SHMT1; mitochondrial, SHMT2)
results in the synthesis of other amino acids, including glycine and, through intermediates of the
methionine cycle, cysteine (Anderson and Stover, 2009; Yu et al., 2019). The methylene unit from
serine also serves as a one-carbon donor for the folate cycle. The products of the folate cycle and
the methionine cycle contribute to purine and pyrimidine synthesis, homocysteine recycling for
DNA methylation processes, and the generation of NADH, NADPH, and adenosine triphosphate
(ATP) (Frezza, 2016; Newman and Maddocks, 2017). Additionally, de novo serine biosynthesis
utilizes glutamate and produces αKG, which can be converted to D-2-hydroxyglutarate (D-2HG),
an oncometabolite (Fan et al., 2015). As a result, the increased expression of PHGDH, as well as
the other enzymes in the serine biosynthetic pathway, indicates that cells are utilizing these
processes for proliferation and production of biomass.
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Figure 3.2 – Role of Serine in Cellular Processes

Figure 3.2 – Role of Serine in Cellular Processes
Role of serine in biological processes in the cell. (3PG, 3-phosphoglycerate; PEP,
phosphoenolpyruvate; PKM1/2, pyruvate kinase isoforms M1/M2; PHGDH, 3-phosphoglycerate
dehydrogenase; 3-PHP, 3-phosphohydroxypyruvate; PSAT, phosphoserine aminotransferase;
3PS, 3-phosphoserine; PSPH, phosphoserine phosphatase; NAD+, nicotinamide adenine
dinucleotide, oxidized; NADH, nicotinamide adenine dinucleotide, reduced; Glu, glutamate; αKG,
α-ketoglutarate; SPT, serine palmitoyltransferase; SHMT1, serine hydroxymethyltransferase 1;
5,10-meTHF, 5,10-methylene tetrahydrofolate; mTHF, 5-methyl tetrahydrofolate; THF,
tetrahydrofolate; GSH, reduced glutathione; HCY, homocysteine; SAH, S-adenosyl
homocysteine; SAM, S-adenosyl methionine).
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Serine also plays a role in downstream signalling in the cell. When activated, pyruvate
kinase (PK) catalyses the conversion of phosphoenolpyruvate (PEP) to pyruvate, and is a key
checkpoint for glycolysis (Mazurek, 2011). As such, PK serves an important role in the occurrence
of the Warburg effect, that describes tumour cells as more highly glycolytic than oxidative
(Chiavarina et al., 2011). In its inactive form, PK shunts glucose carbons back through glycolytic
intermediates, supporting the utilization of glucose for biomass synthesis rather than mitochondrial
energy production (Prakasam et al., 2018). PK exists in the body in two isoforms (isoform M1,
PKM1; isoform M2, PKM2). PKM1 is mainly found in skeletal muscle and brain cells. PKM2 is
expressed at a significantly higher ratio in proliferating cells and is the more dominant isoform in
cancer; however, PKM1 has been shown to be expressed in certain cancers and cancer-associated
fibroblasts as well (Chiavarina et al., 2011; Iqbal et al., 2014). Importantly, PKM2 is enzymatically
activated by the direct binding of serine to an allosteric site (Chaneton et al., 2012). Inactive PKM2
can therefore respond to changes in serine availability and direct glycolytic intermediates through
3PG into the biosynthesis of serine, activating PKM2. PKM2 expression is also mediated by a
series of pathways, including phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of
rapamycin (mTOR) (Prakasam et al., 2018; Ye et al., 2012).

3.3.2 Incidences of Decreased PHGDH
Serine deficiency can be extremely detrimental to cells, resulting in limited cellular
proliferation and cell cycle arrest (Sayano et al., 2016). The first report of PHGDH deficiency was
described in 1996, where two brothers with decreased plasma concentrations of serine and glycine
presented with a severe neurological syndrome (Jaeken et al., 1996). This decrease in serine and
glycine was associated with decreased PHGDH expression and activity in the brains of the patients.
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Importantly, subsequent studies found that, although alternate pathways of obtaining serine exist,
PHGDH deficiency resulted in significantly lower plasma serine levels (Shaheen et al., 2014).
Later studies found that phenotypes of PHGDH deficiency can exist on a spectrum and identified
Neu-Laxova syndrome as a more severe example of PHGDH deficiency. Neu-Laxova syndrome
is an autosomal recessive disorder caused by mutations to PHGDH and subsequent loss of serine,
and is characterized by neurological impairment, impaired fetal development, and skeletal
anomalies (Acuna-Hidalgo et al., 2014; Shaheen et al., 2014).
At the cellular level, PHGDH deficiency can result in loss of DNA methylation. As the
methylene unit provided to the folate cycle by the conversion of serine to glycine can transfer into
the methionine cycle, serine indirectly supports the recycling of homocysteine to methionine, as
well as the generation of precursors for S-adenosylmethionine (SAM) (Herbig et al., 2002; Sibani
et al., 2002). SAM is a common methyl-group donor required for DNA methylation (Pike et al.,
1978). In acute serine-starvation conditions, SAM is no longer used to methylate DNA and RNA
(Maddocks et al., 2016). Importantly, metabolic remodelling in cells during acute serine starvation
allow for the upregulation of serine biosynthesis and serine uptake, to compensate for this loss
(Maddocks et al., 2013).
De novo serine biosynthesis also provides the precursors for the generation of
phosphatidylserine and sphingolipids; PHGDH deficiency can alter sphingolipid homeostasis by
prompting the generation of deoxysphingolipids (Esaki et al., 2015; Lowther et al., 2012).
Sphingolipids are produced by the enzyme serine palmitoyltransferase (SPT) that incorporates
serine into palmitoyl-coA to produce a precursor to sphingosine. With decreased environmental
serine, SPT instead utilizes alanine as a cofactor, resulting in the generation of deoxysphingolipids
(Lone et al., 2019; Lowther et al., 2012). Deoxysphingolipids cannot be incorporated into cellular
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membranes, and increased levels of deoxysphingolipids can result in mitochondrial dysfunction
(Alecu et al., 2017).
The results of decreased serine and loss of PHGDH activity are generally not beneficial to
cells, unless extracellular serine concentrations are sufficiently high to support cellular utilization
of the amino acid. The mechanism of negative regulation of PHGDH, therefore, is critical to
explore. In melanoma, PHGDH expression is transcriptionally downregulated by wildtype p53
(Ou et al., 2015). It was found that PHGDH was a transcriptional target of the tumour suppressor
p53, and that suppression of PHGDH resulted in promotion of apoptosis in p53-wildtype
melanoma. These findings indicate the importance of PHGDH in the baseline functioning of the
cell, but also highlight the utility of increased PHGDH as an oncogene in cancer.
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3.4 The Tumorigenic Consequences of Elevated PHGDH
The increased expression of serine synthetic enzymes can signal that a cell is proliferating
and generating biomass at a rapid rate, a hallmark of cancer (Hanahan and Weinberg, 2011).
PHGDH has been demonstrated to be upregulated in a wide variety of biologically distinct cancers,
including osteosarcoma, colorectal cancer (Jia et al., 2016), gastric cancer (Xian et al., 2016),
breast cancer (Locasale et al., 2011; Possemato et al., 2011), melanoma (Mullarky et al., 2011),
Ewing’s sarcoma (Issaq et al., 2020), cervical cancer (Jing et al., 2013), pancreatic cancer (Song
et al., 2018), thyroid cancer (Sun et al., 2016), colon cancer (Yoon et al., 2015), lung
adenocarcinoma (Zhang et al., 2017), and non-small cell lung cancer (Zhu et al., 2016).
Furthermore, increased PHGDH expression has been linked to brain metastasis (Ngo et al., 2020).

3.4.1 Mutations to TP53
As previously stated, wildtype p53 can transcriptionally decrease gene expression of
PHGDH (Ou et al., 2015). Most of the cancers that present an overexpression of PHGDH harbour
TP53 mutations, including osteosarcoma (90 % TP53 mutation), colorectal cancer (55% - 60%
TP53 mutation), intestinal gastric cancer (66% TP53 mutation), melanoma (85% TP53 mutation),
and non-small cell lung cancer (50% TP53 mutation) (Bodner et al., 1992; Busuttil et al., 2014;
Nakayama and Oshima, 2018; Stretch et al., 1991; Wunder et al., 2005). This suggests that cancers
with non-wildtype TP53 may have increased PHGDH expression, though this has not yet been
explored. Additionally, mutant p53 can regulate PKM2 through an mTOR-mediated
phosphorylation at Tyr105 (Dando et al., 2016; Wu and Le, 2013). The effects that mutant p53 can
have on serine synthetic enzymes and downstream metabolic enzymes can contribute to mutant
p53-driven tumorigenesis.
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3.4.2 Cell Growth and Proliferation
Increased PHGDH activity results in increased de novo serine biosynthesis. As previously
described, serine supports a variety of cellular processes, including amino acid, nucleotide, and
lipid synthesis, increased DNA methylation, and indirect αKG generation. De novo serine
biosynthesis can in turn drive the synthesis of glycine, as well as the synthesis of cysteine from
homocysteine within the methionine cycle, supporting protein synthesis (Singh et al., 2018; Yu et
al., 2019). Glycine is also directly incorporated into purine nucleotides. Furthermore, serine can
be incorporated into lipids to produce phosphoserine and is a precursor to sphingosine, from which
all sphingolipids are derived (Mattaini et al., 2016). These processes support the generation of
biomass and nucleic acid replication for the rapid proliferation of cancer cells.

3.4.3 Redox Homeostasis
The increased production of glycine and cysteine from serine can also contribute to
maintenance of redox balance in cells, as these are the precursors for glutathione (Amelio et al.,
2014). Glutathione, which exists in a reduced form (GSH) and an oxidized form (GSSG is the
primary ROS scavenger of the cell (Estrela et al., 2006). Generation of αKG, an essential
component of the citric acid (TCA) cycle, also contributes to maintaining redox balance, as αKG
has antioxidative functions in the cell (Liu et al., 2018). Furthermore, PHGDH can directly catalyse
the conversion of αKG to D-2-hydroxyglutarate (D-2HG), an oncometabolite (Fan et al., 2015).
This reverse enzymatic activity requires the oxidation of NADH to NAD+, an important co-factor
in metabolism and redox homeostasis (Badur et al., 2018; Fan et al., 2015).
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3.4.4 The NAD+ Salvage Pathway
PHGDH utilizes NAD+ as a co-factor for enzymatic activity, producing NADH during the
synthesis of 3PHP from 3PG (Samanta and Semenza, 2016). In order to be utilized, NAD+ must
be continually synthesized from tryptophan or regenerated from NADH. The NAD+ salvage
pathway occurs through the recycling of nicotinamide to nicotinamide mononucleotide, and is
therefore required for functional serine biosynthesis (Murphy et al., 2018). Conversely,
mitochondrial serine catabolism has been demonstrated to supplement NADH levels through the
folate cycle, suggesting that PHGDH and serine metabolism are directly regulated by
NAD+/NADH availability (Yang et al., 2020).

3.4.5 Metastasis
Increased PHGDH expression has been demonstrated to not only promote cancer growth
and proliferation, but also drive secondary tumour formation and metastasis (Samanta et al., 2016).
In a study on lung metastasis, increased PHGDH increased hypoxia-inducible factor (HIF)-target
gene expression. As increased PHGDH results in elevated production of glutathione, the resultant
hypoxic conditions could be maintained by glutathione, subsequently executing metastatic
programs (Samanta et al., 2016). Furthermore, in a study in brain metastases, increased PHGDH
expression was correlated with increased metastatic potential to the brain. Interestingly, in this
study, inhibiting PHGDH attenuated metastasis without affecting extra-cranial tumour growth,
suggesting that the consequences of increased PHGDH expression were directly related to
upregulated metastasis (Ngo et al., 2020). Finally, this study highlighted the limited environmental
availability of serine in the brain, demonstrating the subsequent reliance on de novo serine
biosynthesis (Ngo et al., 2020).
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Taken together, baseline PHGDH expression contributes to de novo serine biosynthesis in
the cell and supports a multitude of cellular pathways. Overexpression of PHGDH drives
numerous pathways that are particularly useful for the initiation and progression of cancer.
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3.5 The Role of Increased PHGDH in Cancer Drug
Resistance
Given that increased PHGDH contributes to tumorigenesis, the role of PHGDH in cancer
resistance is multi-faceted. Elevated PHGDH expression drives a reliance on certain metabolic
pathways that cancer therapeutics directly target, thus resulting in a series of inhibitors to which
cancers with increased PHGDH can develop resistance (Figure 3.1).

3.5.1 Tyrosine Kinases
Tyrosine kinases catalyse the phosphorylation of tyrosine residues, and have been shown
to be constitutively active in oncogenic programs (Paul and Mukhopadhyay, 2004). Sorafenib
targets multiple tyrosine kinases, primarily the rapidly accelerated fibrosarcoma kinase (RAF)
pathway, but also the vascular endothelial growth factor receptor (VEGFR) and platelet-derived
growth factor (PDGFR) pathways (Schöffski et al., 2006; Wei et al., 2019). The inhibition of RAF1 by sorafenib leads to inhibition of cellular proliferation and tumour growth. RAF-1 inhibition
elevates ROS levels through stimulation of the Raf/MEK/Erk pathway, causing apoptosis (Cesi et
al., 2017). Sorafenib has been approved for use in hepatocellular carcinoma (HCC), renal cell
cancer, and thyroid cancer (Larkin and Eisen, 2006). A study exploring the mechanisms driving
sorafenib resistance found that increased PHGDH expression was a critical for this process in HCC
(Wei et al., 2019). As PHGDH and the serine synthesis pathway generate antioxidants (including
glutathione and αKG), elevated PHGDH can combat the increased ROS levels induced by
sorafenib treatment, thereby repressing apoptosis. Additionally, A-RAF, a RAF paralog, increases
activation of PKM2 in the presence of serine, offering an additional target for sorafenib and another
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resistance mechanism in PHGDH-overexpressed cancers (Desideri et al., 2015; Prakasam et al.,
2018).

3.5.2 Epidermal Growth Factor Receptor
Erlotinib is an inhibitor of epidermal growth factor receptor (EGFR), another tyrosine
kinase associated with a number of signalling cascade pathways, including the Ras/Raf/MEF/ERK,
PI3K/Akt, and STAT pathways (Wieduwilt and Moasser, 2008). The MEF/ERK pathway in
particular links EGFR signalling to increased glycolysis, and Akt pathway signalling links EGFR
to increased PKM2 activity (Yang et al., 2012a, 2012b). EGFR has been demonstrated to be a
driver of lung adenocarcinoma, and erlotinib treatment has been approved for treatment of nonsmall cell lung cancer in patients with and without EGFR mutations (Normanno et al., 2003; Wang
et al., 2012).
Erlotinib binds to EGFR and inhibits downstream signalling cascades. Disruption of these
signalling cascades results in decreased cell cycle progression, oxidative stress, and apoptosis.
PHGDH is upregulated in erlotinib-resistant lung adenocarcinomas, likely due to the upregulation
of glutathione and αKG synthesis as a cellular response to oxidative stress (Dong et al., 2018).
Furthermore, increased PHGDH expression and serine biosynthesis drives increased PKM2
activity and glycolysis, increasing the utilization of EGFR-related pathways.

3.5.3 Hypoxia-inducible Factors
Hypoxia-inducible factors (HIFs) contain two subunits that have transcription factor
activity in hypoxic cells. The α-subunit HIF2α mediates redox homeostasis and can therefore
modulate the effects of drugs such as sorafenib by decreasing resultant ROS levels and improving
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oxygen supply (Lee et al., 2019). HIF2α is regulated by c-Myc activation and promotes hypoxic
cell proliferation (Gordan et al., 2007). Therapies targeting HIF2α have therefore been explored
as replacements for some tyrosine kinase inhibitors, such as sunitinib, in clear-cell renal cell
carcinoma (Yoshino et al., 2017). PHGDH is significantly overexpressed in HIF2α knockout
tumours, as well as tumours that have shown sunitinib resistance (Yoshino et al., 2017). The redox
homeostasis maintenance conferred by PHGDH overexpression may be implicated here.
Interestingly, HIF1α, but not HIF2α, can also regulate the expression of SHMT, the enzyme
that converts serine to glycine (Ye et al., 2014). Increased SHMT1/2 expression can drive serine
catabolism, increasing mitochondrial NADH production and fuelling the NAD+ salvage pathway
required for PHGDH activity and serine biosynthesis (Murphy et al., 2018; Ye et al., 2014).

3.5.4 The Proteasome
Based on the potential role of c-Myc in resistance to HIF2α inhibitors, the role of NMYC
in systems associated with PHGDH has been explored. NMYC activates ATF4, subsequently
increasing PHGDH expression and activating a dependence on the serine biosynthetic pathway
(Selvarajah et al., 2019; Xia et al., 2019; Zhao et al., 2016). Proteasome inhibitors downregulate
c-Myc, and have therefore been utilized to combat c-Myc-driven cancers (Wang et al., 2019).
Bortezomib is a proteasome inhibitor that has been highly effective for the treatment of multiple
myeloma, a cancer in which c-Myc is highly active (Chng et al., 2011). Proteasome inhibition by
bortezomib results in the accumulation of unfolded proteins in the endoplasmic reticulum,
resulting in cell death from the overproduction of reactive oxygen species (ROS) (Masaki, 2016).
PHGDH is upregulated in bortezomib-resistant multiple myeloma; interestingly, this mechanism
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has also been identified as being through increased glutathione synthesis (Rizzieri et al., 2019; Wu
et al., 2020b; Zaal et al., 2017) and subsequent ROS scavenging.

3.5.5 Mitogen-activated protein kinase kinase
Mitogen-activated protein kinases (MAPK) and extracellular signal-regulated kinases
(ERK) make up a series of proteins that transduce signals from the extracellular environment to
inform cellular processes. This pathway can be overactive in some cancers, and activates
transcription factors that are responsible for the progression of cancers such as melanoma
(Dahlman et al., 2012; McCain, 2013). In melanoma, tumour growth is enhanced through
activation of the MAPK pathway, which is primarily driven by activating mutations in two
oncogenes: BRAF and NRAS (Heppt et al., 2017). Mitogen-activated protein kinase kinase (MEK)
enzymes are a part of the MAPK/ERK pathway, and activate the final kinases in this signalling
pathway (McCain, 2013). MEK inhibitors target this pathway and inhibit cell proliferation,
ultimately causing apoptosis (Cheng and Tian, 2017). Importantly, BRAF mutations can increase
susceptibility to MEK inhibitors; however, NRAS mutations that can over-activate MEK/ERK
signalling can lead to resistance to MEK inhibitors (Dahlman et al., 2012; Nguyen et al., 2020).
In an NRAS mutation model of melanoma, PHGDH was found to be upregulated. PHGDH
is upregulated in melanoma at baseline, and is also upregulated in MEK inhibitor-resistant
melanomas (Nguyen et al., 2020; Ross et al., 2017). Overactive MEK/ERK signalling in BRAFand NRAS-mutated cancers can overexpress PHGDH through ATF4 activation, driving utilization
of the serine synthesis pathway to generate glutathione as a resistance mechanism. In addition,
increased levels of folic acid, which can occur through increased flux of carbons from serine
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synthesis through the folate cycle, is a possible mechanism of resistance to MEK inhibitors in
BRAF inhibitor-resistant melanomas (Nguyen et al., 2020; Ross et al., 2017).

3.5.6 Cisplatin
PHGDH is elevated in cervical adenocarcinoma, and is associated with poorer prognosis
(Jing et al., 2015). The first-line therapy for cervical adenocarcinoma is platinum-based
chemotherapy. Cisplatin induces the DNA damage response in cells and causes mitochondrial
apoptosis through Bcl2 (Jing et al., 2015). Given that PHGDH drives the indirect synthesis of
nucleotides, upregulation of PHGDH could improve the DNA damage response in cells treated
with cisplatin. PHGDH knockdown in cervical adenocarcinoma resulted in a decrease in Bcl2
expression, suggesting that baseline high PHGDH could also result in increased Bcl2, thereby
mitigating the mitochondrial apoptotic response (Jing et al., 2015). Interestingly, in ovarian
carcinoma, increased PHGDH is a marker of cisplatin sensitivity, rather than resistance (Teng et
al., 2014). Further exploration of this and other pathways involved in cisplatin resistance is
therefore needed.

3.5.7 Other therapies
Elevated PHGDH also has the potential to play a role in resistance to therapies that have
not yet been mechanistically explored. A critical therapy to therefore mention is the use of folate
cycle inhibitors such as methotrexate and raltitrexed (Lee and Wong, 2017). Methotrexate targets
dihydrofolate reductase (DHFR), while raltitrexed targets thymidylate synthase (TYMS). These
drugs require functioning folate cycles in order to be effective, and increased expression of folaterelated enzymes is highlighted as a current mechanism of resistance (Guo et al., 1999; Hagner and
52

Joerger, 2010). As increased serine synthetic pathway activity can contribute more methyl units to
the folate cycle, elevated PHGDH could be directly related to resistance to methotrexate treatment.
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3.6 The Inhibition of PHGDH to Combat Chemo-Resistance
3.6.1 Single-agent inhibition of PHGDH
Given the increased expression of PHGDH in a variety of cancers, the single-agent
inhibition of PHGDH seems to be a promising prospect for cancer therapy. A series of small
molecule inhibitors against PHGDH have been developed, primarily targeting the enzymatic
activity of PHGDH. These inhibitors include NCT-503, CBR-5884, PKUMDL-WQ-2101, BI4924, and others under preclinical and clinical development (Locasale et al., 2011; Mullarky et al.,
2016; Reid et al., 2018; Rohde et al., 2018; Wang et al., 2017a; Weinstabl et al., 2019). It is
important for the field to validate any finding with small-molecule inhibitors with knockdown and
rescue or structural analysis to ensure that the effects of the drug are as a result of PHGDH biology
and not an off-target effect of small-molecule inhibitors as a class of inhibitors. Iterations of these
compounds have shown increasingly less off-target effects, with structure-based approaches used
to synthesize PKUMDL-WQ-2101 in order to confirm specific binding to PHGDH (Wang et al.,
2017a). PKUMDL-WQ-2101 and NCT-503 have been widely used in in vitro and in vivo research
to interrogate the role of PHGDH and serine metabolism in normal and cancer cells (Pacold et al.,
2016; Wang et al., 2017a).
When cancer cells with elevated PHGDH expression are treated with high doses of NCT503, cellular proliferation is attenuated and, in some cases, cell death is observed (Issaq et al.,
2020; Pacold et al., 2016; Wu et al., 2020b). This phenotype can also be observed in vivo, as
numerous studies have demonstrated that NCT-503 treatment results in decreased tumour growth
for tumours and cell line-derived xenografts of PHGDH-high cancers. Knockout studies of
PHGDH have also suggested mild suppressive effects on proliferation (Wei et al., 2019).
Furthermore, metabolites downstream of the serine biosynthetic pathway, such as one carbon units,
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folate intermediates, and pyrimidine intermediates, were also dysregulated by PHGDH inhibition
(Pacold et al., 2016; Reid et al., 2018).
As of yet, direct PHGDH inhibition has not been tested in human clinical studies. However,
as cells with increased PHGDH expression can develop resistance to apoptotic cell death by
various drug treatments, cells treated with PHGDH inhibitors can rapidly alter their metabolism to
take advantage of other mechanisms of fuel oxidation and redox maintenance (Ravez et al., 2017).
As a result, PHGDH inhibition must be approached in a different way to optimize it for clinical
development.

3.6.2 Dual-agent inhibition of PHGDH and associated pathways
Given the highly adaptable nature of cancer metabolism, synergistic drug combinations are
the future of metabolism-based drug resistance. Identifying increased PHGDH expression as a
resistance mechanism for a variety of cancer therapeutics offers the opportunity to combine
PHGDH inhibition with small molecule therapeutics. For example, increased PHGDH expression
has been associated with both erlotinib and cisplatin resistance. Treatment with NCT-503 in these
systems conferred sensitivity to the targeted therapy erlotinib and the chemotherapy cisplatin,
respectively (Dong et al., 2018; Jing et al., 2015). Furthermore, increased PHGDH expression was
associated with resistance to sorafenib (Wei et al., 2019). Treatment with NCT-503 mildly
suppressed proliferation in hepatocellular carcinoma cells, but combining NCT-503 with sorafenib
caused complete attenuation of proliferation and induced significant apoptosis (Wei et al., 2019).
Beyond the known therapies that PHGDH confers resistance to, the combination of NCT503 with the targeting of other cellular pathways can mitigate resistance. An understanding of the
downstream mechanistic actions of PHGDH activity can unveil new therapies that could have
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action in PHGDH-overexpressed cancers. Given that PHGDH activity requires the NAD+ salvage
pathway, a study that explored the use of NCT-503 with a nicotinamide phosphoribosyltransferase
(NAMPT) inhibitor. This combination with a NAMPT that blocks the NAD+ salvage pathway
resulted in synergistic cell death (Issaq et al., 2020). Recent studies have also explored the
metabolic implications and pro-survival adaptations that occur as a result of PHGDH inhibition,
implicating decreased TCA cycle activity, mTOR-independent and -dependent autophagy, and
enhanced lipid metabolism and formation of lipid bodies (Esaki et al., 2015; Pacold et al., 2016;
Sharif et al., 2018; Sim et al., 2020). The combination of PHGDH inhibition with inhibitors of
these pro-survival metabolic adaptations should therefore yield synergistic and dramatic results in
PHGDH-high cancers.
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3.7 Concluding Remarks
3-phosphoglycerate dehydrogenase (PHGDH) expression in cancer has been linked to
shorter progression-free survival, increased rates of metastasis, and poorer overall survival. An indepth analysis of the biological consequences of enhanced PHGDH expression shows the links
between de novo serine biosynthesis and a series of metabolic pathways that are targeted by current
chemotherapies. In particular, cancers are capable of developing resistance to chemotherapies that
induce apoptosis through increased ROS by increasing PHGDH, as PHGDH generates the
necessary metabolic precursors for antioxidant and ROS scavenging activity. Therefore, increased
levels of PHGDH, while contributing to tumorigenicity, can contribute to the innate or acquired
resistance of cancers to current chemotherapies.
The direct inhibition of PHGDH by small-molecule inhibitors results in a decrease in
cellular proliferation in vitro, with marginal inhibition of tumour growth in vivo. Inhibition of
PHGDH also results in a series of metabolic adaptations that can acutely sensitize tumour cells to
various chemotherapies. Current and future research on the adaptive mechanisms of resistance to
PHGDH is needed to harness the upregulation of PHGDH in cancer. A multi-agent metabolic
therapy can then be developed utilizing PHGDH as a biomarker for treatment efficacy and
potential resistance.
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Chapter 4: Inhibition of Serine Biosynthesis Induces
mTORC1 Activation as a Pro-Survival Mechanism

This chapter is in press as an original research article. The citation will be:
Rathore R, Caldwell KE, Schutt CR, Brashears CB, Prudner BC, Ehrhardt WR, Leung CH, Lin
H, Daw NC, Beird HC, Giles A, Wang WL, Lazar AJ, Chrisinger JSA, Livingston JA, Van Tine
BA. “Metabolic Compensation Activates Pro-Survival mTORC1 Signaling Upon 3Phosphoglycerate Dehydrogenase Inhibition in Osteosarcoma”. Cell Reports (2020).

4.1 Abstract
Osteosarcoma is the most common pediatric and adult primary malignant bone cancer.
Curative regimens target the folate pathway, downstream of serine metabolism, with high-dose
methotrexate. The rate-limiting enzyme in the biosynthesis of serine from glucose, 3phosphoglycerate dehydrogenase (PHGDH), was examined, and an inverse correlation between
PHGDH expression and relapse-free and overall survival in osteosarcoma patients was found.
PHGDH inhibition in osteosarcoma cell lines attenuated cellular proliferation, without causing cell
death, prompting a robust metabolic analysis to characterize pro-survival compensation. Using
metabolomic and lipidomic profiling, cellular response to PHGDH inhibition was identified as
accumulation of unsaturated lipids, branched chain amino acids, and methionine cycle
intermediates, leading to activation of pro-survival mTORC1 signaling. Increased mTORC1
activation sensitized cells to mTORC1 pathway inhibition, resulting in significant, synergistic cell
death in vitro and in vivo. Identifying a therapeutic combination for PHGDH-high cancers offers
preclinical justification for the first dual metabolism-based combination therapy for osteosarcoma.

58

4.2 Introduction
Osteosarcoma is the most common type of primary malignant bone tumor in both children
and adults, accounting for approximately 4 % of all childhood cancers and 56 % of pediatric
malignant bone tumors (Geller and Gorlick, 2010). Current curative therapy for osteosarcoma is
neoadjuvant chemotherapy, consisting of a combination of cisplatin, doxorubicin, and high-dose
methotrexate, resection, and additional cycles of chemotherapy (Heare et al., 2009). High-dose
methotrexate has been a key component of standard-of-care treatment for osteosarcoma since the
1970s, based on small cohort clinical trials that measured levels of tumor necrosis at time of
surgery (Grem et al., 1988; Rosen et al., 1974, 1979). While these trials showed that the majority
of the patients demonstrated no viable tumor tissue with methotrexate treatment, it was noted that
high levels of toxicity were associated with this treatment (Li et al., 2019; Perez et al., 1978; Rosen
et al., 1974, 1979). The doses required for histologic response were as high as 8-20 g/m2, which
can result in kidney injury or liver toxicity, especially in adult patients (Howard et al., 2016; Rosen
et al., 1974; Wippel et al., 2019). Methotrexate can also have long-term effects on fertility, a
consequence of special concern for pediatric patients and adults of childbearing age (Lloyd et al.,
1999). Therefore, less toxic therapies for osteosarcoma have been the goal of the field (Shaikh et
al., 2016).
A variety of molecular targeted therapies have been investigated for osteosarcoma.
Recently, clinical trials have focused on tyrosine kinase inhibitors (Davis et al., 2019; Italiano et
al., 2020). mTOR has also been a target of interest in osteosarcoma; however, single agent studies
of mTOR inhibitors have failed to show meaningful clinical efficacy in osteosarcoma trials (Ding
et al., 2016). Combinations of mTOR inhibitors with inhibitors of other pathways, including a trial
exploring the tyrosine kinase inhibitor sorafenib with mTOR inhibition (Grignani et al., 2015),
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have also been explored, suggesting that molecular targets based on tumor-specific biomarkers are
an active avenue for the development of new therapies. However, no agents have been added to
the front line therapy since the addition of high-dose methotrexate.
At the cellular level, methotrexate inhibits dihydrofolate reductase (DHFR), a component
of the folate cycle. Through the input of a single carbon unit from the conversion of serine to
glycine, the folate cycle catalyzes the production of purines and pyrimidines within the cell.
Methotrexate-mediated inhibition of DHFR decreases tetrahydrofolate levels, resulting in
decreased methylation, impaired DNA synthesis, and diminished nucleotide synthesis (Tian and
Cronstein, 2007). These effects have made the folate cycle, and more broadly, one-carbon
metabolism, a key player in the evolution of cancer research (Ducker and Rabinowitz, 2017).
Serine hydroxymethyl transferase (SHMT) catalyzes the conversion of serine and
tetrahydrofolate (THF) to glycine and 5,10-methylene-THF, thus transferring a one-carbon unit
into the folate cycle (García-Cañaveras et al., 2020). Proliferating cells can obtain this serine
exogenously or through de novo serine biosynthesis from glucose. The rate-limiting enzyme of
serine biosynthesis, 3-phosphoglycerate dehydrogenase (PHGDH), has been identified as being
upregulated in a large subset of cancers, including melanoma (Mullarky et al., 2011), Ewing
sarcoma (Issaq et al., 2020), breast (Locasale et al., 2011; Possemato et al., 2011), colorectal (Jia
et al., 2016), pancreatic (Song et al., 2018), and non-small cell lung cancers (Zhu et al., 2016).
PHGDH

converts

the

glycolytic

intermediate

3-phosphoglycerate

(3PG)

into

3-

phosphohydroxypyruvate (3PP), producing NADH from NAD+ as a reaction byproduct (Fan et
al., 2015). Increased PHGDH levels and subsequent increases in de novo serine biosynthesis result
in the upregulation of the cellular events fueled by the folate cycle, including increased DNA
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synthesis and increased biomass production, and can also contribute to tumor stem cell
differentiation (Baksh et al., 2020; Possemato et al., 2011).
Given the importance of DHFR inhibition, PHGDH inhibition has been explored as a
possible replacement for methotrexate and other folate pathway inhibitors. NCT-503 was
identified in a screen of PHGDH inhibitors to have inhibitory capacity in vitro and in vivo (Pacold
et al., 2016). Several other small molecule PHGDH inhibitors have been identified to have similar
cytostatic effects in vitro (Mullarky et al., 2016; Wang et al., 2017a). Investigation of broader
metabolic changes due to PHGDH inhibition have highlighted continued glycolytic flux of
glucose, as well as increased total intracellular serine (Pacold et al., 2016). Notably, PHGDH
inhibition in PHGDH-high cell lines has primarily shown a decrease in proliferation, with cell
death only seen at high concentrations that are likely not clinically translatable (Pacold et al.,
2016).
This study demonstrates that high levels of PHGDH correlated with both poor overall
relapse-free and poor overall survival outcomes in osteosarcoma patients treated with standard
chemotherapy. PHGDH inhibition has a cytostatic effect, consistent with previous publications in
other PHGDH-high cancers (Mullarky et al., 2016; Wang et al., 2017a; Wei et al., 2019). Given
the metabolic systems associated with serine biosynthesis; metabolomics, lipidomics, and gene
expression analyses were conducted. These data showed that cells treated with the PHGDH
inhibitor NCT-503 accumulated a series of metabolites, including unsaturated fatty acids and
branched chain amino acids, that resulted in pro-survival activation of the mTORC1 signaling
network. Cells treated with a combination of NCT-503 and perhexiline, a non-rapalog inhibitor of
the mTORC1 pathway (Balgi et al., 2009), exhibited significant cell death in vitro and in vivo. The
mechanism of perhexiline in this system was also explored, with the accumulation of branched
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chain amino acids and methionine cycle intermediates, suggesting involvement of the SAMTORGATOR1-KICSTOR pathway (Gu et al., 2017; Wolfson et al., 2017). Taken together, these data
suggest that activation of the mTORC1 signaling pathway in osteosarcoma can sensitize cells to
treatment with metabolically active mTORC1 inhibitors. These findings offer the preclinical
justification for the first metabolic therapy for osteosarcoma.
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4.3 Materials and Methods
4.3.1 Cell culture
All cell lines (NOS1, Saos2, U2OS, MG63, MNNG, MDA-MB-231, and MDA-MB-468)
were obtained from ATCC (Manassas, VA, USA). NOS1, Saos2, U2OS, and MNNG were
cultured in MEM (Cat # 11095072, Gibco, Thermo Fisher, Waltham, MA) supplemented with 10
% FBS (Cat # S11150, R&D Systems, Bio-Techne, Minneapolis, MN), 1.3 %
penicillin/streptomycin (Cat # 15140122, Gibco, Thermo Fisher, Waltham, MA), 286 µM serine
(Cat # AAJ6218709, Fisher Scientific, Hampton, NH) and 286 µM glycine (Cat # 67419, SigmaAldrich, St. Louis, MO). MG63, MDA-MB-231, and MDA-MB-468 were cultured in DMEM (Cat
# 11965084, Gibco, Thermo Fisher, Waltham, MA) supplemented with 10 % FBS and 1.3 %
penicillin/streptomycin. All cells were cultured in prophylactic plasmocin (Cat # ant-mpp,
InvivoGen, San Diego, CA) and checked regularly for mycoplasma contamination.

4.3.2 NucRed and shPHGDH Cell Line Generation
All cell lines were transduced with IncuCyte NucLight Red lentivirus reagent (EF-1 Alpha
promoter, Puromycin selection) (Cat # 4476, Sartorius, Ann Arbor, MI, USA). Briefly, cells were
seeded and allowed to adhere for 24 hours to reach approximately 20-40 % confluence. NucLight
reagent was diluted in DMEM containing 8 µg/mL polybrene (Cat # sc-134220, Santa Cruz
Biotechnology, Dallas, TX) and added to cells for 48 hours. Media was then replaced with fresh
DMEM containing 3 µg/mL puromycin (Cat # MIR 5940, Mirus Bio, Madison, WI). Red
fluorescence was monitored on the IncuCyte ZOOM system (Sartorius, Ann Arbor, MI), and
analyzed using the IncuCyte image analysis software (Sartorius, Ann Arbor, MI). Similarly,
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shPHGDH cells were generated using lentiviral transduction particles (shPHGDH_1,
TRCN0000028520, Sigma Aldrich, St. Louis, MO, USA; shPHGDH_2, TRCN0000233033,
Sigma Aldrich, St. Louis, MO, USA). shGFP vectors were utilized as transduction controls.
Knockdown of PHGDH was validated using the Wes Automated Western Blotting System
(ProteinSimple, Bio-Techne, Minneapolis, MN), which uses automated capillary technology to
measure protein expression and total protein concentration, per manufacturer’s protocol.

4.3.3 Compounds
Methotrexate (Cat # 13960, Cayman Chemical, Ann Arbor, MI) was solubilized in DMSO
(Cat # D2438, Sigma Aldrich, St. Louis, MO). All other compounds were purchased from Sigma
Aldrich (St. Louis, MO). NCT-503 inactive control (Cat # SML1671) was solubilized in DMSO
and used at 10 µM unless otherwise specified. NCT-503 (Cat # SML1659) was solubilized in
DMSO and used at 15 µM unless otherwise specified. All assays using NCT-503 contained 10 µM
NCT-inactive in solution. PKUMDL-WQ-2101 (Cat # SML1970) was solubilized in DMSO and
used at 10 µM unless otherwise specified. BPTES (Cat # SML0601) was solubilized in DMSO.
Rapamycin (Cat # R8781) was purchased as a 2.5 mg/mL solution in DMSO. Perhexiline (Cat #
SML0120) was solubilized in DMSO. Etomoxir (Cat # 5.09455) was purchased as a 50 mM
solution in water.

4.3.4 Proliferation and Cell Death Assays
NucRed cells were seeded in 96 well tissue-culture plates (Cat # TP92096, Midwest
Scientific, Valley Park, MO). At time of treatment, culture media was removed from wells, and
was replaced with treatment condition of interest, diluted in phenol red-free MEM (Cat #
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51200038, Gibco, Thermo Fisher, Waltham, MA) supplemented with 10 % FBS or 10 % dialyzed
FBS (Cat # A3382001, Gibco, Thermo Fisher, Waltham, MA) or 10 % lipoprotein-depleted FBS
(Cat # 880100-5, Kalen Biomedical, Germantown, MD), 2 mM L-glutamine (Cat # 25030081,
Gibco, Thermo Fisher, Waltham, MA), 286 µM serine, and 286 µM glycine. Red nuclear
fluorescence was monitored on the IncuCyte ZOOM system and analyzed using the IncuCyte
image analysis software. Proliferation was normalized to red count/mm2 at starting timepoint. Cell
death assays were conducted in a similar way, with treatment media including 50 nM YOYO-1
Iodide (Cat # Y3601, Invitrogen, Carlsbad, CA). Green YOYO-1 iodide fluorescence and red
nuclear fluorescence were monitored on the IncuCyte ZOOM system and analyzed using the
IncuCyte image analysis software. Cell death was quantified by normalizing green count/mm2 to
red count/mm2 to account for differences in cell density, and then normalized to starting timepoint.
Percent cell death was calculated using a 100 % death endpoint measurement. CalcuSyn software
was utilized to measure combination index for synergy assays. Quantification of analyses are
summarized as mean ± SEM, with variance across groups compared for statistical significance by
student’s t-test on Prism 8 software (GraphPad Software, San Diego, CA). Asterisks represent pvalues: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.

4.3.5 Immunohistochemistry
Tumor microarray of osteosarcoma patient samples was obtained from the University of
Texas MD Anderson Cancer Center. Immunohistochemistry was conducted using anti-PHGDH
antibody. Briefly, slides were baked at 50 ºC for 2 hours. Slides were then deparaffinized in xylene
(Cat # 247642, Sigma-Aldrich, St. Louis, MO) (2 x 5 minutes) and rehydrated with 100 % ethanol
(EtOH) (Cat # A4094, Fisher Scientific, Hampton, NH) (2 x 2.5 minutes), 95 % EtOH (2 x 2
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minutes), and 75 % EtOH (1 minute). Endogenous peroxidase was blocked using 3 % hydrogen
peroxide, made from 30 % hydrogen peroxide (Cat # 216763, Sigma-Aldrich, St. Louis, MO)
diluted in 1X PBS (Cat # 14190136, Gibco, Thermo Fisher, Waltham, MA). Antigen unmasking
was conducted using citrate-based antigen unmasking solution (Cat # H-3300-250, Vector
Laboratories, Burlingame, CA). Blocking was conducted using blocking buffer (3 % w/v BSA
(Cat # A9418, Sigma-Aldrich, St. Louis) in 1X PBS). Primary antibody for PHGDH (anti-rabbit,
Cat # HPA021241, Sigma-Aldrich, St. Louis, MO) was diluted 1:1000 in blocking buffer. Slides
were then washed 3 x 5 minutes with 1X Tris-Buffered Saline (Cat # T5912, Sigma-Aldrich, St.
Louis, MO) with 0.1 % Tween 20 Detergent (Cat # P9416, Sigma-Aldrich, St. Louis, MO) (TBST).
Secondary anti-rabbit antibody (Cat # 211-032-171, Jackson ImmunoResearch, West Grove, PA)
was diluted 1:1000 in blocking buffer. Hematoxylin/eosin were used to counterstain. Slides were
mounted using anti-fade mounting media (Cat # P36934, Invitrogen, Carlsbad, CA) and visualized
using an Olympus BX51 fluorescence microscope (Olympus Life Science, Waltham, MA) by one
party. A second party blind scored the slides. A third party correlated the blind scoring to patient
data. RNA sequencing data with available outcomes data for the second TMA was obtained from
the University of Texas MD Anderson Cancer Center (Wu et al., 2020a).

4.3.6 Immuno Assays
Lysates were obtained for all cell lines by collecting 2 x 106 cells and washing three times
with 1X PBS. Cells were then pelleted and lysed per reagent protocol for cell lysis buffer (Cat #
9803, Cell Signaling Technology, Danvers, MA) with supplemented protease and phosphatase
inhibitors (Cat # 78440, Thermo Scientific, Waltham, MA). Protein concentration within cell
lysates were determined using Bradford Assay (Cat # 5000202, Bio-Rad, Hercules, CA). Protein
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expression was analyzed using the Wes Automated Western Blotting System (ProteinSimple, BioTechne, Minneapolis, MN), which uses automated capillary technology to measure protein
expression and total protein concentration, per manufacturer’s protocol. Protein expression was
detected using 12-230 kDa Separation Modules. Anti-PHGDH antibody (anti-rabbit, Cat #
HPA021241, Sigma-Aldrich, St. Louis, MO) was diluted 1:100 for signal detection. Anti-SREBP1
antibody (anti-mouse, Cat # sc-13551, Santa Cruz Biotechnology, Dallas, TX) was diluted 1:50
for signal detection. Anti-mTOR antibody (anti-rabbit, Cat # 2972, Cell Signaling Technology,
Danvers, MA) was diluted 1:50 for signal detection. Anti-phospho p70 S6 Kinase (Thr389)
antibody (anti-rabbit, Cat # 9205, Cell Signaling Technology, Danvers, MA) was diluted 1:50 for
signal detection. Anti-p70 S6 Kinase antibody (anti-rabbit, Cat # 9202, Cell Signaling Technology,
Danvers, MA) was diluted 1:50 for signal detection. Protein levels were visualized and quantified
using Compass for SimpleWestern software (ProteinSimple, Bio-Techne, Minneapolis, MN).
Quantification of analyses are summarized as mean ± SEM, with variance across groups compared
for statistical significance by student’s t-test. Asterisks represent p-values: * < 0.05, ** < 0.01, ***
< 0.005, **** < 0.001.

4.3.7 Seahorse Metabolomics Analysis
Cells were plated in Seahorse XF96 Cell Culture Microplates (Cat # 101085-004, Agilent
Technologies, Santa Clara, CA). Seeding density was optimized for Seahorse based on
recommended ranges of oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) for baseline data (Seahorse XF Assay Basic Procedures). Basal mitochondrial respiration
was measured using the Seahorse XF Cell Mito Stress Test Kit (Cat # 103015-100, Agilent
Technologies, Santa Clara, CA) per kit protocol. Basal glycolytic rate and glycolytic proton efflux
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rate were measured using the Seahorse XF Glycolytic Rate Test Kit (Cat # 103710-100, Agilent
Technologies, Santa Clara, CA) per kit protocol. Mitochondrial fuel source flexibility was
measured using the Seahorse XF Mito Fuel Flex Test Kit (Cat # 103260-100, Agilent
Technologies, Santa Clara, CA) per kit protocol. All assays were run on a Seahorse XFe96
Analyzer (Agilent Technologies, Santa Clara, CA), and data was quantified and reported using
Seahorse Wave Desktop Software (Agilent Technologies, Santa Clara, CA) automated reports.
Quantification of analyses are summarized as mean ± SEM, with variance across groups compared
for statistical significance by student’s t-test. Asterisks represent p-values: * < 0.05, ** < 0.01, ***
< 0.005, **** < 0.001.

4.3.8 Intracellular Metabolomics Analysis
NOS1 cells were plated at 8 x 105 cells per dish in 10 cm dishes and treated with either
DMSO or 15 µM NCT-503, diluted in MEM containing 10 % FBS, 286 µM serine, and 286 µM
glycine for 48 hours. Methanol metabolite extraction was performed according to the Human
Metabolome Technologies (HMT) Metabolomics Analysis Sample Preparation Protocol method
for adherent cells (Human Metabolome Technologies, Boston, MA). Metabolite concentrations
were normalized to cell count. Samples were submitted in triplicate. Quantification of analyses are
summarized as mean ± SEM, with variance across groups compared for statistical significance by
student’s t-test. Pathway analysis of metabolites was conducted using MetaboAnalyst 4.0
(Montreal, Quebec, Canada). Data was glog transformed and Pareto scaled, and p-values were
adjusted (Chong et al., 2019). Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, ****
< 0.001.
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4.3.9 Intracellular [U-13C] Tracing Analysis
Saos2 cells were plated at 2.8 x 106 cells per dish in 10 cm dishes and allowed to adhere
for 24 hours. Prior to experiment, dialyzed FBS was complexed with palmitate (Cat # P0500-25G,
Sigma Aldrich, St. Louis, MO) or [U-13C] palmitate (Cat # CLM-409-PK, Cambridge Isotope
Laboratories, Tewksbury, MA) by rocking at 37 ºC overnight (Kamphorst et al., 2014). Cells were
treated with either 10 µM NCT-inactive or 15 µM NCT-503, diluted in DMEM containing 5.5
mM glucose, 2 mM glutamine, and 10 % FBS for 21 hours to reach steady state. Media was then
replaced with fresh media containing drug for 3 hours. Media was then replaced with fresh media
containing dialyzed FBS supplemented with palmitate and [U-13C] glucose (Cat # CLM-1396-0.5,
Cambridge Isotope Laboratories, Tewksbury, MA) for glucose tracing, or with [U-13C] palmitate
and unlabeled glucose for palmitate tracing. Cells were maintained in labeled medium for 24 hours
(Locasale et al., 2011; Reid et al., 2018). Methanol metabolite extraction was performed according
to the Human Metabolome Technologies (HMT) Metabolomics Analysis Sample Preparation
Protocol method for adherent cells (Human Metabolome Technologies, Boston, MA). Metabolite
concentrations were normalized to cell count and [U-13C] concentrations were corrected for natural
abundance. Samples were submitted in triplicate. Quantification of analyses are summarized as
mean ± SEM, with variance across groups compared for statistical significance by student’s t-test.
Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.

4.3.10

BODIPY Kinetic Assays

For BODIPY fluorescence assays, NucRed cells were seeded in 96 well tissue-culture
plates. When at optimal confluence, culture media was removed from wells, and was replaced with
media containing BODIPY 493/503 (Cat # D3922, Invitrogen, Carlsbad, CA) diluted 1:1000 in
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phenol red-free media. Green fluorescence and red nuclear fluorescence were monitored on the
IncuCyte ZOOM system and analyzed using the IncuCyte image analysis software. Neutral fatty
acid levels were quantified by normalizing green count/well to red count/well to account for
differences in cell density, and then normalized to starting timepoint. Quantification of analyses
are summarized as mean ± SEM, with variance across groups compared for statistical significance
by two-way ANOVA. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.

4.3.11

Lipidomics Analysis

Cells were plated at 1 x 106 cells per dish in 10 cm dishes and treated with either 10 µM
NCT-inactive or 10 µM NCT-inactive with 15 µM NCT-503 for 48 hours. Cells were collected by
cell scraping, washed with 1X PBS, and were counted. A total of 2 x 106 cells were submitted to
Washington University in St. Louis Diabetic Cardiovascular Disease Center for lipidomics
analysis, where analytes were measured by liquid chromatography/mass spectrometry (LC-MS).
All data were reported as peak area ratio of analyte relative to internal standard. Samples were
submitted in triplicate. Quantification of analyses are summarized as mean ± SEM, with variance
across groups compared for statistical significance by student’s t-test. Asterisks represent p-values:
* < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.

4.3.12

NanoString Metabolism Gene Panel

Cells were plated at 1 x 106 cells per dish in 10 cm dishes and treated with either 10 µM
NCT-inactive or 10 µM NCT-inactive with 15 µM NCT-503 for 24 hours. Cells were then lysed
and RNA was collected using the Direct-zol RNA Miniprep Plus Kit (Cat # R2070, Zymo
Research, Irvine, CA), and 250 ng of RNA were sent to NanoString; samples were submitted in
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triplicate. Quantification of analyses are summarized as mean ± SEM, with variance across groups
compared for statistical significance by student’s t-test. Asterisks represent p-values: * < 0.05, **
< 0.01, *** < 0.005, **** < 0.001.

4.3.13

MilliPlex MAP Magnetic Bead-Based Assay

Cells were plated in 6-well plates. When confluent, cells were serum-starved for four hours.
After four hours, media was replaced with DMEM containing serum and relevant treatment
conditions: serum alone (NT), 10 µM NCT-inactive, 5 µM perhexiline, or 10 µM rapamycin. Cells
were incubated at 37 ºC for 24 hours. Samples were collected according to manufacturer’s
instructions (Cat # 48-612MAG, Millipore, Burlington, MA) and 16 µg of sample were submitted
for analysis. Measurements were taken on a Luminex FlexMap 3D system. Quantification of
analyses are summarized as mean ± SEM, with variance across groups compared for statistical
significance by student’s t-test. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005,
**** < 0.001.

4.3.14

Activity and Metabolite Assays

Cells were plated at 3 x 106 cells per dish in 10 cm dishes and treated with either 10 µM
NCT-inactive or 10 µM NCT-inactive with 15 µM NCT-503 for 48 hours. PHGDH activity was
assessed using cell lysates in the PHGDH Activity Assay Kit (Cat # PK-CA577-K569, PromoCell,
Heidelberg, Germany) per manufacturer’s protocol. Extracellular lactate levels were assessed
using extracellular medium in the PicoProbe Lactate Fluorometric Assay Kit (Cat # K638,
Biovision, Milpitas, CA) per manufacturer’s protocol. Total and serine-derived αKG levels were
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assessed using cell lysates in the Alpha Ketoglutarate (alpha KG) Assay Kit (Cat # ab83431,
Abcam, Cambridge, United Kingdom) per manufacturer’s protocol.

4.3.15

Xenograft Studies

Mouse xenograft protocols were approved by Washington University in St. Louis
Institutional Animal Care and Use Committee (IACUC). Mice were maintained under IACUC
guidelines. 2 x 106 U2OS cells were collected in 75 µL of DMEM and combined with 75 µL of
Matrigel (Cat # 354234, Corning, Corning, NY), and grafted by subcutaneous injection into the
right flank of athymic nude mice (female, 4-6 weeks old, homozygous for Foxn1nu, Cat # 002019,
Jackson Laboratories, Bar Harbor, ME). Length and width of resulting tumors from xenograft were
measured daily, and tumor volumes were calculated using the formula (length x width2)/2. Cell
line-derived xenografts were allowed to grow to an average volume of 200 mm3, at which point
mice were randomly assigned to treatment groups of either vehicle (5 % ethanol, 35 %
polyethylene glycol 300 (Cat # 8.17002, Sigma Aldrich, St. Louis, MO), 60 % aqueous 30 %
hydroxyropyl-beta-cyclodextrin (Cat # H107, Sigma Aldrich, St. Louis, MO)) daily, 40 mg/kg
NCT-503 (in vehicle) intraperitoneally (IP) daily, 8 mg/kg perhexiline (in 1.8 % w/v
hydroxypropyl-beta-cyclodextrin) by oral gavage daily, or 40 mg/kg NCT-503 IP and 8 mg/kg
perhexiline by oral gavage daily. Tumors were allowed to grow to volumes of 2000 mm3 or until
30 days had passed. Ten mice per treatment group were utilized for all studies. Investigators were
not blind to treatment groups. Tumor growth curves are shown as mean ± SEM, with variance
across groups compared for statistical significance by two-way ANOVA. Asterisks represent pvalues: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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4.3.16

Lysosome Localization Assays

For antibody-based fluorescence assays, wildtype cells were seeded in 96 well tissueculture plates. When at optimal confluence, culture media was removed from wells, and was
replaced with phenol red-free media containing relevant treatment conditions, antibody diluted
1:1500, and LysoTracker Deep Red (Cat # L12492, Invitrogen, Thermo Fisher, Waltham, MA)
diluted to 50 nM. Antibodies used were anti-ITFG2 (anti-mouse, Cat # sc-271420, Santa Cruz
Biotechnology, Dallas, TX) and anti-NPRL2 (anti-mouse, Cat # sc-376986, Santa Cruz
Biotechnology, Dallas, TX). Green fluorescence and red fluorescence were monitored on the
IncuCyte ZOOM system at 20X magnification and analyzed using the IncuCyte image analysis
software. Protein localization to the lysosome was quantified using IncuCyte image analysis
software to quantify overlap of green and red, and normalizing this metric to cell density, which
was then normalized to starting timepoint. Quantification of analyses are summarized as mean ±
SEM, with variance across groups compared for statistical significance by student’s t-test.
Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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4.4 Results
4.4.1 Folate cycle inhibition results in cytostasis in vitro.
To test the effect of methotrexate, the osteosarcoma cell line NOS1 was cultured in the
presence of increasing doses of methotrexate for up to 96 hours, and cellular proliferation rate was
measured by nuclear red count using the IncuCyte ZOOM live cell analysis system (Figure 4.1A).
While proliferation was inhibited with high doses of methotrexate (greater than 75 micromolar
(µM)), a decrease in cell count at high doses was not observed, suggesting cytostasis and not cell
death. To address this, cell death was measured using YOYO-1 iodide fluorescence (Figure 4.1B).
Methotrexate was shown to cause no significant cell death up to concentrations as high as 5
millimolar (mM) at 48 hours. These findings demonstrate that exceedingly high doses of
methotrexate are required to show an anti-proliferative effect in vitro.
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Figure 4.1 – Osteosarcomas exhibit cytostasis with folate cycle inhibition and
demonstrate correlation between upstream PHGDH expression and poor
patient prognosis
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Figure 4.1 – Osteosarcomas exhibit cytostasis with folate cycle inhibition and demonstrate
correlation between upstream PHGDH expression and poor patient prognosis
(A) Counts of nuclear red staining in NOS1 cell lines treated with increasing doses of methotrexate
for up to 96 hours, normalized to starting time point.
(B) Percent cell death at 72 hours in NOS1 cell line treated with increasing doses of methotrexate,
measured using YOYO-1 Iodide counts/mm2, normalized to total cell count using red nuclear
staining.
(C) Schematic of metabolic pathways linking folate metabolism to de novo serine synthesis
pathway.
(D) Representative immunohistochemistry for PHGDH of a tumor microarray containing 392
tumor samples from 260 osteosarcoma patients, with hematoxylin/eosin cross-staining. Scale bars
represent 100 µm.
(E) Relapse-free survival for osteosarcoma patients with medium to high levels of PHGDH (blue)
compared to none to low levels of PHGDH (yellow).
(F) Overall survival for osteosarcoma patients with medium to high levels of PHGDH (blue)
compared to none to low levels of PHGDH (yellow).
(G) Protein expression of PHGDH in precursor mesenchymal stem cell, osteosarcoma cell lines
MG63, MNNG, NOS1, Saos2, and U2OS, and breast cancer cell lines MDA-MB-231 and MDAMB-468. Cell lysates were analyzed using the WES automated capillary blotting system and
normalized to total protein levels within the capillary. Band image is representative.
Abbreviations: 3PG, 3-phosphoglycerate; PEP, phosphoenolpyruvate; PHGDH, 3phosphoglycerate dehydrogenase; SHMT, serine hydroxymethyl transferase; me-THF, methylene
tetrahydrofolate; MTHFD1, methylene tetrahydrofolate dehydrogenase; TYMS, thymidylate
synthetase; DHF, dihydrofolate; DHFR, dihydrofolate reducatase; THF, tetrahydrofolate. Bars
represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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4.4.2 PHGDH expression correlates with poor patient prognosis in
osteosarcoma.
Given the lack of cell death induced by methotrexate, upregulation of the serine
biosynthetic pathway was investigated (Figure 4.1C). Expression of PHGDH, the rate-limiting
enzyme in serine biosynthesis, was characterized in a triple-blind fashion using
immunohistochemistry on a tumor microarray of 392 tumor samples from 260 osteosarcoma
patients (Figure 4.1D, patient characteristics presented in Table 4.1). A blinded independent
pathologist scored tumors by standard pathology grading, where tumors were scored for staining
intensity as 0 (no PHGDH), +1 (low PHGDH), +2 (medium PHGDH), or +3 (high PHGDH).
These blinded scores were then correlated with survival data for the tumor microarray by a blinded
independent biostatistician.
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Table 4.1 – Patient Characteristics of Osteosarcoma TMA
Patient Characteristics
Factor
Age at diagnosis, median (range)
Gender

n (%)
18 (4-90)
Male
Female

153 (59)
107 (41)

Asian
Black
Hispanic
White

9 (3)
35 (14)
75 (29)
140 (54)

Race

Stage at presentation
Localized
Metastatic

215
45

Primary Site
Femur
Tibia
Fibula
Humerus
Radius/ulna
Mandible
Rib/chest wall
Pelvis/acetabulum
Other

140 (54)
43 (17)
10 (4)
32 (12)
3 (1)
1 (0)
7 (3)
18 (7)
5 (2)

Osteoblastic
Chondroblastic
Fibroblastic
Telangiectatic
Dedifferentiated parosteal
Small cell
High grade surface
Other – high grade
Other – intermediate/low grade
Radiation Induced Osteosarcoma
No
Yes
Grade
Low
Intermediate
High
Pathologic Response (patients receiving pre-op chemo)
Good (≥ 90 % necrosis)
Poor (< 90 % necrosis)

110 (42)
49 (19)
46 (18)
23 (9)
12 (5)
6 (2)
3 (1)
6 (2)
5 (2)

Histologic Subtype

250 (97)
8 (3)
6 (2)
1 (0)
253 (97)
108 (45)
133 (55)

Table 4.1 – Patient Characteristics of Osteosarcoma TMA
Patient characteristics of osteosarcoma tumors included in tumor microarray.
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Of the tumors assayed, 53 % (208/392) were found to have medium to high expression of
PHGDH. Furthermore, medium to high levels of PHGDH were associated with decreased relapsefree survival (median RFS 1.25 years (low) vs. >15 years (not reached) (medium/high)) (HR 1.93
(1.20-3.10), p=0.006; Figure 4.1E) and decreased overall survival (median OS 4.6 years (low) vs.
>15 years (not reached) (medium/high)) (HR 1.86 (1.11-3.10), p=0.018; Figure 4.1F) in resection
samples for osteosarcoma patients with localized disease who received neoadjuvant chemotherapy.
This demonstrated that high PHGDH expression was correlated with osteosarcomas with poorer
outcomes. Using a second available osteosarcoma patient data set that was selected for cases with
higher risk due to relapsed or metastatic disease, high PHGDH expression by RNAseq was also
correlated with poor disease-free survival (DFS) (p=0.031) (Figure 4.2A, patient characteristics
presented in Figure 4.2B). Given the bias in the dataset, the correlation between high PHGDH
expression and poor OS was consistent but not significant (Figure 4.2C).
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Figure 4.2 – Osteosarcomas demonstrate correlation between PHGDH RNA
expression and poor survival
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Figure 4.2 – Osteosarcomas demonstrate correlation between PHGDH RNA expression and
poor survival.
(A) Disease-free survival for osteosarcoma patients with PHGDH RNA levels below the median
(blue) compared to PHGDH RNA levels above the median (yellow).
(B) Patient characteristics of osteosarcoma patients corresponding to RNA data.
(C) Overall survival for osteosarcoma patients with PHGDH RNA levels below the median (blue)
compared to PHGDH RNA levels above the median (yellow).
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Osteosarcoma cell lines (MG63, MNNG, NOS1, Saos2, and U2OS), human mesenchymal
stem cells (the progenitor cell to bone-producing cells), and two breast cancer cell lines (MDAMB-231 and MDA-MB-468) with known PHGDH status (null and high, respectively) were
selected for further in vitro analysis of PHGDH biology (Pacold et al., 2016). PHGDH expression
levels were measured (Figure 4.1G), and all osteosarcoma cell lines were found to have PHGDH
levels that were significantly higher than mesenchymal cells or the known negative breast cancer
cell line.

4.4.3 PHGDH inhibition causes attenuation of cellular proliferation.
To test the impact of inhibiting PHGDH in osteosarcoma cell lines, NCT-503, a small
molecule inhibitor of PHGDH, or an NCT-503 inactive control (NCT-inactive) was utilized.
PHGDH inhibition caused significant attenuation of cellular proliferation with 15 µM NCT-503
in NOS1 (Figure 4.3A), as well as Saos2 and U2OS (Figures 4.4A and 4.4B), but no cell death
was observed until concentrations of 20 µM (Figure 4.3B). Greater than 50 % cell death was not
seen until concentrations of 30 µM or higher, at which point cell death could not be directly
attributed to PHGDH inhibition due to the potential for off-target effects. The inhibitory capacity
of NCT-503 on PHGDH has been previously reported (Pacold et al., 2016) and was assessed in
osteosarcoma cell lines using a PHGDH activity assay (Figure 4.4C). EC-50 values for NCT-503
were calculated for each cell line (Figure 4.4D), and 15 µM NCT-503 was used for in vitro
experiments for the remainder of the study.
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Figure 4.3 – PHGDH inhibition causes attenuation of cellular proliferation and
TCA cycle activity
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Figure 4.3 – PHGDH inhibition causes attenuation of cellular proliferation and TCA cycle
activity
(A) Counts of nuclear red staining in NOS1 cells treated with DMSO (vehicle control), 10 µM
NCT-503 inactive control, or 15 µM NCT-503, normalized to starting time point.
(B) Percent cell death at 72 hours in NOS1 cells treated with increasing doses of NCT-503,
measured using YOYO-1 Iodide counts/mm2, normalized to nuclear red count.
(C) Counts of nuclear red staining in NOS1 cells treated with DMSO (vehicle control) or 10 µM
PKUMDL-WQ-2101, normalized to starting time point.
(D) Percent cell death at 72 hours in NOS1 cells treated with increasing doses of PKUMDL-WQ2101, measured using YOYO-1 Iodide counts/mm2, normalized to nuclear red count.
(E) Counts of nuclear red staining normalized to starting time point and (F) percent cell death in
NOS1 cells cultured with media containing dialyzed FBS with or without supplemented 286 µM
serine and glycine and treated with 10 µM NCT-inactive or 15 µM NCT-503.
(G) Oxygen consumption rate (OCR) for MDA-MB-231, MDA-MB-468, NOS1, and Saos2 cells
treated with 10 µM NCT-inactive or 15 µM NCT-503.
(H) Glycolytic proton efflux rate (GlycoPER) for NOS1, Saos2, and U2OS cells treated with 10
µM NCT-inactive or 15 µM NCT-503.
(I) Concentration of 13C and unlabeled C in 3PG in presence of 10 µM NCT-inactive or 15 µM
NCT-503, measured by mass spectrometry.
(J) Percent incorporation of [U-13C] labeled glucose into serine and (K) glycine in presence of 10
µM NCT-inactive or 15 µM NCT-503, measured by mass spectrometry.
(L) Concentration of 13C and unlabeled C in lactate in presence of 10 µM NCT-inactive or 15 µM
NCT-503, measured by mass spectrometry.
(M) Metabolite levels in NOS1 cells treated with DMSO (vehicle control) or NCT-503 for 48
hours. Dashed lines indicate potential sources of acetyl-coA.
(N) Percent incorporation of [U-13C] labeled glucose into carbons of acetyl-coA in presence of 10
µM NCT-inactive or 15 µM NCT-503, measured by mass spectrometry.
Abbreviations: 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate;
PHGDH, 3-phosphoglycerate dehydrogenase; 3PP, 3-phosphohydroxypyruvate; 3PSer, 3phophoserine. Bars represent mean of values; error bars represent SEM. All assays were conducted
with n = three replicates. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** <
0.001.
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Figure 4.4 – PHGDH inhibition causes attenuation of cellular proliferation and
TCA cycle activity and increases glycolysis
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Figure 4.4 – PHGDH inhibition causes attenuation of cellular proliferation and TCA cycle
activity and increases glycolysis
(A) Relative count of red nuclear staining in Saos2 and (B) U2OS cells treated with DMSO
(vehicle control), 10 µM NCT-503 inactive control, or 15 µM NCT-503.
(C) NADH produced by PHGDH in presence of 10 µM NCT-inactive, 15 µM NCT-503, or
positive assay control.
(D) Calculated EC-50 of NCT-503 for osteosarcoma cell lines.
(E) Relative count of red nuclear staining in U2OS shGFP, shPHGDH_1, and shPHGDH_2 cells
and (F) MDA-MB-231 shGFP, shPHGDH_1, and shPHGDH_2 cells. Corresponding protein
expression of PHGDH in cell lysates, analyzed using the WES automated capillary blotting system
and normalized to total protein levels within the capillary. Band image is representative. Percent
PHGDH was calculated using shGFP as 100 %.
(G) Percent incorporation of [U-13C] labeled glucose into glycolytic metabolites in presence of 10
µM NCT-inactive or 15 µM NCT-503, measured by mass spectrometry.
(H) Relative levels of extracellular lactate in presence of 10 µM NCT-inactive or 15 µM NCT503.
(I) Percent incorporation of [U-13C] labeled glucose into TCA cycle metabolites in presence of 10
µM NCT-inactive or 15 µM NCT-503, measured by mass spectrometry.
(J) Concentration of 13C and unlabeled C in α-ketoglutarate (αKG) in presence of 10 µM NCTinactive or 15 µM NCT-503, measured by mass spectrometry.
(K) Percent of αKG produced in presence of 10 µM NCT-inactive (all cellular sources) or 15 µM
NCT-503 (serine synthesis pathway). Percent of αKG produced by cellular sources not including
serine synthesis was obtained by subtracting serine-derived αKG from total αKG.
Abbreviations: G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; F16P, fructose-1,6bisphosphate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate.
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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To recapitulate the proliferation phenotype with another small molecule inhibitor of
PHGDH, the effects of PKUMDL-WQ-2101 in this system were also assayed, and showed that 10
µM PKUMDL-WQ-2101 could slow cellular proliferation (Figure 4.3C), while concentrations of
greater than 50 µM were required to see greater than 50 % cell death (Figure 4.3D). Finally, to
verify that the decrease in proliferation was due to the on-target inhibition of PHGDH, stable
knockdown cell lines of PHGDH were generated using shRNA, and proliferation rates were
measured (Figure 4.4E). PHGDH knockdown decreased proliferation rates in U2OS, but had no
effect on proliferation in the reference PHGDH-negative breast cancer cell line, MDA-MB-231
(Figure 4.4F).
Previous reports of PHGDH inhibition have shown that PHGDH-high cells were more
sensitive to NCT-503 in the absence of serine and glycine (Mullarky et al., 2016). To test the
sensitivity of osteosarcoma cells to extracellular serine and glycine concentrations, NOS1 cells
were cultured in media supplemented with dialyzed FBS, with and without serine and glycine.
NCT-503 still decreased the proliferation rate of osteosarcoma, but this was not dependent on the
presence or absence of serine and glycine (Figure 4.3E), nor was there an increase in cell death at
48 hours (Figure 4.3F). This suggests that osteosarcoma cell lines with high levels of PHGDH are
likely are not dependent on extracellular serine.

4.4.4 Inhibition of serine synthesis blocks TCA cycle activity.
To identify the pro-survival compensatory mechanisms associated with PHGDH
inhibition, the mitochondrial respiration of cells treated with NCT-503 was determined. There was
no change in oxygen consumption rate in MDA-MB-231 after PHGDH inhibition with NCT-503,
while osteosarcoma cell lines NOS1 and Saos2, as well as the reference PHGDH-positive breast
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cancer cell line, MDA-MB-468, showed significant decrease in oxygen consumption rate with
NCT-503 (Figure 4.3G). This identified broader effects on the cells than the direct obstruction of
serine biosynthesis by PHGDH inhibition.
Given that inhibition of PHGDH would limit the amount of 3-phosphoglycerate (3PG), the
starting product in the PHGDH enzymatic reaction, entering de novo serine synthesis, the fate of
glucose in this system was explored. With PHGDH inhibition, glycolytic rate in osteosarcoma cell
lines was increased, demonstrating that instead of entering de novo serine biosynthesis through
3PG, glucose was shunting through glycolytic intermediates (Figure 4.3H). To confirm that
glucose was not entering the serine synthesis pathway through 3PG, [U-13C] glucose tracing was
conducted in Saos2. Total 3PG metabolite levels were decreased, with the 3PG present in the
system fully labeled with 13C from extracellular glucose (Figure 4.3I). Glucose entry into serine
biosynthesis was completely abrogated with PHGDH inhibition, with no 13C labeling in serine or
glycine (Figures 4.3J and 4.3K), verifying the targeted effect of NCT-503. Levels of glycolytic
intermediates downstream of the rate-limiting enzyme, phosphofructokinase, were decreased
(Figure 4.4G), and glucose incorporation into lactate was increased (Figure 4.3L). Extracellular
lactate levels were also independently measured and elevated (Figure 4.4H), further demonstrating
increased glycolysis in cells treated with NCT-503.
To characterize the metabolic compensation occurring with PHGDH inhibition,
metabolomics were conducted for NOS1. Metabolite levels of 3-phosphoserine (3PSer), the stable
product of 3-phosphopyruvate, were decreased, demonstrating on-target inhibition of PHGDH by
NCT-503 (Figure 4.3M). Levels of 3PG were again decreased with NCT-503 treatment, and
metabolites in glycolysis were depleted until lactate. Metabolites in the TCA cycle, including
citrate, isocitrate, α-ketoglutarate (αKG), succinatate, fumarate, and malate, were all significantly
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decreased with PHGDH inhibition (Figure 4.3M). There was also significantly decreased
incorporation of 13C into these metabolites (Figure 4.4I). Given that αKG can be synthesized from
glucose through the TCA cycle, but also from glutamate through phosphoserine aminotransferase
1 (PSAT1), an enzyme in de novo serine biosynthesis, levels of 13C from glucose into αKG were
measured (Figure 4.4J). As there was no incorporation of 13C into αKG, any αKG present after
PHGDH inhibition was not from glucose or from glutamate through serine synthesis, and was
therefore from alternative sources (Figure 4.4K). An accumulation of non-glucose-derived acetylcoA was also identified (Figure 4.3N, potential sources of acetyl-coA indicated by dashed lines).
Taken together, these data confirmed that NCT-503 treatment inhibited both de novo serine
biosynthesis and the TCA cycle, correlating with the lack of mitochondrial respiration and increase
in glycolysis in PHGDH-expressing cell lines as seen by Seahorse (Figures 4.3G and 4.3H).

4.4.5 PHGDH inhibition causes accumulation of intracellular
unsaturated fatty acids.
Citrate can be reversibly converted into acetyl-coA to direct TCA cycle metabolites away
from the mitochondria for fatty acid synthesis, or for gene expression through histone acetylation
(Shi and Tu, 2015). The decrease in citrate and accumulation of acetyl-coA showed that glucose
was likely not entering the TCA cycle for mitochondrial respiration, and the accumulation of
glutamine and glutamate suggested that glutamine was also not being utilized as an oxidative fuel
source (Figure 4.3M). Treatment with BPTES showed no cytotoxic effect on osteosarcoma cells
(Figure 4.5A), and levels of asparagine and aspartate were significantly decreased (Figures 4.5B
and 4.5C), suggesting that at baseline, these cells were not dependent on glutamine metabolism.
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Seahorse analyses were therefore performed to identify how the preferences of mitochondria for
three fuel sources (glucose, glutamine, and fatty acids) changed as a result of PHGDH inhibition.
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Figure 4.5 – Osteosarcoma cells do not utilize glutamine metabolism at baseline
but accumulate fatty acids in the presence of NCT-503
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Figure 4.5 – Osteosarcoma cells do not utilize glutamine metabolism at baseline but
accumulate fatty acids in the presence of NCT-503
(A) Percent cell death at 72 hours in U2OS cells treated with increasing doses of BPTES and NOS1
cells treated with highest dose of BPTES, with or without 15 µM NCT-503, measured using
YOYO-1 Iodide counts/mm2, normalized to nuclear red count.
(B) Concentration of 13C and unlabeled C in asparagine and (C) aspartate in presence of 10 µM
NCT-inactive or 15 µM NCT-503, measured by mass spectrometry.
(D) Percent incorporation of [U-13C] labeled palmitate into O-acetylcarnitine and (E) Nacetylaspartic acid in presence of 10 µM NCT-inactive or 15 µM NCT-503, measured by mass
spectrometry.
(F) Protein expression of SREBP-1 in NOS1 (n=2), Saos2 (n=3), and U2OS (n=3) cell lysates
treated with either NCT-inactive or NCT-503. Cell lysates were analyzed using the WES
automated capillary blotting system and normalized to total protein levels within the capillary.
Band image is representative.
(G) Fold change cell death in Saos2 cells cultured with media containing normal FBS or
lipoprotein-depleted FBS, and treated with NCT-503 inactive control or NCT-503.
(H) Relative abundance by peak area ratio of five most abundant unsaturated fatty acids in Saos2
and U2OS and (I) MDA-MB-231 and MDA-MB-468.
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates unless otherwise specified. Asterisks represent p-values: * < 0.05, ** < 0.01, *** <
0.005, **** < 0.001.
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In three osteosarcoma cell lines, treatment with NCT-503 resulted in increased capacity to
utilize fatty acids (Figures 4.6A, 4.6B, and 4.6C), demonstrating that when treated with NCT-503,
osteosarcoma cells had an increased relative capacity to oxidize fatty acids when glucose or
glutamine are unavailable. [U-13C] palmitate labeling was utilized to identify any targets of fatty
acid incorporation. Increased 13C incorporation into O-acetylcarnitine and N-acetylaspartic acid
suggested that palmitate was used for acetyl-coA synthesis, thereby supplementing lack of glucose
incorporation into acetyl-coA (Figure 4.3M, Figures 4.5D and 4.5E). However, given the lack of
TCA cycle respiration, mitochondrial usage of fatty acids for oxidative phosphorylation was
unlikely. Therefore, BODIPY 493/503 fluorescence levels were quantified over time using the
IncuCyte S3 live cell analysis system. This demonstrated that neutral fatty acids were
accumulating intracellularly with NCT-503 treatment (Figure 4.6D).
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Figure 4.6 – PHGDH inhibition causes accumulation of intracellular
unsaturated fatty acids
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Figure 4.6 – PHGDH inhibition causes accumulation of intracellular unsaturated fatty acids
(A) Percent fuel oxidation of mitochondrial capacity to utilize fuel sources glucose, glutamine, and
fatty acids, after treatment with 48 hours of NCT-inactive or NCT-503 in NOS1, (B) Saos2, and
(C) U2OS cells. Bars represent means of values; error bars represent SEM. n = six replicates.
(D) Counts of green BODIPY 493/503 staining in NOS1 cells treated with NCT-inactive or NCT503, normalized to starting time point.
(E) Relative abundance by peak area ratio of total saturated fatty acids and (F) total unsaturated
fatty acids measured by LC-MS in Saos2, U2OS, MDA-MB-231, and MDA-MB-468 cells treated
with NCT-inactive or NCT-503.
(G) Relative abundance by peak area ratio of five most abundant unsaturated fatty acids in
osteosarcoma cell lines and (H) breast cancer cell lines (statistics presented in Supplemental
Figures 2C and 2D).
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates unless otherwise specified. Asterisks represent p-values: * < 0.05, ** < 0.01, *** <
0.005, **** < 0.001.
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To characterize the source of these lipids, levels of SREBP-1, a transcription factor that
regulates triglyceride synthesis, were assayed by immunoblot (Eberlé et al., 2004). PHGDH
inhibition did not change the protein expression of SREBP-1 (Figure 4.5F), suggesting the
accumulation of lipids was not due to increased synthesis. Cells were then cultured in media
containing normal or lipid-depleted FBS, and treated with NCT-503. Depletion of lipids from the
culture media did not significantly change cell death with NCT-503 treatment (Figure 4.5G). To
identify the lipids that were accumulating, unbiased lipidomics analyses for free fatty acids
(unsaturated and saturated), phospholipids, and cholesterol esters were conducted in cells treated
with NCT-503 or NCT-inactive control. There was no change in phospholipids, cholesterol esters,
or saturated fatty acids (Figure 4.6E), but an increase in unsaturated fatty acids with NCT-503
treatment (Figure 4.6F). The lipidomic analysis also indicated changes in unsaturated fatty acid
subspecies, from which the five most abundant demonstrated significant increases with NCT-503
treatment (Figures 4.6G and 4.6H, statistics presented in Figures 4.5H and 4.5I). Taken together,
these findings confirmed that PHGDH inhibition by NCT-503 caused a decrease in mitochondrial
respiration, and an accumulation of metabolites and fatty acids that feed into the mitochondria.

4.4.6 Inhibition of serine synthesis and subsequent accumulation of
branched chain amino acids leads to mTORC1 activation.
To determine additional metabolic compensation that cells undergo with NCT-503
treatment, a metabolic gene expression analysis was conducted using the NanoString Metabolism
Gene Panel Analysis. Genes were assigned to pathways through the nSolver Advanced Analysis
system, and scores were generated that showed upregulation or downregulation of metabolic
pathways as a whole (Figure 4.7A). Upon further analysis, several genes related to cellular nutrient
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and fatty acid sensing, including amino acid synthesis genes and mTOR pathway genes, showed
significant upregulation, suggesting a role of these pathways in the pro-survival transcriptional
adaptations of the cell (Figure 4.7B). To further investigate this, the pathway scores of a number
of pathways related to serine synthesis and nutrient sensing were explored. Plotting the pathway
scores calculated for nucleotide synthesis, the result of carbon input into the folate cycle, showed
that genes related to nucleotide synthesis were largely downregulated (Figure 4.7C). This was
corroborated by significantly decreased metabolite levels in the purine metabolism (p=0.0003) and
pyrimidine metabolism (p < 0.0001) pathways (Figure 4.8A). Importantly, genes related to the
mTOR pathway, which is directly involved in nutrient sensing in the cell, were significantly
upregulated (Figure 4.7D).
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Figure 4.7 – Inhibition of serine synthesis and subsequent accumulation of
branched chain amino acids leads to mTORC1 activation
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Figure 4.7 – Inhibition of serine synthesis and subsequent accumulation of branched chain
amino acids leads to mTORC1 activation
(A) Heat map of pathway scores for pathways characterized by NanoString Metabolism Gene
Panel in NOS1 cells treated with NCT-inactive or NCT-503. Bars with shades of orange indicate
upregulation, bars with shades of blue indicate downregulation.
(B) Gene set analysis plot for significant and non-significant (black) genes in amino acid synthesis
pathway (purple) and mTOR pathway (blue).
(C) Pathway signature score for nucleotide synthesis pathway and (D) mTOR pathway in NOS1
cells treated with NCT-inactive or NCT-503. Pathway signatures are relative to NCT-inactive.
(E) Linear normalized gene counts for ATF4 in NOS1 and Saos2 cells treated with NCT-inactive
or NCT-503.
(F) Pathway signature score for amino acid synthesis pathway in NOS1 cells treated with NCTinactive or NCT-503. Pathway signatures are relative to NCT-inactive.
(G) Linear normalized gene counts for PHGDH and (H) PSAT1 in NOS1 and Saos2 cells treated
with NCT-inactive or NCT-503.
(I) Levels of amino acids in NOS1 cells treated with DMSO or NCT-503 for 48 hours, including
leucine, (J) isoleucine, (K) valine, and (L) alanine.
(M) Ratio of protein expression of phosphorylated (Thr389) p70S6K to total p70S6K in NOS1,
Saos2, and U2OS cell lines in presence of NCT-inactive or NCT-503. Cell lysates were analyzed
using the WES automated capillary blotting system and normalized to total protein levels within
the capillary.
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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Figure 4.8 – NCT-503 modulates amino acid metabolism and transporter gene
expression

Figure 4.8 – NCT-503 modulates amino acid metabolism and transporter gene expression
(A) Plot of pathway impact vs. -log10(p value) for amino acid metabolism pathways affected by
NCT-503 treatment in NOS1 cells. Analysis conducted using MetaboAnalyst 4.0.
(B) Linear normalized gene counts for SLC7A5 and (C) SLC3A2 in NOS1 and Saos2 cells treated
with NCT-inactive or NCT-503.
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.

100

Given that mTORC1 responds to decreased nucleotide levels, and increases purine and
pyrimidine biosynthesis by activating ATF4 (Ben-Sahra et al., 2016), gene expression levels of
ATF4 were analyzed. NanoString analysis showed that ATF4 expression was significantly
upregulated with NCT-503 treatment (Figure 4.7E). ATF4 has been shown to increase transcription
of serine synthesis genes (Zhao et al., 2016). Analysis of the pathway scores for amino acid
synthesis revealed an increase with NCT-503 treatment (Figure 4,7F). PHGDH inhibition also
resulted in increased gene expression of serine synthetic pathway enzymes PHGDH (Figure 4.7G)
and PSAT1 (Figure 4.7H).
The mTORC1 signaling pathway, in addition to sensing nucleotide levels, is highly
responsive to changes in amino acid levels (Dyachok et al., 2016). Gene expression profiling
showed an increase in serine biosynthetic enzymes, indicating a targeted response to PHGDH
inhibition. Given that mTORC1 can sense amino acids other than serine, amino acid levels were
measured by mass spectrometry. PHGDH inhibition resulted in increased intracellular
concentrations of branched chain amino acids (BCAAs) leucine, isoleucine, and valine (Figures
4.7I, 4.7J, and 4.7K), as well as increased expression of BCAA transporters SLC7A5 and SLC3A2
(Figures 4.8B and 4.8C). Importantly, not all amino acids levels were increased in the cell; for
example, levels of alanine, an amino acid that can be synthesized from pyruvate, decreased with
NCT-503 treatment (Figure 4.7L). Confirming that these regulatory and nutrient stimuli were
resulting in mTORC1 activation, levels of threonine 389 (Thr389) phosphorylation on p70 S6
kinase were elevated with NCT-503 treatment as seen by Wes capillary electrophoresis (Figure
4.7M). These data demonstrate that cellular sensing of decreased nucleotide synthesis and changes
in amino acid levels as a result of PHGDH inhibition drives an activation of the mTOR signaling
pathway.
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4.4.7 Perhexiline, but not rapamycin, causes cell death in osteosarcoma
and other PHGDH-high cell lines when combined with PHGDH
inhibition.
Accumulation of BCAAs have been shown to activate mTOR signaling, through both
Sestrin-mediated GATOR2 activity, as well as leucine-based nutrient signaling pathways, further
implicating mTOR activation as a survival mechanism of PHGDH inhibition (Kim et al., 2015;
Nicklin et al., 2009; Persaud et al., 2018). Therefore, the possibility that PHGDH inhibition could
sensitize osteosarcoma cell lines to cell death by an mTORC1 inhibitor was explored. Treatment
with rapamycin, which has been previously shown to slow proliferation in osteosarcoma (Zhao et
al., 2015), caused a decrease in proliferation when treated as a single agent (Figure 4.9A).
However, combination of rapamycin and NCT-503 caused no significant cell death at varying
concentrations of rapamycin (Figure 4.9B, Figure 4.10A).
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Figure 4.9 – Perhexiline, but not rapamycin, causes cell death in osteosarcoma
and other PHGDH-high cell lines when combined with PHGDH inhibition
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Figure 4.9 – Perhexiline, but not rapamycin, causes cell death in osteosarcoma and other
PHGDH-high cell lines when combined with PHGDH inhibition
(A) Counts of nuclear red staining in NOS1 cells treated with DMSO (vehicle control) or 10 µM
rapamycin, normalized to starting time point.
(B) Percent cell death at 72 hours in NOS1 cells treated with DMSO (vehicle control), NCT-503,
rapamycin, or a combination of NCT-503 and rapamycin, measured using YOYO-1 Iodide
counts/mm2, normalized to nuclear red count.
(C) Total protein levels of RSP6 in NOS1 cells treated with NCT-inactive, perhexiline, rapamycin,
or a no treatment serum control.
(D) Counts of nuclear red staining in NOS1 cells treated with DMSO (vehicle control), 5 µM
perhexiline, or 10 µM perhexiline, normalized to starting time point.
(E) Percent cell death at 72 hours in NOS1 cells treated with NCT-inactive, NCT-503, 5 µM
perhexiline, or a combination of NCT-503 and 5 µM perhexiline, measured using YOYO-1 Iodide
counts/mm2, normalized to nuclear red count.
(F) Percent cell death at 72 hours in NOS1 cells treated with 10 µM PKUMDL-WQ-2101, 5 µM
perhexiline, or a combination of PKUMDL-WQ-2101 and 5 µM perhexiline, measured using
YOYO-1 Iodide counts/well, normalized to total cell count using red nuclear staining.
(G) Plot of combination index (CI) against fractional effect for the interaction of increasing doses
of NCT-503 combined with increasing doses of perhexiline in NOS1 cells. CI > 1.0, antagonistic;
1.1 < CI < 0.9, additive; CI < 0.9, synergistic.
(H) Percent cell death at 72 hours in MDA-MB-468 and (I) MDA-MB-231 cells treated with NCTinactive, NCT-503, perhexiline, or a combination of NCT-503 and perhexiline, measured using
YOYO-1 Iodide counts/well, normalized to nuclear red count.
(J) Tumor volume of U2OS xenografts under various conditions: vehicle (n = 10), NCT-503 (n =
10), perhexiline (n = 10), and NCT-503 combined with perhexiline (n = 10).
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates unless otherwise specified. Asterisks represent p-values: * < 0.05, ** < 0.01, *** <
0.005, **** < 0.001.
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Figure 4.10 – Unique biology of perhexiline as a non-rapalog mTORC1
inhibitor causes significant cell death when combined with NCT-503 in
PHGDH-high cancer cell lines
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Figure 4.10 – Unique biology of perhexiline as a non-rapalog mTORC1 inhibitor causes
significant cell death when combined with NCT-503 in PHGDH-high cancer cell lines
(A) Percent cell death with increasing doses of rapamycin combined with 15 µM NCT- in NOS1
cells.
(B) Oxygen consumption rate (OCR) for Saos2 cells with increasing doses of etomoxir or (C)
perhexiline.
(D) Percent cell death at 72 hours in U2OS cells treated with increasing doses of etomoxir and
NOS1 cells treated with highest dose of etomoxir, with or without 15 µM NCT-503, measured
using YOYO-1 Iodide counts/mm2, normalized to nuclear red count.
(E) Total protein levels of mTOR in NOS1 cells treated with NCT-inactive, NCT-503, perhexiline,
NCT-503 and perhexiline, or rapamycin.
(F) Protein expression of mTOR in NOS1 cell lysates treated with NCT-inactive, NCT-503,
perhexiline, or NCT-503 and perhexiline. Cell lysates were analyzed using the WES automated
capillary blotting system and normalized to total protein levels within the capillary. Band image is
representative.
(G) Percent cell death at 72 hours in Saos2, (H) U2OS cells, and (I) U2OS shPHGDH cells treated
with NCT-inactive, NCT-503, 5 µM perhexiline, or a combination of NCT-503 and 5 µM
perhexiline, measured using YOYO-1 Iodide counts/well, normalized to total cell count using red
nuclear staining.
(J) Change in mouse weight, calculated as final weight (g) – starting weight (g) for mice treated
with vehicle (n = 10), NCT-503 (n = 10), perhexiline (n = 10), or NCT-503 combined with
perhexiline (n = 10).
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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Previously, etomoxir and perhexiline, two inhibitors of CPT1/2 and beta-oxidation, were
tested to demonstrate their effect on fatty acid oxidation and cell viability in osteosarcoma cell
lines. Interestingly, a discordance was found. Neither CPT1 inhibitor caused a change in oxygen
consumption rate, even when cells were exposed to up to eight times the working concentration of
etomoxir, or four times the working concentration of perhexiline (Figures 4.10B and 4.10C).
Furthermore, etomoxir alone or in combination with NCT-503 had no cytostatic or cytotoxic
effects (Figure 4.10D). Based on the specificity of etomoxir as a CPT1/2 inhibitor, and the known
non-rapalog mTORC1 inhibitory capacity of perhexiline at lower doses (Balgi 2009), lower
concentrations of perhexiline were also tested as mTOR inhibitors.
A multiplex bead-based assay for mTOR targets showed that levels of total RPS6, a
downstream target of mTOR, were significantly decreased by perhexiline, as well as rapamycin
(Figure 4.9C). Additionally, total mTOR expression was found to decrease with perhexiline
treatment (Figures 4.10E and 4.10F). Indeed, perhexiline treatment at relatively low concentrations
(10 µM) did inhibit cellular proliferation (Figure 4.9D) and cause cell death (Figure 5E). At lower
concentrations (5 µM), perhexiline as a single agent did not inhibit proliferation (Figure 4.9D), but
in combination with NCT-503 was found to cause significant cell death in NOS1 (Figure 4.9E), as
well as Saos2 and U2OS (Figures 4.10G and 4.10H).This phenotype was also shown with
PKUMDL-WQ-2101 combined with perhexiline, demonstrating that this was an on-target effect
of PHGDH inhibition (Figure 4.9F). Using CalcuSyn software, the effects of perhexiline in
combination with NCT-503 were also demonstrated to be synergistic (Figure 4.9G). Furthermore,
this could be replicated in other PHGDH-high (Figure 4.9H), but not PHGDH-low (Figure 4.9I),
cell lines. Combination treatment also did not cause cell death in PHGDH stable knockdown cell
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lines, demonstrating that this combination is only cytotoxic in PHGDH-high cell lines (Figure
4.10I).
Finally, to test the efficacy of this dual inhibition in vivo, U2OS cells were xenografted
onto the right flank of athymic nude mice, and mice were treated with either vehicle, NCT-503,
perhexiline, or a combination of NCT-503 and perhexiline. Single-agent NCT-503 was not able to
slow tumor growth when compared to vehicle. Single-agent perhexiline had a slight but significant
decrease in tumor growth rate. Importantly, the combination of NCT-503 and perhexiline had a
significant and marked effect on U2OS xenografts in vivo, resulting in sustained inhibition of
tumor growth over 30 days of treatment (Figure 4.9J, Figure 4.10J).

4.4.8 Accumulation of SAM and methionine contribute to activation of
GATOR pathway, suggesting mTORC1 inhibitory mechanism of
perhexiline.
Given the differential mTORC1 inhibitory activity of perhexiline and rapamycin and the
limited literature regarding perhexiline as an mTORC1 inhibitor, the mechanism by which
perhexiline inhibits the mTORC1 signaling pathway was explored. Metabolomic analyses of
pathways involved in mTORC1 regulation showed that PHGDH inhibition caused an
accumulation of intermediates of the methionine cycle, including methionine (Met) and Sadenosylmethionine (SAM) (Figure 4.11A). As methionine synthesis requires a one-carbon unit
from the folate cycle, a lack of flux through the folate cycle would also inhibit flux through the
methionine cycle, as shown by lack of change in S-adenosyl homocysteine (SAHC) (Figure
4.11A).
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Figure 4.11 – Accumulation of SAM and methionine contribute to activation of
GATOR pathway, suggesting mTORC1 inhibitory mechanism of perhexiline
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Figure 4.11 – Accumulation of SAM and methionine contribute to activation of GATOR
pathway, suggesting mTORC1 inhibitory mechanism of perhexiline.
(A) Levels of methionine cycle metabolites Methionine (Met), S-adenosyl methionine (SAM), and
S-adenosyl homocysteine (SAHC) in NOS1 cells treated with DMSO (vehicle control) or NCT503 for 48 hours.
(B) Schematic showing effect of PHGDH inhibition on SAM and leucine metabolite levels,
downstream mTORC1 pathway activation.
(C) Images of NOS1 cells labeled with fluorescent antibody against NPRL2 (GATOR1) (green),
fluorescent Lysotracker dye (red), and overlay of green and red showing NPRL2 localization at
lysosome (yellow) in various conditions: NCT-inactive, NCT-503, perhexiline, and NCT-503
combined with perhexiline for 48 hours. Scale bars represent 50 µm.
(D) Quantification of overlap of NPRL2 antibody with Lysotracker, normalized to cell count.
(E) Images of NOS1 cells labeled with fluorescent antibody against ITFG2 (KICSTOR) (green),
fluorescent Lysotracker dye (red), and overlay of green and red showing ITFG2 localization at
lysosome (yellow) in various conditions: NCT-inactive, NCT-503, perhexiline, and NCT-503
combined with perhexiline for 48 hours. Scale bars represent 50 µm.
(F) Quantification of overlap of ITFG2 antibody with Lysotracker, normalized to cell count.
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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SAM accumulation has been implicated in the activation of mTOR through the SAMTORGATOR1 interaction (Gu et al., 2017). The GATOR1 complex is an mTORC1 inhibitory complex
when bound to the lysosome through recruitment by the KICSTOR protein complex (Wolfson et
al., 2017). When bound to SAM, the SAMTOR protein dissociates from the KICSTOR-GATOR1
complex, inhibiting GATOR1 and allowing for mTORC1 activation (Figure 4.11B). Furthermore,
the accumulation of branched chain amino acids noted earlier can bind to Sestrin, which releases
the GATOR2 complex and further inhibits GATOR1 (Kim et al., 2015). Given the combined
metabolite data implicating the activation of this pathway with PHGDH inhibition, the effects of
perhexiline on the KICSTOR-GATOR pathway were explored.
Real-time fluorescent antibody labeling of NPRL2 (the lysosome-binding component of
GATOR1) and lysosomes (Figure 4.11C) by IncuCyte S3 live cell analysis demonstrated that there
was significantly increased NPRL2 localization at the lysosome with perhexiline treatment in
NOS1, which was further enhanced with the combination treatment of NCT-503 and perhexiline
(Figure 4.11D). Similarly, labeling of ITFG2 (the lysosome-binding component of KICSTOR) and
the lysosome (Figure 4.11E) showed that this localization was also significantly increased with
perhexiline treatment in NOS1, and further enhanced with the combination (Figure 4.11F).
Importantly, this localization was found to hold in the PHGDH-low breast cancer MDA-MB-231
as well (Supplemental Figure 4.12), demonstrating that the mechanism of increased localization
of KICSTOR-GATOR1 to the lysosome by perhexiline is not PHGDH-dependent. Taken together,
these findings suggest a possible mechanism of mTORC1 inhibition by perhexiline, beyond
decreased mTORC1 protein expression, where perhexiline treatment increases localization of
mTORC1-inhibiting sensor complexes to the lysosome.
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Figure 4.12 – NPRL2 and ITFG2 localize to lysosome with perhexiline
treatment in PHGDH-negative breast cancer
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Figure 4.12 – NPRL2 and ITFG2 localize to lysosome with perhexiline treatment in PHGDHnegative breast cancer
(A) Images of MDA-MB-231 cells, labeled with fluorescent antibody against NPRL2 (GATOR1
component) (green), fluorescent Lysotracker dye (red), and overlay of green and red showing
NPRL2 localization at lysosome (yellow) in various conditions: NCT-inactive, NCT-503,
perhexiline, and NCT-503 combined with perhexiline for 48 hours. Scale bars represent 50 µm.
(B) Quantification of overlap of NPRL2 antibody with Lysotracker, normalized to cell count.
(C) Images of MDA-MB-231 cells labeled with fluorescent antibody against ITFG2 (KICSTOR
component) (green), fluorescent Lysotracker dye (red), and overlay of green and red showing
ITFG2 localization at lysosome (yellow) in various conditions: NCT-inactive, NCT-503,
perhexiline, and NCT-503 combined with perhexiline for 48 hours. Scale bars represent 50 µm.
(D) Quantification of overlap of ITFG2 antibody with Lysotracker, normalized to cell count.
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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4.5 Discussion
High-dose methotrexate has been part of the standard-of-care in osteosarcoma for over 40
years. While effective in the clinic, high doses of methotrexate can be significantly toxic,
particularly in adults. Given the emergence of precision medicine based on biomarkers,
identification of the cellular phenotype of osteosarcomas and specific therapies that could target
these subtypes is of high clinical importance. As high doses of methotrexate are required to see
anti-proliferative effects in vitro, we predicted that osteosarcoma likely depended on a metabolic
pathway related to, but not directly involved with, the folate cycle.
3-phosphoglycerate dehydrogenase (PHGDH) has been demonstrated to be highly
expressed in a wide variety of cancers. Preferential utilization of the serine biosynthetic pathway
offers an increased capacity for cancer cells to generate genetic material and biomass, facilitating
rapid growth and cell division. The increased levels of PHGDH in cancerous tissue as opposed to
normal tissue offer a metabolic target for novel therapies with a high therapeutic index. Our finding
that high levels of PHGDH RNA and protein correlate with poorer overall survival is of interest
both as a prognostic marker and a potential predictive biomarker, and corroborates other studies
that have shown increased PHGDH to be a characteristic of more aggressive biology (Jia et al.,
2016; Ma et al., 2019; Mullarky et al., 2011; Xian et al., 2016). Furthermore, PHGDH has been
shown to be negatively regulated by wildtype p53 in melanoma (Ou et al., 2015). A study from St.
Jude and MD Anderson found that more than 90 % of surveyed osteosarcoma patients had some
alteration in p53, suggesting a possible mechanism for PHGDH overexpression, not just in
osteosarcoma, but in other p53-mutant cancers as well (Chen et al., 2014). PHGDH could therefore
be explored as a potential tumor biomarker in other tumor types, as high expression may predict
for treatment resistance.
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PHGDH inhibition only causes a decrease in cellular proliferation, unless paired with
serine- and glycine-deprived conditions or very high concentrations of inhibitor, which are likely
not feasible for treating patients (Chen et al., 2013; Mullarky et al., 2016). In osteosarcoma,
depriving cells of serine and glycine did not change the efficacy of PHGDH inhibition (Figures
4.3E and 4.3F), suggesting possible mechanisms of serine- and glycine-indifference that are unique
to bone tumors. RNAseq data from the Cancer Cell Line Encyclopedia (CCLE) indicated relatively
low baseline mRNA expression of the serine transporter ASCT2/SLC1A5, which could explain
why PHGDH inhibition cannot be compensated for with extracellular serine and glycine in
osteosarcoma cells (Barretina et al., 2012). This could also be due to the biology of the bone
microenvironment, which has shown to benefit from cells that have endogenous serine production
(Pollari et al., 2011). Delving deeper, the metabolomic implications of PHGDH inhibition show a
complex regulatory network that integrates not only serine and glycine synthesis, but also synthesis
of other amino acids, nucleotide synthesis, mitochondrial respiration, and molecular signaling
pathways that promote cellular survival in the presence of a PHGDH inhibitor.
The entry of a one-carbon unit from serine into the folate cycle links serine biosynthesis to
one-carbon metabolism, which incorporates the folate cycle and methionine cycle. These
metabolic pathways regulate amino acid synthesis, purine and pyrimidine metabolism, SAM levels
and subsequent epigenetic modulation capacity, as well as the maintenance of cellular redox and
energy balance through glutathione (GSH), ATP, and NADPH generation (Shuvalov et al., 2017),
making upregulation of this system critical for the generation of biomass in cancer cells. PHGDH
inhibition in osteosarcoma cell lines resulted in significantly decreased purine and pyrimidine
metabolism (Figure 4.8A), which results in a diminished deoxynucleotide pool and contributes to
attenuation of proliferation (Lunt et al., 2015).
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The independent metabolomics and [U-13C] glucose tracings conducted in osteosarcoma
cell lines demonstrated additional consistent modified pathways in PHGDH-high osteosarcomas.
Both metabolomics analyses identified increased glucose flux through glycolysis and decreased
TCA cycle activity with NCT-503 treatment (Figure 4.3, Figure 4.4). Critical to the impact of
PHGDH inhibition on the TCA cycle is the contribution of de novo serine biosynthesis to the total
αKG pool. The second enzyme in serine synthesis, PSAT1, converts 3-phosphohydroxypyruvate
(3PP) into 3-phosphoserine (3PSer). The same enzymatic reaction converts glutamate to αKG (Fan
et al., 2015), and is a key pathway by which glucose is incorporated into αKG. Glutaminolysis and
isocitrate dehydrogenation provide additional sources of αKG to the cell (Maus and Peters, 2017).
The detection of αKG by mass spectrometry is difficult, given the high flux of αKG into various
cellular pathways, including the synthesis of 2-hydroxyglutarate (2-HG), an oncometabolite, as
well as the amino acids proline, arginine, and glutamine. However, our finding that unlabeled αKG
is present in our system validates the presence of other cellular pathways that supplement the αKG
pool in the absence of de novo serine biosynthesis (Abla et al., 2020; Maus and Peters, 2017).
The accumulation of fatty acids as a result of PHGDH inhibition was a particular metabolic
phenotype of interest. Fatty acids were found to likely come not from fatty acid synthesis by
SREBP1 or extracellular uptake (Figures 4.5F and 4.5G), but from decreased mitochondrial
activity. Given that osteosarcoma cells have high levels of PHGDH, and subsequently high levels
of de novo serine biosynthesis, the basal flux of glucose would likely be through the serine
synthetic pathway, necessitating alternate fuel sources for the mitochondria, such as fatty acids.
Glutamine metabolism likely did not contribute to mitochondrial oxidative phosphorylation
(Figures 4.5A-C). However, [U-13C] palmitate tracing did demonstrate incorporation of fatty acids
to downstream metabolites of acetyl-coA with NCT-503 treatment, suggesting cellular capacity to
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utilize fatty acids at some degree (Figures 4.5D and 4.5E). With net TCA cycle inhibition by NCT503, however, the fatty acid fuel source accumulates, contributing to mTORC1 activation via lipid
sensing pathways (Menon et al., 2017).
Similarly, PHGDH inhibition also resulted in accumulation of branched chain amino acids
(Figures 4.7I-K), which further contribute to activation of the mTORC1 pathway (Wolfson et al.,
2016). NanoString analysis highlighted the increased expression of SLC3A2 and SLC7A5 with
PHGDH inhibition (Figure 4.8). These two amino acid transporters drive the increased transport
of leucine into the lysosome, resulting in mTORC1 activation from yet another pathway (Milkereit
et al., 2015). The genetic response to small molecule inhibition also showed increased expression
of serine biosynthetic enzymes PHGDH and PSAT1, as well as ATF4 (Figure 4.7), which has been
associated with serine biosynthetic pathway regulation at the transcriptional level (Zhao et al.,
2016). Importantly, mTORC1 has been shown to activate ATF4 in response to cellular
requirements for purine synthesis (Ben-Sahra et al., 2016), a metabolic consequence of PHGDH
inhibition. Finally, increased phosphorylation at Thr389 of p70 S6 kinase with NCT-503 treatment
confirmed an increase in mTORC1 kinase activity (Figure 4.7M). These data all highlighted a
series of metabolic changes that drove an increase in mTORC1 signaling in osteosarcoma cells
treated with NCT-503.
Prior work from our laboratory has shown that, as metabolic rewiring and redundant
systems are built into cellular function, single-agent metabolic therapies are rarely effective in a
clinical setting (Kremer et al., 2017; Prudner et al., 2019; Robinson et al., 2019). Given that
PHGDH inhibition results in metabolite and lipid accumulation that activated mTORC1 from
multiple pathways, including changes in oxygen consumption rate that were specific to PHGDHexpressing cells, we hypothesized that NCT-503 could be sensitizing osteosarcoma cells to
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mTORC1 inhibition. mTOR has already been implicated as a possible target in osteosarcoma (Mita
and Tolcher, 2007). Previous studies have observed that PHGDH inhibition induced autophagy in
carcinoma cells, but have attributed this effect to an mTOR-independent mechanism due to lack
of response to rapamycin treatment (Sharif et al., 2018). The lack of activity of rapamycin in this
system, as well as previous reports, correlates with published literature demonstrating that mTOR
inhibitors combined with other agents have had limited clinical efficacy in osteosarcoma (Fleuren
et al., 2014; Martin-Broto et al., 2017).
The implications of PHGDH inhibition in combination with non-rapalog mTORC1
inhibition offer some insight into previous negative clinical trials using similar agents. The clinical
trial of sorafenib and everolimus in osteosarcoma (Grignani et al., 2015) was somewhat effective.
However, recent research has shown that high PHGDH expression could be a critical driver of
sorafenib resistance (Wei et al., 2019). This offers clinical justification for pursuing PHGDH
inhibition specifically in conjunction with mTORC1 inhibition. The significant effects of NCT503 combined with perhexiline in vivo, with minimal toxicity and dramatic tumor control, show
that PHGDH inhibition with mTORC1-signaling inhibition are a very promising combination in
PHGDH-high cancers.
In that vein, identifying the possible mechanism of perhexiline as a non-rapalog mTORC1signaling inhibitor offers a new class of metabolic signaling inhibitors for exploration in cancer
therapy. Though the primary use of perhexiline is as a CPT1/2 inhibitor, the IC50 for these effects
ranges from 70-150 µM (Kennedy et al., 2000). At lower concentrations (10 µM), perhexiline has
been shown to have anti-mTORC1 activity. As combination with NCT-503 was significantly more
effective with perhexiline rather than rapamycin, and as NCT-503 combined with perhexiline was
synergistic in causing cytotoxicity in osteosarcoma, the possible mechanisms of perhexiline-
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mediated inhibition of mTORC1 signaling could be explored via the metabolic changes that
occurred with PHGDH inhibition. Additionally, as perhexiline is already utilized in the clinic for
cardiomyopathy patients (Beadle et al., 2015), this drug has the clinical potential to be re-applied
as a mTORC1-inhibiting cancer therapeutic.
The accumulation of branched chain amino acids, as well as the accumulation of SAM and
Met, implicated GATOR biology. The protein complex GATOR1, consisting of NPRL2, NPRL3,
and DEPDC5, has been shown to be an inhibitor of mTORC1 when recruited to the lysosome by
KICSTOR (Wolfson et al., 2017). GATOR2, a protein complex consisting of WDR24, WDR59,
MIOS, SEH1L, and SEC13, also regulates mTORC1 by inhibiting GATOR1 (Kim et al., 2015).
Upon PHGDH inhibition, the accumulation of SAM supports the SAMTOR-mediated inhibition
of GATOR1, while the accumulation of branched chain amino acids, and specifically leucine,
support Sestrin 1/2-mediated GATOR2 activation. The effects of perhexiline treatment on
GATOR1 and KICSTOR localization to the lysosome offer an interesting mechanism for
mTORC1 inhibition. The increased localization of KICSTOR and GATOR1 to the lysosome
drives the inhibition of mTOR and provides a novel mechanism of inhibition that is unique from
rapamycin. A more complete understanding of perhexiline as an mTORC1 pathway inhibitor is
the focus of ongoing work.
Given the significantly poorer overall survival in patients with high PHGDH expression,
there is likely a large subset of osteosarcoma patients that would not benefit from exposure to highdose methotrexate. PHGDH could therefore be important not only as a prognostic marker, but also
as a predictive biomarker to avoid ineffective and potentially toxic treatment in osteosarcoma
patients with high expression. This subset of patients could be considered for alternative
approaches that target PHGDH expression via a combination therapy that could replace toxic high-
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dose methotrexate. Our data showing the significant tumor control potential of the combination of
NCT-503 and perhexiline in vivo emphasize the importance of repurposing perhexiline, which is
already in clinical trials for the treatment of angina in hypertrophic cardiomyopathy, for oncology
clinical trial purposes. This work therefore provides the preclinical rationale for testing a metabolic
combination therapy targeting PHGDH and mTORC1 biology as replacement to high-dose
methotrexate in osteosarcoma.
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Chapter 5: PHGDH Inhibition Causes GSK3-induced
Glycogen Accumulation and Sensitization to Cell
Death

5.1 Abstract
The small molecule inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) results in
a series of metabolic alterations that affect one-carbon metabolism, nucleotide biosynthesis, and
attenuate oxidative phosphorylation, and activate the mTORC1 signaling pathway, sensitizing to
cell death with non-rapalog mTORC1 inhibitors such as perhexiline. In this study, we aimed to
identify the mechanism of non-rapalog mTORC1 inhibition using ALPI3MT55, a novel PI3Kinase/mTOR inhibitor. We found that treatment with both perhexiline and ALPI3MT55 cause a
decrease in phosphorylation of GSK3α and GSK3β, where treatment with rapamycin did not.
Decreased GSK3 phosphorylation results in increased activity of GSK3, an inhibitor of glycogen
synthase. Furthermore, treatment with NCT-503, a small molecule inhibitor of PHGDH, affected
the composition of adenylate pools, causing an increased flux of glucose into glycogenesis. The
combination of NCT-503 and ALPI3MT55 was demonstrated to have a synergistic and antitumoral effect in vitro and in vivo, similar to perhexiline, offering pre-clinical justification for the
use of this combination in the treatment of PHGDH-high osteosarcoma.
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5.2 Introduction
One-carbon metabolism is a critical component of the abnormal acceleration of cellular
growth and proliferation that is characteristic of cancer (Ducker and Rabinowitz, 2017). These
metabolic pathways consist of the de novo serine biosynthetic pathway, the folate cycle, and the
methionine cycle, and support nucleotide biosynthesis, amino acid biosynthesis, epigenetic
regulation, redox homeostasis, and metabolite levels that contribute to cellular signaling and
mitochondrial oxidative phosphorylation (Maddocks et al., 2016; Shuvalov et al., 2017). The ratelimiting enzyme of de novo serine biosynthesis, 3-phosphoglycerate dehydrogenase (PHGDH) has
been demonstrated to be elevated in several cancers, including osteosarcoma. Previous studies
have shown that the small molecule inhibition of PHGDH is associated with decreased TCA cycle
activity, decreased nucleotide synthesis, increased glycolytic activity and fermentation, and
elevated mTORC1 signaling, as described in Chapter 4.
The inhibition of mTOR has been explored through several avenues. Rapamycin is the
main canonical mTOR inhibitor, which functions by binding to FK506-binding protein of 12 kDA
(FKBP12) and interacts with the FKBP12-rapamycin binding (FRB) domain of mTORC1
(Laplante and Sabatini, 2009b; Leone et al., 2006). mTOR inhibitors including sirolimus,
temsirolimus, and everolimus are all analogs of rapamycin (Fleuren et al., 2014; Goudarzi et al.,
2014). Given the dysregulation of mTOR signaling in osteosarcoma, rapamycin-based therapies
have been attempted with varying degrees of success, both in the lab and in the clinic (Bishop and
Janeway, 2016; Ding et al., 2016; Grignani et al., 2015). The second generation of mTOR
inhibitors are called mTOR kinase inhibitors or non-rapalog mTOR inhibitors, as they do not
contain a motif that can bind to FKBP12 (Ballou and Lin, 2008). Instead, these mTOR kinase
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inhibitors function by competing with ATP in the catalytic site of mTOR, thus inhibiting the
functional activity of mTORC1 and mTORC2 (Wang et al., 2014).
In this study, the effects of non-rapalog mTOR inhibition with perhexiline or a novel PI3Kinase/mTOR inhibitor, ALPI3MT55, were explored in the context of PHGDH inhibition in
osteosarcoma. The inhibition of PHGDH with NCT-503 demonstrated a decrease in the
intracellular ATP:AMP ratio, driving an increased flux of glucose into glucose-1-phosphate, the
precursor to glycogen synthesis. Given that modulated adenylate pools can affect AMPK
signaling, and AMPK is an inhibitor of mTORC1, the effect of perhexiline and ALPI3MT55 on
pathways downstream of AMPK was explored. Treatment with both perhexiline and ALPI3MT55
caused a decrease in phosphorylation of GSK3α and GSK3β, where treatment with rapamycin did
not. Decreased GSK3 phosphorylation results in increased activity of GSK3, an inhibitor of
glycogen synthase and. The combination of NCT-503 and ALPI3MT55 was also demonstrated to
have a synergistic and anti-tumoral effect in vitro and in vivo, offering pre-clinical justification for
the use of this combination in the treatment of PHGDH-high osteosarcoma, and opening an
interesting avenue of exploration for the link between de novo serine biosynthesis and mTOR
inhibition in cancer.
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5.3 Materials and Methods
5.3.1 Cell culture
NOS1 and Saos2 cell lines were obtained from ATCC (Manassas, VA, USA). Cell lines
were cultured in MEM (Cat # 11095072, Gibco, Thermo Fisher, Waltham, MA) supplemented
with 10 % FBS (Cat # S11150, R&D Systems, Bio-Techne, Minneapolis, MN), 1.3 %
penicillin/streptomycin (Cat # 15140122, Gibco, Thermo Fisher, Waltham, MA), 286 µM serine
(Cat # AAJ6218709, Fisher Scientific, Hampton, NH) and 286 µM glycine (Cat # 67419, SigmaAldrich, St. Louis, MO). All cells were cultured in prophylactic plasmocin (Cat # ant-mpp,
InvivoGen, San Diego, CA) and checked regularly for mycoplasma contamination.

5.3.2 NucRed Cell Line Generation
All cell lines were transduced with IncuCyte NucLight Red lentivirus reagent (EF-1 Alpha
promoter, Puromycin selection) (Cat # 4476, Sartorius, Ann Arbor, MI, USA). Briefly, cells were
seeded and allowed to adhere for 24 hours to reach approximately 20-40 % confluence. NucLight
reagent was diluted in DMEM containing 8 µg/mL polybrene (Cat # sc-134220, Santa Cruz
Biotechnology, Dallas, TX) and added to cells for 48 hours. Media was then replaced with fresh
DMEM containing 3 µg/mL puromycin (Cat # MIR 5940, Mirus Bio, Madison, WI). Red
fluorescence was monitored on the IncuCyte ZOOM system (Sartorius, Ann Arbor, MI), and
analyzed using the IncuCyte image analysis software (Sartorius, Ann Arbor, MI).
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5.3.3 Compounds
NCT-503 inactive control (Cat # SML1671, Sigma Aldrich, St. Louis, MO) was solubilized
in DMSO and used at 10 µM unless otherwise specified. NCT-503 (Cat # SML1659, Sigma
Aldrich, St. Louis, MO) was solubilized in DMSO and used at 15 µM unless otherwise specified.
All assays using NCT-503 contained 10 µM NCT-inactive in solution. Rapamycin (Cat # R8781,
Sigma Aldrich, St. Louis, MO) was purchased as a 2.5 mg/mL solution in DMSO. Perhexiline (Cat
# SML0120, Sigma Aldrich, St. Louis, MO) was solubilized in DMSO. ALPI3MT55 (Advenchen
Laboratories, Los Angeles, CA) was solubilized in DMSO.

5.3.4 Cell Death Assays
NucRed cells were seeded in 96 well tissue-culture plates (Cat # TP92096, Midwest
Scientific, Valley Park, MO). At time of treatment, culture media was removed from wells, and
was replaced with treatment condition of interest, diluted in phenol red-free MEM (Cat #
51200038, Gibco, Thermo Fisher, Waltham, MA) supplemented with 10 % FBS, 2 mM Lglutamine (Cat # 25030081, Gibco, Thermo Fisher, Waltham, MA), 286 µM serine, and 286 µM
glycine. Red nuclear fluorescence was monitored on the IncuCyte ZOOM system and analyzed
using the IncuCyte image analysis software. Cell death assays were conducted with treatment
media including 50 nM YOYO-1 Iodide (Cat # Y3601, Invitrogen, Carlsbad, CA) for measuring
cell death or 2 µM CellEvent Caspase-3/7 Green Detection Reagent (Cat # C10423, Invitrogen,
Carlsbad, CA) for measuring apoptosis. Green YOYO-1 iodide or Capase-3/7 fluorescence and
red nuclear fluorescence were monitored on the IncuCyte ZOOM system and analyzed using the
IncuCyte image analysis software. Cell death was quantified by normalizing green count/mm2 to
red count/mm2 to account for differences in cell density, and then normalized to starting timepoint.
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Percent cell death was calculated using a 100 % death endpoint measurement. Quantification of
analyses are summarized as mean ± SEM, with variance across groups compared for statistical
significance by student’s t-test on Prism 8 software (GraphPad Software, San Diego, CA).
Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.

5.3.5 Immuno Assays
Lysates were obtained for all cell lines by collecting 2 x 106 cells and washing three times
with 1X PBS. Cells were then pelleted and lysed per reagent protocol for cell lysis buffer (Cat #
9803, Cell Signaling Technology, Danvers, MA) with supplemented protease and phosphatase
inhibitors (Cat # 78440, Thermo Scientific, Waltham, MA). Protein concentration within cell
lysates were determined using Bradford Assay (Cat # 5000202, Bio-Rad, Hercules, CA). Protein
expression was analyzed using the Wes Automated Western Blotting System (ProteinSimple, BioTechne, Minneapolis, MN), which uses automated capillary technology to measure protein
expression and total protein concentration, per manufacturer’s protocol. Protein expression was
detected using 12-230 kDa Separation Modules. Anti-AMPKα antibody (anti-rabbit, Cat # 5831,
Cell Signaling Technology, Danvers, MA) was diluted 1:50 for signal detection. Anti-phospho
AMPKα (Thr172) antibody (anti-rabbit, Cat # 2535, Cell Signaling Technology, Danvers, MA)
was diluted 1:50 for signal detection. Protein levels were visualized and quantified using Compass
for SimpleWestern software (ProteinSimple, Bio-Techne, Minneapolis, MN). Quantification of
analyses are summarized as mean ± SEM, with variance across groups compared for statistical
significance by student’s t-test. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005,
**** < 0.001.
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5.3.6 Intracellular Metabolomics Analysis
NOS1 cells were plated at 8 x 105 cells per 10 cm dish and treated with either DMSO or
15 µM NCT-503, diluted in MEM containing 10 % FBS, 286 µM serine, and 286 µM glycine for
48 hours. Methanol metabolite extraction was performed according to the Human Metabolome
Technologies (HMT) Metabolomics Analysis Sample Preparation Protocol method for adherent
cells (Human Metabolome Technologies, Boston, MA). Metabolite concentrations were
normalized to cell count and submitted in triplicate. Quantification of analyses are summarized as
mean ± SEM, with variance across groups compared for statistical significance by student’s t-test.
Pathway analysis of metabolites was conducted using MetaboAnalyst 4.0 (Montreal, Quebec,
Canada). Data was glog transformed and Pareto scaled, and p-values were adjusted (Chong et al.,
2019). Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.

5.3.7 Intracellular [U-13C] Tracing Analysis
Saos2 cells were plated at 2.8 x 106 cells per dish in 10 cm dishes and allowed to adhere
for 24 hours. Prior to experiment, dialyzed FBS was complexed with palmitate (Cat # P0500-25G,
Sigma Aldrich, St. Louis, MO) by rocking at 37 ºC overnight (Kamphorst et al., 2014). Cells were
treated with either 10 µM NCT-inactive or 10 µM NCT-inactive with 15 µM NCT-503, diluted in
DMEM containing 5.5 mM glucose, 2 mM glutamine, and 10 % FBS for 21 hours to reach steady
state. Media was then replaced with fresh media containing drug for 3 hours. Media was then
replaced with fresh media containing dialyzed FBS supplemented with palmitate and [U-13C]
glucose (Cat # CLM-1396-0.5, Cambridge Isotope Laboratories, Tewksbury, MA). Cells were
maintained in labeled medium for 24 hours (Locasale et al., 2011; Reid et al., 2018). Methanol
metabolite extraction was performed according to the Human Metabolome Technologies (HMT)
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Metabolomics Analysis Sample Preparation Protocol method for adherent cells (Human
Metabolome Technologies, Boston, MA). Metabolite concentrations were normalized to cell count
and [U-13C] concentrations were corrected for natural abundance. Samples were submitted in
triplicate. Quantification of analyses are summarized as mean ± SEM, with variance across groups
compared for statistical significance by student’s t-test. Asterisks represent p-values: * < 0.05, **
< 0.01, *** < 0.005, **** < 0.001.

5.3.8 NanoString Metabolism Gene Panel
Cells were plated at 1 x 106 cells per dish in 10 cm dishes and treated with either DMSO,
10 µM NCT-inactive, 10 µM NCT-inactive with 15 µM NCT-503, or 500 nM ALPI3MT55 for 24
hours. Cells were then lysed and RNA was collected using the Direct-zol RNA Miniprep Plus Kit
(Cat # R2070, Zymo Research, Irvine, CA), and 250 ng of RNA were sent to NanoString; samples
were submitted in triplicate. Quantification of analyses are summarized as mean ± SEM, with
variance across groups compared for statistical significance by student’s t-test. Asterisks represent
p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.

5.3.9 MilliPlex MAP Magnetic Bead-Based Assay
Cells were plated in 6-well plates. When confluent, cells were serum-starved for four hours.
After four hours, media was replaced with DMEM containing serum and relevant treatment
conditions: serum alone (NT), 10 µM NCT-inactive, 10 µM NCT-inactive with 15 µM NCT-503,
5 µM perhexiline, 500 nM ALPI3MT55, or 10 µM rapamycin. Cells were incubated at 37 ºC for
30 minutes for short-term phosphorylation studies, or for 24 hours for steady-state phosphorylation
studies. Samples were collected according to manufacturer’s instructions (Cat # 48-612MAG,
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Millipore, Burlington, MA) and 16 µg of sample were submitted for analysis. Measurements were
taken on a Luminex FlexMap 3D system. Quantification of analyses are summarized as mean ±
SEM, with variance across groups compared for statistical significance by student’s t-test.
Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.

5.3.10

Xenograft Studies

Mouse xenograft protocols were approved by Washington University in St. Louis
Institutional Animal Care and Use Committee (IACUC). Mice were maintained under IACUC
guidelines. 2 x 106 U2OS cells were collected in 75 µL of DMEM and combined with 75 µL of
Matrigel (Cat # 354234, Corning, Corning, NY), and grafted by subcutaneous injection into the
right flank of athymic nude mice (female, 4-6 weeks old, homozygous for Foxn1nu, Cat # 002019,
Jackson Laboratories, Bar Harbor, ME). Length and width of resulting tumors from xenograft were
measured daily, and tumor volumes were calculated using the formula (length x width2)/2. Cell
line-derived xenografts were allowed to grow to an average volume of 200 mm3, at which point
mice were randomly assigned to treatment groups.
Mice were treated with either vehicle (5 % ethanol, 35 % polyethylene glycol 300 (Cat #
8.17002, Sigma Aldrich, St. Louis, MO), 60 % aqueous 30 % hydroxyropyl-beta-cyclodextrin (Cat
# H107, Sigma Aldrich, St. Louis, MO)) daily, 40 mg/kg NCT-503 (in vehicle) intraperitoneally
(IP) daily, 12 mg/kg ALPI3MT55 (in 1X PBS) by oral gavage daily, or 40 mg/kg NCT-503 IP and
12 mg/kg ALPI3MT55 by oral gavage daily. Tumors were allowed to grow to volumes of 2000
mm3 or until 30 days had passed. More than six mice per treatment group were utilized for all
studies. Investigators were not blind to treatment groups. Tumor growth curves are shown as mean
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± SEM, with variance across groups compared for statistical significance by two-way ANOVA.
Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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5.4 Data and Discussion
5.4.1 Non-rapalog mTOR inhibitors affect different cellular signaling
pathways from rapamycin.
PHGDH inhibition has been demonstrated to drive a metabolic shift that activates
mTORC1 signaling in osteosarcoma cells. The changes to various metabolites resulted in a cellular
phenotype that sensitized osteosarcoma cells to mTORC1 inhibition by non-rapalog perhexiline,
but not rapamycin. To elucidate the differences in activity between rapamycin and non-rapalog
mTOR inhibitors such as perhexiline, a Milliplex MAP assay measuring phosphorylation and total
protein levels of various targets in PI3-K/mTOR signaling pathways. Osteosarcoma cells were
treated with 10 µM rapamycin, 5 µM perhexiline, or 500 nM ALPI3MT55, a novel PI3-K/mTOR
inhibitor for 24 hours.
Three key components of mTOR signaling were differentially regulated with rapamycin as
compared to perhexiline and ALPI3MT55. The ratio of phosphorylated Akt at Ser473 to total Akt
was increased with rapamycin treatment and unchanged with perhexiline or ALPI3MT55
treatment, though not significantly (Figure 5.1A). Perhexiline and ALPI3MT55 treatment
significantly decreased phosphorylation of TSC2 at Ser939 compared to serum control, where
rapamycin significantly increased phosphorylation of TSC2 at Ser939 (Figure 5.1B). Finally,
perhexiline and ALPI3MT55 both caused a significant decrease in GSK3α phosphorylation at
Ser21 (Figure 5.1C) and GSK3β phosphorylation at Ser9, where rapamycin had no significant
effect (Figure 5.1D).
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Figure 5.1 – Glycogen synthase kinase is activated by non-rapalog mTORC1
inhibitors perhexiline and ALPI3MT55
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Figure 5.1 – Glycogen synthase kinase is activated by non-rapalog mTORC1 inhibitors
perhexiline and ALPI3MT55
(A) Ratio of phosphorylated Akt (Ser473) levels to total protein levels of Akt in NOS1 cells treated
with perhexiline, ALPI3MT55, rapamycin, or a no treatment serum control.
(B) Ratio of phosphorylated TSC2 (Ser939) levels to total protein levels of TSC2 in NOS1 cells
treated with perhexiline, ALPI3MT55, rapamycin, or a no treatment serum control.
(C) Ratio of phosphorylated GSK3α (Ser21) levels to total protein levels of GSK3α in NOS1 cells
treated with perhexiline, ALPI3MT55, rapamycin, or a no treatment serum control.
(D) Ratio of phosphorylated GSK3β (Ser9) levels to total protein levels of GSK3β in NOS1 cells
treated with perhexiline, ALPI3MT55, rapamycin, or a no treatment serum control.
Bars represent mean of values; error bars represent SEM. All assays were conducted using the
Milliplex MAP phospho- and total-protein assay with n = three replicates. Asterisks represent pvalues: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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Phosphorylation at Ser473 of Akt is an activating modification by Rictor, a component of
mTORC2 (Ricchi et al., 2009; Vadlakonda et al., 2013). Given that none of the agents specified
should have affected mTORC2 kinase activity, the non-significant changes in Akt are expected.
Importantly, Akt phosphorylates TSC2 at Ser939; therefore, decreased Akt activity would result
in decreased TSC2 phosphorylation, which was identified in the non-rapalog-treated samples but
not in the rapamycin-treated samples.
Phosphorylation of GSK3α at Ser21 and GSK3β at Ser9 results in an inactive kinase (Koo
et al., 2014). Therefore, decreased GSK3 phosphorylation with perhexiline or ALPI3MT55
treatment would result in increased GSK3 activity as compared to rapamycin treatment. TSC2 can
also be phosphorylated by GSK3 at Ser 1341 and Ser1337, but only when TSC2 has been
previously primed by AMPK phosphorylation at Ser1345 (Inoki et al., 2006). To verify increased
GSK3 activity with perhexiline or ALPI3MT55 treatment, levels of TSC2 phosphorylation at each
of these sites should also be measured. This would also demonstrate TSC2-mediated inhibition of
mTOR through GSK3 phosphorylation.
Broadly, these data indicate that non-rapalog mTOR inhibitors such as perhexiline and
ALPI3MT55 have activity in pathways that rapamycin does not target. As PHGDH inhibition
sensitizes to cell death with non-rapalog mTOR inhibition, but not with rapamycin, these pathways
are implicated as possible pathways of interest as a result of PHGDH inhibition.
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5.4.2 PHGDH inhibition alters cellular energetics, increasing glucose
flux to glycogen synthesis.
To explore the role of GSK3-Akt biology as a survival mechanism of PHGDH inhibition
in osteosarcoma cells, the cellular response to NCT-503 treatment was explored in greater detail.
PHGDH inhibition has previously been demonstrated to inhibit glucose entry into de novo serine
biosynthesis, causing an accumulation of metabolites in the folate and methionine cycles while
driving glucose through glycolysis and into lactate fermentation. Glycine and 10formyltetrahydrofolate, a metabolite in the folate cycle, contribute to the synthesis of inosine
monophosphate, the precursor to adenine synthesis (Reid et al., 2018). Akt phosphorylation is
stabilized by ATP binding, and therefore serves as a sort of intracellular adenylate sensor. Given
that TSC2 can also be regulated by the equilibrium of the adenylate pool through AMPK signaling,
concentrations of adenylates were measured in NOS1 cells using mass spectrometry. Significantly
less AMP, ADP, and ATP were found with NCT-503 treatment (Figures 5.2A-C). The ratio of
ATP:ADP did not change with NCT-503 treatment (Figure 5.2D), while the ratio of ATP:AMP
significantly decreased with PHGDH inhibition (Figure 5.2E).
When energetic stress results in increased intracellular AMP levels, AMPK is activated.
However, increased phosphorylation of AMPK was not observed, suggesting that intracellular
levels of AMP were not decreased enough to activate this pathway (Figure 5.2F). Furthermore,
these data indicate that AMPK is likely not activated with PHGDH inhibition, and therefore cannot
phosphorylate the required site on TSC2 to facilitate GSK3-mediated phosphorylation of TSC2
and subsequent inhibition of mTOR activity. These data support that PHGDH inhibition results in
an active mTORC1 signaling pathway in osteosarcoma cells.
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Figure 5.2 – PHGDH inhibition alters cellular energy status, driving glucose
flux from de novo serine synthesis to glycogen production

136

Figure 5.2 – PHGDH inhibition alters cellular energy status, driving glucose flux from de
novo serine synthesis to glycogen production
(A) Relative abundance of AMP, (B) ADP, (C) and ATP in presence of 10 µM NCT-inactive or
15 µM NCT-503, measured by mass spectrometry.
(D) Ratio of ATP:ADP and (E) ATP:AMP in presence of 10 µM NCT-inactive or 15 µM NCT503, measured by mass spectrometry.
(F) Ratio of protein expression of phosphorylated AMPK-α at Thr172 to total AMPK-α in NOS1
and Saos2 cell lines. Cell lysates were analyzed using the WES automated capillary blotting system
and normalized to total protein levels within the capillary.
(G) Percent incorporation of [U-13C] labeled glucose into glucose-1-phosphate in presence of 10
µM NCT-inactive or 15 µM NCT-503, measured by mass spectrometry.
Bars represent mean of values; error bars represent SEM. All assays were conducted with n = three
replicates. Asterisks represent p-values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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Given that activation of Akt signaling can stimulate glycogen metabolism, the fate of
glucose when PHGDH is inhibited was further explored (Hermida et al., 2017). [U-13C] glucose
tracing was conducted in the presence of 10 µM NCT-inactive or 15 µM NCT-503, and glucose
incorporation into branch-off points of glycolysis was measured. As previously demonstrated,
glucose did not enter the TCA cycle (Figure 4.4I). There was increased glucose incorporation into
glucose-1-phosphate, the second metabolite of glycogenesis (Figure 5.2G). Taken together, this
data suggests that in addition to stimulating fermentation and lactate production, PHGDH
inhibition also causes metabolic alterations that affect cellular energy status, potentially
stimulating glycogenesis. To confirm this, levels of glycogen must be quantified.
Importantly, glycogenesis generally occurs when cells have elevated levels of glucose, as
glycogen synthesis allows for a mechanism of glucose storage. Given that PHGDH inhibition
results in increased cellular capacity to utilize fatty acids as a mitochondrial fuel source, it is
possible that cells treated with NCT-503 therefore shunt imported glucose into glycogen and
lactate, rather than utilize it for energy production. Given that both perhexiline and ALPI3MT55
treatment caused decreased GSK3α and GSK3β phosphorylation, which would ultimately result
in increased GSK3 activity and decreased glycogen synthase activity, validating the glycogen
phenotype in cells treated with NCT-503 would therefore offer a mechanism for cell survival
upon PHGDH inhibition.

5.4.3 PHGDH inhibition combined with ALPI3MT55 causes cell death
in osteosarcoma.
GSK3β activation and localization at the mitochondria is correlated with suppression of
mitochondrial complex I, leading to a reduction of ATP production and induction of caspase 3138

dependent apoptosis (King et al., 2008). This activity was enhanced in neuroblastoma cell lines
when cells were treated with rotenone, a complex I inhibitor (King et al., 2008). Given that NCT503 treatment results in TCA cycle inhibition in osteosarcoma cells, the combination of NCT-503
with non-rapalog mTOR inhibitors that are known to activate GSK3α and GSK3β was tested for
cytotoxicity. As previously shown, NCT-503 combined with perhexiline caused synergistic cell
death in vitro and in vivo (Figure 4.9).
Using a Caspase-3/7 detection probe, apoptosis was measured in NOS1 cells treated with
NCT-inactive control, NCT-503, ALPI3MT55, or a combination of NCT-503 with ALPI3MT55.
NCT-503 combined with ALPI3MT55 caused significantly more cell death by apoptosis in NOS1
than either single agent (Figure 5.3A). To test the effects of these drugs in vivo, U2OS cells were
injected into the flanks of nude mice to generate cell line-derived xenografts. Xenografts were then
treated with vehicle control, NCT-503, ALPI3MT55, or a combination of NCT-503 and
ALPI3MT55. NCT-503 and ALPI3MT55 as single agents had little effect on the outgrowth of the
tumors (Figure 5.3B). However, combination of NCT-503 and ALPI3MT55 resulted in
significantly abrogated tumor growth (Figures 5.3B and 5.3C).
The enhanced anti-tumor activity of ALPI3MT55 in combination with NCT-503 provides
the preclinical justification for PHGDH inhibition with non-rapalog mTOR inhibition in
osteosarcoma. The alternative mechanisms of non-rapalog mTOR inhibitors as GSK3 activators
offer a unique avenue into the cellular energetics of osteosarcoma that may also open a new class
of treatments for this cancer.
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Figure 5.3 – PHGDH inhibition combined with ALPI3MT55 causes cell death
in osteosarcoma
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Figure 5.3 – PHGDH inhibition combined with ALPI3MT55 causes cell death in
osteosarcoma
(A) Percent cell death at 60 hours in NOS1 cells treated with 10 µM NCT-inactive, 15 µM NCT503, 500 nM ALPI3MT55, or a combination of 15 µM NCT-503 and 500 nM ALPI3MT55,
measured using CellEvent Caspase 3/7 Green fluorescence area/well, normalized to total cell count
using red nuclear staining.
(B) Tumor volume of U2OS xenografts under various conditions: vehicle (n = 10), NCT-503 (n =
10), ALPI3MT55 (n = 7), and NCT-503 combined with ALPI3MT55 (n = 7).
(C) Change in mouse weight, calculated as final weight (g) – starting weight (g) for mice treated
with vehicle (n = 10), NCT-503 (n = 10), ALPI3MT55 (n = 7), or NCT-503 combined with
ALPI3MT55 (n = 7).
Points and bars represent mean of values; error bars represent SEM. Asterisks represent p-values:
* < 0.05, ** < 0.01, *** < 0.005, **** < 0.001.
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Chapter 6: Future Directions and Concluding
Remarks

The complex biology of cancer encompasses cellular energetics, biomass production and
proliferation, redox homeostasis, genetic and epigenetic regulation, and environmental factors like
immune response, angiogenesis, and invasion and metastasis (Hanahan and Weinberg, 2011).
Understanding the intricacies of tumor metabolism offers a significant advantage to treatment
development. Serine, glycine, and one-carbon (SGOC) metabolism consists of energetic and
metabolite-based pathways that drive cancer growth, proliferation, and metastasis; as such, it
makes sense that this network of proteins and genes are upregulated in many types of cancer.
The rate-limiting enzyme of de novo serine biosynthesis, 3-phosphoglycerate
dehydrogenase (PHGDH), has been demonstrated to be elevated in a number of cancers, including
breast cancer, melanoma, and most recently, osteosarcoma. This elevation could be due to
increased biomass production through upregulated de novo serine biosynthesis. However,
elevation of PHGDH may also be due to the p53 status of most osteosarcomas. Over 90 % of
osteosarcomas exhibit some form of mutation or lack-of-function in TP53 (Chen et al., 2014).
Wildtype p53 has been shown to negatively regulate PHGDH expression by inhibiting PHGDH
transcription (Ou et al., 2015). Therefore, p53 mutant osteosarcomas may have elevated PHGDH
due to lack of transcriptional inhibition by p53. Furthermore, p53 mutational status can elevate the
expression of several other potential biomarkers in osteosarcoma, including ABCB1, which
demonstrates a similar transcriptional dependence on wildtype p53 (Bush and Li, 2002).
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An apparent first response to the overexpression of enzymes such as PHGDH is to inhibit
it and observe the response of the tumor. Use of single-agent small molecule inhibitors of PHGDH,
such as CBR-5884, NCT-503, and PKUMDL-WQ-2101, demonstrates a decrease or attenuation
in cellular proliferation. Further exploration of the metabolic response to PHGDH inhibition
demonstrates that the lack of de novo serine biosynthesis results in decreased glucose entry into
the TCA cycle, effectively blocking mitochondrial oxidative phosphorylation using glucose as a
fuel source. Importantly, in osteosarcoma, entry of other fuel sources into the mitochondria, such
as fatty acids or glutamine, are also limited as a result of PHGDH inhibition.
This highlights a potential avenue for further exploration in the field, as glucose, fatty acids,
and glutamine, while the main fuel sources for the mitochondria, are not the only fuel sources. The
elevated levels of intracellular lactate with PHGDH inhibition suggest that osteosarcoma cells
either do not export fermented lactate or increase import of lactate (Figure 4.3M). Cells expressing
monocarboxylate transporter 1 (MCT1) and monocarboxylate transporter 4 (MCT4) have been
demonstrated to import lactate, the byproduct of glycolysis produced from pyruvate by the
bidirectional enzyme lactate dehydrogenase (LDH). LDH can then convert lactate back to
pyruvate, enabling lactate-derived pyruvate import back into the mitochondria for oxidative
phosphorylation. MCT1 and MCT4 have both been demonstrated to be overexpressed in
osteosarcoma and correlated with poorer prognosis, suggesting that elevated MCT expression may
play a role in osteosarcoma aggressiveness (Liu et al., 2019b; Zhao et al., 2014). Furthermore,
downregulating MCT1 expression in MCT1-high osteosarcoma cells decreased tumor growth and
invasion and enhanced the efficacy of chemotherapies, highlighting this pathway as a potential
escape mechanism for stressed cells (Lee et al., 2016; Zhao et al., 2014).
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Further understanding of the metabolic and bioenergetic shifts that occur with PHGDH
inhibition would also be useful for continued exploration in the field of PHGDH biology in
osteosarcoma. As noted above, PHGDH inhibition results in increased intracellular lactate, as well
as increased intracellular SAM and methionine, branched chain amino acids, and glutathione in its
oxidized form (GSSG). Elevated intracellular GSSG suggests that there may be an effect on ROS
biology in cells with PHGDH inhibition. Proper function of the TCA cycle requires a constant
supply of electron carriers, including NADH and FADH2. NCT-503-induced inhibition of the TCA
cycle would impact the recycling and replenishing of cellular NAD+ and FAD, thereby affecting
redox homeostasis (Martínez-Reyes and Chandel, 2020). Furthermore, inhibition of PHGDH also
affects NAD+ regeneration through the NAD+ salvage pathway, further contributing to redox stress
(Murphy et al., 2018). Identifying specific alterations in redox biology and sources of increased
ROS could highlight additional survival mechanisms that can be targeted in concert with PHGDH
inhibition.
The survival mechanisms induced in osteosarcoma cells as a result of PHGDH inhibition
sensitize cells to treatment with perhexiline or ALPI3MT55. The synergistic effect of combination
therapies allow less of each inhibitor to be used, mitigating side effects, and also allow for
treatments to be more specifically targeted to the unique biology of the cancer. Further
investigation of the effects of perhexiline and ALPI3MT55 on GSK3 biology from both the
transcriptional and protein levels may identify additional therapies that can be used in combination
with NCT-503. GSK3β is known to negatively regulate the nuclear factor erythroid 2 (NF-E2)related factor 2 (Nrf2) pathway by modulating Nrf2 cellular localization and degradation,
particularly when the cell is in oxidative stress (Armagan et al., 2019; Rojo et al., 2008).
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PHGDH inhibition and PHGDH knockdown both induce oxidative stress, as demonstrated
in Chapter 4 (Wei et al., 2019). Nrf2 is known to regulate serine biosynthesis, controlling
expression of serine biosynthetic enzymes including PHGDH, PSAT1, and SHMT2 by increasing
expression of ATF4 (DeNicola et al., 2015). NanoString gene expression analysis demonstrated
that NCT-503 treatment increased ATF4 RNA expression (Figure 6.1A), suggesting that the cell
increases ATF4 expression by increasing Nrf2 activity in response to lack of de novo serine
biosynthesis. Interestingly, ALPI3MT55 treatment, which activates GSK3 and therefore should
negatively regulate NRf2 expression, also increases ATF4 expression to a higher degree than
NCT-503 does (Figure 6.1B). As was previously demonstrated in neuroblastoma lines, the caspase
3-dependent apoptosis induced by GSK3β activation was enhanced when cells were treated with
rotenone first (King et al., 2008). The activation of certain pathways can therefore drive efficacy
of treatments that would not cause cell death independently. Similarly, ALPI3MT55 may enhance
ATF4 activation, which only causes cell death when ATF4 RNA expression is already enhanced
by PHGDH inhibition (Zong et al., 2017). Exploring the role of overexpressed ATF4 in causing
cell death in osteosarcomas with elevated de novo serine biosynthesis would therefore be an
interesting avenue of exploration.
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Figure 6.1 – NCT-503 and ALPI3MT55 treatment increase ATF4 gene
expression in osteosarcoma cell lines

Figure 6.1 – NCT-503 and ALPI3MT55 treatment increase ATF4 gene expression in
osteosarcoma cell lines
(A) Percent cell death at 60 hours in NOS1 cells treated with 10 µM NCT-inactive, 15 µM NCT503, 500 nM ALPI3MT55, or a combination of 15 µM NCT-503 and 500 nM ALPI3MT55,
measured using CellEvent Caspase 3/7 Green fluorescence area/well, normalized to total cell count
using red nuclear staining.
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Exploring the subcellular localization of GSK3 is another avenue of research that will
greatly enhance the specificity of this study. Canonical Wnt signaling requires that GSK3 be
sequestered in endosomes in order for Wnt and β-catenin signaling to be induced (Huang et al.,
2017). GSK3 localization can affect apoptosis, as increased mitochondrial GSK3β activity is
required to induce caspase 3-dependent apoptosis. GSK localization can also be regulated by SAM
and methionine (Figure 6.2). SAM allosterically inhibits methylenetetrahydrofolate reductase
(MTHFR), the enzyme that converts 5,10-mTHF to mTHF (Zheng et al., 2019). SAH can compete
with SAM for binding on MTHFR, thereby providing a switch to turn on enzymatic activity based
on methionine cycle activity. GSK3 has been demonstrated to phosphorylate MTHFR at Ser30,
and this phosphorylation is maintained by adequate concentrations of SAM (Zheng et al., 2019).
Conversely, when there is limited environmental SAM, MTHFR is prone to dephosphorylation.
Decreased levels of methionine, the metabolite upstream of SAM, cause significantly
reduced vesicular GSK3, suggesting that increased methionine and increased intracellular SAM is
required for sequestration of GSK3 in endosomes (Albrecht et al., 2019). Methotrexate has been
demonstrated to inhibit Wnt signaling through SGOC metabolism by decreasing cellular
abundance of SAM, thereby allowing release of GSK3 and inhibition of β-catenin stabilization
(Albrecht et al., 2019). These data suggest that PHGDH inhibition, which results in an
accumulation of SAM and methionine, would drive sequestration of GSK3, inhibiting it and
activating Wnt signaling. Stabilized β-catenin would also activate nuclear cMyc activity,
increasing expression of enzymes required for glycolysis, the cellular response to PHGDH
inhibition (Figure 4.4H). GSK3 activation by perhexiline or ALPI3MT55 would alleviate NCT503-induced GSK3 sequestration, offering another mechanism for synergistic cell death.
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Figure 6.2 – NCT-503 alters metabolites that activate mTOR-regulated
transcriptional pathways, sensitizing to ALPI3MT55 treatment

Figure 6.2 – NCT-503 alters metabolites that activate mTOR-regulated transcriptional
pathways, sensitizing to ALPI3MT55 treatment
Schematic of components of PHGDH-mTOR axis that can drive transcriptional changes that affect
glycolysis and glycogenesis.
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Cellular metabolism and bioenergetic pathways are critical to the progression of cancer.
Therefore, identifying combination therapies that can target these pathways while exploiting the
dynamic metabolic shifts that cancer cells can undertake has the potential to develop much more
effective therapies. PHGDH and SGOC metabolism have been identified as being complex
pathways that are upregulated in osteosarcoma and metabolically linked to several highly adaptive
interrelated processes within the cell. This research provides the preclinical justification to explore
the combination of PHGDH and non-rapalog mTORC1 inhibition in osteosarcoma, as well as other
PHGDH-high cancers, using therapies, like perhexiline, that are already used in the clinical setting.
Further exploration into biomarker-based combinations will offer a more targeted, less toxic
treatment strategy for aberrant metabolism-reliant cancers.
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